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ABSTRACT 
 
RACHEL COTE’: The Contribution of Prostanoids to Allergy and Lung Inflammation 
(Under the direction of Beverly H. Koller) 
     
Through respiration, the airway is exposed to foreign materials and relies on the immune 
system to interpret each novel antigen’s pathogenicity.  Failure to establish unresponsiveness to 
innocuous particles can initiate atopy, characterized by elevated immunoglobulin E (IgE) levels.  In 
susceptible individuals, asthma can develop, causing airway inflammation, reversible airflow 
obstruction, and airway hyperresponsiveness (AHR).  Leukocytes rely on information received in the 
form of cytokines, chemokines, and lipid mediators to determine if an immune response is warranted 
or, alternatively, if immune tolerance should be established.   
Prostanoids are lipid mediators, produced by cyclooxygenase (COX) enzymes, which can 
both promote and limit inflammatory processes.  Rodent models of atopic pulmonary allergy 
demonstrate that inhibition of prostanoid synthesis, by either COX isoform, augments disease 
parameters, assigning a protective role to these pathways.  We evaluated the role of prostaglandin E2 
(PGE2) to this process, utilizing mice lacking microsomal PGE2 synthase 1 (mPGES1).  Unlike a loss 
of COX activity, a deficiency in mPGES1 ameliorates airway inflammation at a step subsequent to 
sensitization, suggesting that this prostanoid augments the effector arm of pulmonary allergy.  
Further, synthesis of PGE2 from the lung, itself, is implicated in our model. 
PGI2, another prostanoid, is thought to limit disease in multiple pulmonary afflictions.  
Utilizing IP -/- animals and COX-1 -/- animals, we demonstrate a contribution for this prostanoid in 
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COX-1-dependent protection during atopic pulmonary episodes, potentially by inhibiting 
inflammatory cytokine release.  While mediation by PGI2 occurs during both branches of an allergic 
response, the contribution is more substantial during allergy elicitation, perhaps indicating that local 
antigen exposure is a requirement for PGI2-mediated airway protection.  Further we show that this 
protection occurs through immune cells recruited to the lung. 
 Finally, we demonstrate that a loss of PGE2 or its receptors does not impede the immune 
system’s ability to establish tolerance in the airways when innocuous antigen is inhaled prior to 
sensitization.  Instead a modest reduction in tolerance is observed when PGI2 signaling through the IP 
receptor is lost.  Taken together, the work presented in this dissertation suggests that PGI2, rather than 
PGE2, limits atopic immune responses in the respiratory tract. 
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CHAPTER I 
INTRODUCTION 
Allergy and Asthma Manifestations and Significance 
The term “allergy” refers to an inappropriate adaptive immune response mounted against an 
innocuous antigen.  The most common form of allergy, atopic allergy, effects more than 25% of the 
worldwide population and results from an overproduction of immunoglobulin E (IgE) antibody 
against a specific antigen.  The development and severity of an allergic response are shaped by many 
factors including the concentration and type of allergen exposure, additional mediators an exposure 
occurs with, and an individual’s genetic makeup. (1)  Allergies can be local, affecting only a specific 
organ, or systemic, resulting in anaphylaxis (2).  Pollen, pet dander/saliva, occupational substances 
and dust mites represent common triggers of atopic allergy.   
Atopy is a risk factor for asthma and 90% of asthmatics are considered atopic.  However, 
asthma is a heterogeneous disease and asthmatic attacks can result from multiple factors beyond 
allergens including: air pollution, aspirin, and excercise (3). Asthma is defined as a chronic 
inflammatory disease of the airways accompanied by reversible airway obstruction and airway 
hyperresponsiveness (AHR).  Clinical manifestations of an acute asthmatic response include the 
presence of a cough, chest tightness, wheezing and loss of breath.  The severity of an attack varies 
and can range from a mild cough to respiratory arrest and death.  Frequent or prolonged exposures to 
an allergen may result in chronic asthma associated with airway remodeling.  A diagnosis of asthma 
can be confirmed by the administration of a pulmonary function test.  This test is designed to identify 
AHR following challenge of the airways with a common bronchoconstrictor, such as methacholine, 
     
  
 
2 
 
which is reversible upon treatment with a bronchodilator. (1)  β2-agonists (bronchodilating agents) 
and glucocorticoids (drugs that ameliorate inflammation by inhibiting key transcription factors) are 
the two most common forms of treatment for asthmatic patients.  These treatments are effective in 90-
95% of patients; however, they do not provide long term prevention of lung function decline. (4)  
The prevalence of allergy and asthma has escalated dramatically in the past decades, 
particularly in westernized countries, affecting an estimated 300 million individuals worldwide (5).  
In the United States alone, approximately 30 million adults and 10 million children report that they’ve 
experienced an asthmatic episode (6).  In 2005, a survey exploring the burden of asthma in adults in 
the U.S reported that, on average, asthmatics were more likely to be unemployed, spend illness-
related days away from work bedridden, have greater limitations on activities, and accrue almost 
$2000 more in medical expenditures, compared to healthy individuals.  The estimated national 
medical expenditure for adult-related asthma was $18 billion dollars annually. (7)   In 2007, this 
affliction resulted in 1.75 million emergency room visits and 3,447 deaths (8).   
Speculation into the source of the inflated prevalence of disease occurring over recent 
decades in westernized countries has led to the theory that urbanization contributes significantly to 
asthma and related allergies.  Proponents for this school of thought site epidemiological studies as 
evidence.  For instance, in Africa, the prevalence of asthma is the highest in South Africa (8.1%), the 
nation considered to be the most developed on the continent (5).   
The Hygiene Hypothesis  
Ninety percent of asthmatics are diagnosed by the age of 6, suggesting that events occurring 
early in life influence allergen sensitization (9).  The “hygiene hypothesis,” originally proposed in 
1989 (10), postulates that exposure to particles ubiquitous in rural environments, such as 
lipopolysaccharide (LPS) or animal dander, during youth reduces one’s risk of developing allergy 
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later in life.  This idea is substantiated by large epidemiological studies reporting that children raised 
on farmland are less prone to allergies than children brought up in urban environments (11-13).  
Additionally, older siblings (14) and early day care attendance (15), factors thought to elevate antigen 
exposure in youth, have been inversely correlated with the development of allergy. 
Mechanistically, the hygiene hypothesis asserts that activation of the innate immune system 
through stimulation of pattern recognition receptors (PRRs), such as the toll like receptor (TLR) 
family, by ubiquitous environmental antigens during early childhood may cause the adaptive immune 
system to favor T helper 1 (TH1) or T regulatory (Treg) cell responses when encountering a novel 
antigen.  Thus, exposure to unrecognized innocuous allergens at later time points does not prime the 
immune system to produce IgE, typical of T helper 2 (TH2) cell-mediated responses.  Multiple human 
studies have noted a correlation between allergy incidence and certain TLR polymorphisms (16, 17) 
and in vivo animal studies have demonstrated that activation of the innate immune system can inhibit 
subsequent allergic responses to novel antigens (18-20).  Blumer and colleagues reported that mice 
exposed prenatally to LPS produced elevated levels of interferon-γ (IFN-γ), a characteristic TH1-
cytokine, at birth and exhibited an attenuated allergic response to ovalbumin (OVA) antigen (21).  
The hygiene hypothesis suggests that as countries become more westernized, their aseptic practices 
improve and early exposure to ubiquitous factors that prime the innate immune system declines.  As a 
result, antigen exposure results in TH2 responses in susceptible individuals.       
Environmental Pollutants 
The hygiene hypothesis cannot account for the disparities observed in allergy prevalence 
existing between socioeconomic classes and racial/ethnic groups.  Studies show that poor inner-city 
minorities have an elevated risk for developing allergy and asthma (22-24).  For instance, compared 
to Caucasians, one report observed that African-Americans were 3 times more likely to require 
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hospitalization for asthma-related illness in 2005 (25).  This trend may arise as a consequence of 
elevated levels of air pollutants found in inner-city areas (26-29).  Diesel fuel (30), nitric dioxide (31), 
ozone (31, 32), and cigarette smoke (33, 34) are linked to elevated allergy incidence in children.  
Additionally, proximity to a major road, where concentrations of diesel fuel and nitrogen dioxide are 
high, is viewed as a risk factor for childhood asthma (35-38).  Experimental evidence suggests that 
inhalation of these pollutants, on their own, is sufficient to alter lung function in humans and rodents 
(39-41). These toxins can also function as adjuvants to initiate adverse immune responses to 
innocuous particles (42-45). 
Air pollutants can both augment IgE production from B cells (46, 47) and enhance the 
expression of TH2 cytokines (42, 48).  Further, these irritants are potent inducers of reactive oxygen 
species (ROS) (49, 50), created only at minimal levels during homeostasis, which can react with 
proteins, DNA, and lipids to cause cellular damage and oxidative stress (51).  Evidence suggests that 
the creation of ROS by air pollutants may, in part, mediate both their independent actions and 
adjuvant properties on lung function.  For instance, the adverse actions of pollutants in the airways 
can be ameliorated by the administration of antioxidants (38, 52).    
Genetics  
While the environment and living conditions a person is exposed to can clearly shape allergic 
and asthmatic reactions, these responses are additionally influenced by an individual’s genetic 
makeup.  This is highlighted by studies showing that asthma concordance is higher among 
monozygotic twins than dizygotic twins (53, 54).  Linkage analysis studies represent an early 
approach for the identification of causative genes.  These studies rely on information generated from 
families in which multiple members are affected.  DNA from these subjects is analyzed at markers 
spanning the genome to identify regions shared by affected individuals at a higher than expected rate.  
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One advantage to this technique is that it has the potential to reveal novel candidate genes, given that 
no prior hypothesis is necessary to generate a linkage analysis report.  For instance, this method 
identified a link to the gene, a disintegrin and metalloproteinase 33 (ADAM33) (55), uncovering a 
previously unrecognized pathway in allergy.   
The complex nature of asthma and allergies limits the usefulness of linkage analysis.  Studies 
utilizing this approach typically identify large regions containing multiple susceptibility loci, each 
with only minimal impact on the risk for disease.  For instance, studies have consistently shown 
asthma and allergy linkage to the region 5q31-33, a stretch of DNA containing the genetic 
information for multiple genes associated with allergy and asthma including interleukin (IL)-4 and 
IL-13. (56) 
Another method for identification of genetic loci linked to atopic disease is the candidate-
gene association approach.  This methodology relies on DNA from unrelated asthmatics and healthy 
controls to characterize allele variants of a hypothesized susceptibility locus linked to disease.  These 
studies allow for a larger sample population and therefore can identify variants that may cause only 
modest phenotypic alterations.  However, because unrelated individuals will have a smaller 
percentage of shared markers at any particular region, this type of scan requires higher resolution than 
family-based studies.  Hypothesis-driven studies which analyze single nucleotide polymorphism 
(SNP) variants of genes involved in allergy pathways have been a useful technique in confirming 
most of the genes currently known to affect susceptibility. (56) 
Genome wide association studies are widely being used for linkage identification in allergy 
and asthma (57).  Utilization of this approach has the advantage of analyzing SNPs located across the 
entire genome to identify the variants most often inherited by individuals symptomatic for disease.  
The availability of the HapMap resource, which identifies common haplotype variations in 4 large 
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populations, the density of SNPs now available across the human genome, and the availability of 
DNA from large populations makes these studies feasible for complex disorders such as asthma (58).   
Respiratory Tract Mucosal Tolerance 
Normal respiration exposes the mucosal surface of the human airways to 10,000 liters of air 
every day.  This air carries within it a broad range of foreign particles, the majority of which are 
innocuous plant and animal-derived antigens ubiquitous in the environment.  With each breath, the 
immune system must accurately interpret the pathogenicity of the material it is exposed to in order to 
combat and expel particulates which pose a risk to the host while avoiding unwarranted immune 
responses directed against harmless environmental constituents. (59)  Some of the innocuous particles 
that the immune system encounters, including pet dander, mold, and pollen, provoke allergic 
responses in susceptible individuals when the immune system mistakes them as dangerous and 
sensitizes the adaptive immune system.  The majority of individuals, however, experience no adverse 
response to the innocuous particles present in the air, instead developing a state of immune 
unresponsiveness, or tolerance, when exposure to these environmental agents occurs.  Research 
indicates that a complex system of checks and balances exists at mucosal surfaces to expel particles, 
sample antigens, and accurately decipher harmful from innocuous antigens.  These mechanisms 
involve the coordinated actions of multiple cell types and mediators.  Rodents have been used to 
explore this phenomenon.  As an example, allergic responses resulting from immunization and 
challenge are significantly attenuated when antigen is introduced to the airways prior to sensitization 
(60-62).   
Epithelial Cells: Physical Barrier Protection and Immune Activation 
 The airway mucosa is covered by an epithelial barrier consisting of ciliated cells and 
secretory cells that contribute to mucociliary clearance in the lumen.  Secretory cells, comprised of 
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goblet, clara, and serous cells, release mucus and surfactant into the airways.  Submucosal glands also 
contribute to these secretions in the large airways.  Water is the main constituent of mucus, making up 
97% of this gelatinous substance.  The remaining 3% consists of mucins, proteins, salts, lipids, and 
cellular debris.  Mucins are complex glycoproteins responsible for the viscoelastic properties of 
mucous secretions.  In the airways, the predominant mucins (MUCs) are MUC5AC and MUC5B.  
These agents enhance trapping of airborne particulates entering the respiratory tract.  Mucus is 
propelled proximally by the actions of cilia to remove inhaled particles.  Independent of ciliary-
mediated clearance, expulsion of particulates from the respiratory tract can be accomplished by a 
cough reflex (63).  In the distal airways, clara cells release surfactant which creates a film barrier over 
the airways, further separating allergens from epithelial cells and aiding ciliary movement (64).  
Additionally, epithelial cells release peptidases, protease inhibitors, and antimicrobial products into 
the lumen that can directly lyse pathogens.  Among these factors, lysozyme, lactoferrin, and secretory 
leukocyte proteinase inhibitor (SLPI) are present in the highest concentrations (65)   
Based on molecular weight, adjacent epithelial cells form tight junctions which serve to 
exclude particles evading mucociliary clearance mechanisms.  These junctions, made up of 
interacting proteins and receptors, including zona occludens 1-3, occludins, and claudins, provide a 
physical barrier between cells designed to regulate the passage of material through the paracellular 
space.  Proteases are capable of breaching the epithelium by cleaving the proteins contributing to tight 
junctions (66, 67) 
 Beyond representing a physical barrier utilized to separate the external environment from 
one’s internal organs, epithelial cells are proficient in identifying and responding to particulates.  
Cells of the epithelium can recognize patterns common to many pathogens through PRRs including: 
TLRs, nucleotide-binding oligomerization domain (NOD) protein like receptors (NLRs), and protease 
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activated receptors (PARs) which activate the innate immune system.  In response to PRR binding, 
epithelial cells can release chemokines that attract the appropriate leukocytes to their surface, in 
addition to releasing cytokines, lipid mediators, reactive oxygen and nitrogen species, and growth 
factors. The combination of factors released from epithelial cells shapes the microenvironment of 
responding leukocytes and mediates their response.  Supernatant from both human and murine 
derived airway epithelial cells are capable of inhibiting the maturation of dendritic cells (68); 
however, some studies emphasize a necessity for physical contact with epithelial cells for immune 
mediation (69).  While the default signals released by epithelial cells may inhibit inflammatory 
immune reactions during homeostasis, activated epithelial cells can mobilize effector cells (70).  For 
instance, evidence suggests that TLR4 signaling on structural cells is critical for the priming of TH2 
responses to the house dust mite (HDM) antigen (71) 
Dendritic Cells 
Dendritic cells (DCs), given their name based on their long branching arms which resemble 
dendrites of the nervous system, uptake antigen and present it to pools of naïve T cells residing in 
local lymph nodes.  DCs exist in a dense network beneath the epithelium of the airways, making them 
an important antigen presenting cell (APC) of the respiratory tract.  In rats, research demonstrates that 
several hundred DCs reside per millimeter squared in the upper airways; however these cells become 
less frequent in the lower airways. (72)  Beyond internalizing antigen that breaches the epithelial 
barrier, evidence indicates that DCs can additionally form tight junctions with epithelial cells, 
extending their dendrites into the lumen to directly sample inhaled particulates (73).  How mucosal 
DCs are able to discriminate between pathogenic and non-pathogenic antigens is unclear; however, 
like epithelial cells, DCs express several classes of PRRs and costimulation of these receptors in the 
context of the mediators released by the epithelial cells may determine how an antigen is received 
(74). 
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DCs surveying the antigenic content of the airways exist in an immature state (75).  This 
implies that these cells are highly specialized to sample and process antigen but are inefficient at 
presenting these particles to naïve T cells.  Once a particle is taken up and processed by a DC, this 
APC no longer acquires new antigen, instead undergoing a maturation process involving the 
upregulation of molecules which aide in presentation including major histocompatibility complex 
(MHC) II and co-stimulatory molecules, such as cluster of differentiation (CD) 80 and CD86.  As part 
of this maturation, DCs become attracted to specific chemokines that promote their migration to local 
lymph nodes, rich in naïve T cells (76).  The cytokines and mediators released by DCs when they 
encounter these target T cells shape the progression of the immune response.  T cells utilize their T 
cell antigen receptor (TCR) to interact with DCs and sample antigen expressed as MHC-peptide 
complexes.  Whereas antigen bound to MHC I attracts CD8
+
 cells, allergen presented by MCH II 
promotes the differentiation and expansion of the CD4
+
 T cell subset.  CD4
+
 cells can differentiate 
into at least 4 types of effector cells depending on the context under which they are stimulated (Fig 
1.1).   
T-cell priming by APCs appears to be a necessary step in the establishment of airway 
tolerance.  Transfer of pulmonary DCs exposed to inhaled antigen confers immune unresponsiveness 
in recipients, however when ICOS-ligand, necessary for T cell interactions, is neutralized on 
transferred DCs, they lose their ability to induce tolerance (77, 78).  Further, neutralizing CD86 at the 
time of antigen inhalation also abrogates immune tolerance (79).  DCs may promote this process by 
stimulating naïve cells to become T regulatory (Treg) cells, cells which release the anti-inflammatory 
cytokines transforming growth factor-beta (TGF-β) or IL-10 (78, 80).  It is not clear what differences 
exist in DCs that allow them to establish tolerance rather than immunogenicity.  One theory asserts 
that when an antigen is internalized, DCs require a second stimulation, through PRR activation, that 
alerts them to danger.  Without this costimulation, DC maturation is incomplete and interactions with 
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T cells result in immune unresponsiveness.  One group observed that although tolerogenic antigen-
loaded DCs had normal expression of costimulatory molecules, MHC II levels were reduced on these 
APCs (77).  The ability to promote tolerance may also depend on the class of DC responsible for 
antigen presentation.  Plasmacytoid (p)DCs may promote airway tolerance while presentation by 
myeloid (m)DCs often elicits allergy (81).   
Alveolar Macrophages  
Alveolar macrophages (AMs) dominate the alveolar space and  conducting airways, 
constituting 90% of the leukocytes present during homeostasis (82).  The main function of AMs 
during homeostasis appears to involve phagocytosis of innocuous particles in order to prevent the 
uptake and presentation of these antigens to the adaptive immune system by DCs (83).  This theory 
arises from the observation that despite the fact that AMs internalize the majority of inhaled antigen 
and inherently possess the ability to present it, they do not migrate to local lymph nodes following 
uptake.  In addition, elimination of AMs results in elevated response to antigens in the airways and 
increased APC presence in draining lymph nodes (84, 85).  Beyond sequestering antigen, AMs may 
promote airway tolerance by suppressing DC maturation and inhibiting the localization of DCs to the 
airway (85, 86).  AMs can also release cytokines with anti-inflammatory properties including IL-10 
(87).    
Regulatory T cells 
 While prevention of autoimmune diseases involves control of autoreactive T cells by several 
mechanisms including anergy and deletion, research exploring the generation and maintenance of 
respiratory tolerance to foreign innocuous antigens focuses on the generation of suppressor Treg cell 
populations.  These cells actively inhibit responses by effector T cells.  Treg cells constitutively 
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express CD25 and are characterized as either naturally occurring or adaptive.  Naturally occurring Treg 
cells, produced in the thymus, constitute 5-10% of the CD4
+
 T cells present during homeostasis in 
humans and mice.  In vitro work reveals that these cells can inhibit the proliferation of effector T cells 
(88).  The significance of naturally occurring Treg cells to immune unresponsiveness is highlighted by 
the discovery that neonatal thymectomy causes organ-specific autoimmune pathology in mice, a 
condition preventable by adoptive transfer of CD4
+
 CD25
+ 
T cells (89).  Unlike naturally occurring 
Treg cells which are produced as a normal branch of the T cell repertoire, adaptive Treg cells originate 
from CD4
+ 
CD25
-
 T cells that are converted to CD25
+
 suppressive cells as a result of signals received 
in the periphery.   
The generation of most Treg cells, both naturally occurring and adaptive, appears to rely on 
actions of the transcription factor forkhead box P3 (Foxp3).  The significance of Foxp3 is 
underscored by the discovery that rodents lacking a functional copy of this transcription factor 
develop a lethal immune syndrome that is inhibited by adoptive transfer of CD4
+
 CD25
+
 Treg cells (90, 
91).  Additionally, mutations in the human gene coding Foxp3 are responsible for 
immunodysregulation, polyendocrinopathy enteropathy, X-linked, a disease associated with 
autoimmune endocrine pathology and allergic manifestations (92).  Foxp3 can also convert effector T 
cells into suppressive Treg cells.  Addition of this factor to cultures of CD25
-
 effector cells converts 
them into Treg cells (91) and conversion of Treg cells in the presence of TGF-β involves activation of 
Foxp3 (93).  However, not all Treg cells are reliant on Foxp3 expression.  A subset of Treg cells which 
produce high levels of IL-10,Tr1 cells, do not appear to express Foxp3, suggesting that at least one 
alternate pathway can be utilized to generate these cells (94).   
While a genetic loss of Treg cells clearly establishes a link between this cell type and the 
prevention of autoimmune diseases, the importance of these cells to the generation and maintenance 
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of immune tolerance in the respiratory tract is also documented.  For instance, adoptive transfer of 
antigen-specific CD4
+
 CD25
+
 cells ameliorates acute allergic lung allergy in recipient animals (95) 
and prevents airway remodeling in a chronic allergy model (96).  Conversely, depletion of these cells 
prior to allergen challenge results in exacerbated lung inflammation (97).  The mechanism utilized in 
this system to promote airway tolerance remains unclear.  Multiple studies have emphasized a 
dependency on cell to cell contact with effector T cells for Treg-mediated suppression (98, 99).   
Alternatively, Treg cells may induce immunosuppression through IL-10-dependent actions.  
Indeed, the significance of IL-10 in this process is suggested by multiple works modeling respiratory 
tract tolerance (100-102) although it is unclear whether the important source of this cytokine is the 
Treg cells or the effector T cells.  Recipients transferred with T cells depleted of CD25
+
 populations 
experience exacerbated pulmonary allergy that is surprisingly accompanied by a decrease in 
bronchoalveolar lavage fluid (BALF) TH2 cytokine levels, including IL-10.  This data suggests that 
Treg cells may not downregulate the actions of TH2 effector cells but rather enhance production of 
anti-inflammatory cytokines from these cells (103).  In agreement with this, Kearley and colleagues 
reported that transfer of immune suppression by Treg cells was dependent on production of IL-10 from 
effector CD4
+
 T cells (95).  TGF-β, another anti-inflammatory cytokine, may also contribute to Treg-
mediated airway tolerance.  However, although production of this factor has been identified as an 
essential step in some models (80), it is generally believed to be more critical to the establishment of 
tolerance in the gastrointestinal (GI) tract (104).   
Immunotherapy 
Exploitation of the mechanisms promoting immune tolerance represents a promising 
approach for the treatment and prevention of allergic responses.  Antigen-specific immunotherapy 
(IT) utilizes incremental delivery, typically through subcutaneous administration, of a specific antigen 
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in an attempt to suppress allergy symptoms.  The benefits of this system are highlighted by studies 
showing recipients have long-term remission upon allergen challenge (105), reduced sensitivity to 
novel antigens (106), and prevention of disease progression to asthma (107).  Treg cell generation is 
thought to account for the success of this treatment regimen.  Indeed, studies have measured elevated 
CD4
+
 CD25
+
 levels and enhanced expression of IL-10 and TGF-β in individuals receiving IT (108, 
109).  Further, a murine model utilizing this system shows long-term abatement of allergen-specific 
IgE production and TH2 responses, potentiated by IL-10-producing Treg cells (110).  This therapy is 
not without its caveats.  The efficacy of this treatment is not as pervasive in asthma as it is in allergy 
(111) and widespread use of subcutaneous treatment is limited by concerns that such a system can 
trigger anaphylaxis.  Research is currently underway to develop a safer mode for IT delivery and may 
involve the use of adjuvants to magnify tolerogenic properties of APCs.  Studies evaluating the safety 
and efficacy of sublingual delivery (112) and peptide IT (113) are being conducted. 
Atopic Allergic Sensitization Phase 
Allergic responses occur in two phases, a sensitization phase and an effector phase.  The early 
events precipitating an allergic reaction occur in much the same manner as those which precede 
respiratory tract immune tolerance.  However, under these circumstances, the microenvironment 
established at the airway epithelium and the signals received by DCs support antigen sensitization 
rather than tolerance (Fig 1.2).  Following antigen uptake, DCs become activated, maturing fully, and 
presentation of antigen to naïve T cells occurs in the presence of IL-4 and IL-2 rather than IL-10.  
Expression of IL-4 promotes the expansion of TH2 cells from naïve CD4
+
 populations (114, 115).  IL-
4 upregulates expression of GATA-binding protein 3 (GATA3), the master regulator of TH2 cell 
differentiation, by inducing phosphorylation of signal transducer and activator of transcription 
(STAT) 6 (116).  STAT6 expression, which also appears to be essential for TH2 cell differentiation 
(117), can be activated in vivo by IL-2, IL-7 or thymic stromal lymphopoietin (118).  Costimulatory 
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signals, including interaction between CD28 on T cells and CD86 on DCs, enhance this 
differentiation (119).     
The differentiation and expansion of antigen-specific TH2 cells is followed by the activation 
of naive B cells into mature IgE producing plasma cells.  This process involves interactions with 
CD40L and CD23 on T cells with their respective receptors on B cells.  Following these interactions, 
B cells undergo class switch recombination to halt production of IgM in favor of antigen specific IgE.  
IL-4 and IL-13, cytokines released from activated TH2 cells, enhance the efficiency of this process 
(120, 121).  After its production, IgE diffuses out of the cell and circulates through the blood, 
eventually binding to the carboxylic fragment of surface high-affinity IgE receptors (FcεRI) 
expressed at high levels predominately on mast cells and basophils. 
Allergic Effector Phase 
TH2 Type Cytokines 
The effector phase of an allergic airway response is initialized upon exposure to an antigen in 
a sensitized organism (Fig 1.3).  Antigen taken up by DCs in sensitized hosts can be presented to 
antigen-specific T cells circulating the mucosal system directly at the airway surface (122).  Once 
activated, these effector TH2 cells release a unique profile of cytokines transcribed from a region on 
human chromosome 5.  This profile includes the production of IL-4, IL-13, IL-5, and IL-9.  Although 
TH2 cells are believed to be the main source of these cytokines during allergic responses, additional 
cell types, including mast cells and eosinophils contribute to their expression (123).  Adoptive 
transfer of allergen-specific TH2 cells into naïve animals prior to antigen challenge can initiate 
eosinophil recruitment, increased mucus production, and AHR (124, 125), underscoring the critical 
contribution of these cells and their cytokines to lung allergy.  
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IL-4 and IL-13 share the IL-4R-α receptor, providing these cytokines with overlapping 
functions.  Polymorphisms in this shared receptor are linked to atopy and asthma in humans (126, 
127)  While each of these factors contributes to both the sensitization and effector arms of allergy 
(128), the actions of IL-4 appear to dominate during antigen sensitization.  Using a neutralizing 
antibody, Coyle et al. demonstrated that loss of IL-4 during atopic sensitization prevents a subsequent 
allergic response from occurring.  However, when the same antibody is administered to sensitized 
animals prior to challenge, blockade of IL-4 does not prevent allergy (129).  While not critical, IL-4 
does contribute to the effector phase of allergy in several ways.  IL-4 enhances the expression of 
adherence factors for leukocytes on endothelial cells at sites of inflammation (130) and may 
contribute to eosinophilia (131).  
 Conversely, the contributions of IL-13 to allergy are more prolific during the effector phase 
of an allergic reaction.  Neutralizing IL-13 during allergen challenge is sufficient to prevent many 
allergic symptoms, especially mucus production and AHR in immunized mice and animals with a 
genetic loss of IL-13 do not develop mucus production or AHR (131).  Conversely, administration of 
IL-13, exogenously or through transgenic overexpression, induces AHR, eosinophilia, IgE 
production, mucus secretions, and subepithelial fibrosis (132-134).  IL-13, like IL-4, is also 
implicated in the recruitment of inflammatory cells to the site of inflammation (135, 136).   
In vitro and ex vivo experimentation has highlighted the role of IL-5 in both the 
differentiation and survival of eosinophils (137-140).  Further, a role for this factor in eosinophil 
recruitment is demonstrated by an in vivo study in which administration of IL-5 reduces eosinophil 
numbers in the bone marrow while concomitantly increasing levels of circulating eosinophils (141).  
Additionally, neutralization of IL-5 in rodents results in a significant attenuation of eosinophilia (142-
144) and a complete loss of eosinophilia is observed in IL-5 deficient rodents (145)  Moreover, 
     
  
 
16 
 
transgenic expression of IL-5 causes spontaneous development of eosinophilia (146, 147).  In 
asthmatic individuals, administration of a single dose of neutralizing antibody against IL-5 effectively 
reduces blood eosinophil levels for up to 16 weeks (148).   
IL-9 was initially recognized as a TH2 cytokine that contributes to T cell and mast cell 
proliferation (149, 150); however, further analysis suggests that IL-9 serves as a growth factor for B 
cells, as well (151).  Interest in the contribution of this cytokine to lung allergy arose following the 
discovery that a polymorphism present in certain breeds of mice, which conveys airway 
hyporesponsiveness, maps to a locus containing the IL-9 gene.  Measurements of this cytokine are 
reduced in these hyporesponsive animals (152).  However, the results of in vivo analysis are 
conflicted regarding the extent to which IL-9 alters lung allergy.  Systemic transgenic expression 
causes mastocytosis in multiple compartments, including in the airways (153) and mice with lung-
specific expression exhibit eosinophilia, mastocytosis, mucus accumulation, subepithelial fibrosis, 
and AHR (154, 155).  However, while IL-9-deficient mice have significantly attenuated goblet cell 
hyperplasia and mastocytosis, in a pulmonary granuloma model, the endogenous development of T, 
B, or mast cell population are unaffected (156).  Further, IL-9-deficient rodents had no significant 
reductions in AHR, eosinophilia or mucus secretion following sensitization with OVA/alum and 
subsequent challenge (157).  Mast cells do not serve a critical function in OVA/alum sensitization 
models of allergy (158) which may explain why no phenotype was observed in these IL-9 -/- mice.  
Collectively, these results may indicate that the major function of IL-9 is to mediate mast cell 
dependent pathology. 
Mast Cells 
In addition to the IL-9 released by TH2 cells, stem cell factor released by epithelial cells can 
recruit mast cells to the site of inflammation (159).  In the airways, antigen binding to IgE/FcεRI 
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complexes aggravates these structures, triggering mast cell degranulation.  This process can transpire 
within minutes of antigen recognition (123).  Degranulation involves the release of preformed 
mediators from mast cell granules, a process involving fusion of the granule’s cytoplasm membrane 
with the plasma membrane of the mast cell (160).  The factors released from mast cells during 
degranulation include vasoactive amines, serine proteases, proteoglycans, and some cytokines.  This 
degranulation exacerbates and contributes to the allergic responses mediated by TH2 cell cytokines. 
Additionally, liberation of these mediators can stimulate sensory nerves and induce coughing (161).  
Beyond the release of these preformed factors, mast cells can de novo synthesize lipid mediators and 
transcribe cytokines and chemokines; however, this process does not occur as rapidly as 
degranulation (162). 
Eosinophils 
Eosinophils are thought to be influential in mediating the late phase events of an allergic 
response.  These events are similar in nature to those observed during the early phase; however late 
phase reactions typically do not occur until several hours after allergen exposure, peaking 6-9 hours 
after challenge and resolving 1-2 days post-exposure (162).  Eosinophils represent bone-marrow 
derived cells recruited to the lung by chemokines released by mast cells, TH2 cells, epithelial cells, 
and endothelial cells.  In addition to IL-5, eotaxin family members produced mainly by epithelial cells 
(163) have been identified as eosinophil-specific chemoattractants.  The importance of eotaxin to this 
process is highlighted by data demonstrating that administration of eotaxin blocking antibody to 
immunized rodents significantly attenuates eosinophil accumulation in the BALF and lung following 
antigen challenge (164, 165).   
Similar to mast cells, eosinophils are granular cells that release preformed factors which 
contribute to allergy manifestations.  Like mast cells, these cells can also de novo synthesize and 
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release lipid mediators and cytokines.  The granular content of eosinophils is comprised of 4 major 
cationic proteins: major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, and 
eosinophil peroxidase (EPO), all of which have toxic effects on cells (166).  The exact function of 
eosinophils in lung inflammation has not fully elucidated.  Two murine models utilizing targeted 
ablation of eosinophils provide evidence that eosinophils contribute to epithelial cell hypertrophy, 
mucus accumulation and AHR in episodes of acute allergy (167, 168).  However, data generated 
using a third method of targeted ablation argues that these features can occur independently of 
eosinophilia (169).  Additional studies suggest that eosinophil granular proteins can damage epithelial 
cells, reducing their barrier function, (170, 171) and can create ROS and nitrogen species (172-174).   
When exposure to an antigen is frequent or prolonged, chronic inflammation and airway 
remodeling can occur, causing structural changes at the site of inflammation resulting from an 
imbalance between tissue repair and regeneration mechanisms.  Airway remodeling is associated with 
deposition of extracellular matrix proteins, goblet cell hyperplasia, alterations in fibroblasts, 
proliferation of airway smooth muscle (ASM) cells, and vascular changes within the parenchyma 
(162).  Studies utilizing targeted ablation of eosinophils suggest that eosinophilia can contribute to 
this process by augmenting subepithelial fibrosis and ASM hyperplasia (169, 175), however studies 
are conflicted on the extent to which TGF-β production, known to enhance airway remodeling, by 
eosinophils contributes to this phenotype.  In addition to TGF-β, eosinophils also release multiple 
growth mediators which may promote airway remodeling (176).  The importance of eosinophils to 
this phenomenon is supported by clinical data demonstrating that administration of anti-IL-5 reduces 
extracellular matrix protein deposition (177). 
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Prostanoid Synthesis 
Prostanoids represent an important class of lipid mediator de novo synthesized and released 
by both leukocytes and structural cells involved in lung allergy.  The production of these bioactive 
oxygenated C20 fatty acid mediators occurs through the metabolism of arachidonic acid (AA) (Fig 
1.3). In response to a broad range of stimuli, cytosolic phospholipase A2 (cPLA2) and other 
phospholipases release AA, an unsaturated fatty acid, from membrane phospholipids (178).  AA is 
initially processed into two intermediate forms, prostaglandin G2 (PGG2) and prostaglandin H2 
(PGH2) by the actions of prostaglandin-endoperoxide synthases (cyclooxygenase, COX), colloquially 
known as COX-1 and COX-2.  COXs are bifunctional enzymes that perform peroxidase activities in 
addition to their cyclooxygenase capacity.  These isoforms share 60-65% sequence identity but are 
the products of unique genes.  While enzymatic activity by COX isoforms is typically exerted through 
the formation of homodimers, the formation of COX-1/COX-2 heterodimers has also been described 
in cells where coexpression occurs (179).  COX-1 is generally believed to produce most basal level 
prostanoids, given that it is constitutively expressed in many cell types.  COX-2 expression, 
conversely, is absent under homeostatic conditions in most cells and instead, is induced by a diverse 
range of stimuli including inflammatory mediators (180).     
The concept that COX-1 synthesizes all basal level prostanoids while induced expression 
relies solely on COX-2 is an oversimplified, antiquated view.  Instead, these enzymes can each 
contribute to the production of autoregulatory, as well as inflammatory prostanoids.  Constitutive 
expression of COX-2 is observed in multiple tissues of both human and rodent origin (181-186) and 
COX-2 deficient animals spontaneously develop severe renal nephropathy (187).  Conversely, COX-1 
expression is elevated in the lactating murine mammary gland and in the inflamed guinea pig gall 
bladder (188, 189).  Further, while a genetic loss of COX-2 has no consequence on ear edema 
induced by AA administration, inflammation is attenuated in the absence of COX-1, implicating this 
     
  
 
20 
 
isoform in prostanoid synthesis in this model (187, 190).  Experimental evidence suggests that COX-
2 actions dominate when levels of AA are below 2.5uM, while levels of AA reaching 10uM and 
higher result in predominately COX-1 enzymatic actions (191).  These findings may indicate that 
immediate responses to inflammatory signals are mediated by COX-1, prior to COX-2 upregulation.  
This idea is supported by a human-based study reporting that early prostanoid production following 
LPS administration is dependent on COX-1 while expression of COX-2 is not measured until an hour 
and a half after endotoxin exposure (192).    
Following the conversion of AA by COX enzymes to PGH2, product-specific synthases 
complete the synthesis into five bioactive prostanoids consisting of prostaglandin D2 (PGD2), 
prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane (TXA2).  
These prostanoids have autocrine/paracrine functions and mediate their actions through the selective 
binding of distinct but cognate rhodopsin-like 7-transmembrane-spanning G-protein coupled 
receptors.  These receptors activate a range of secondary intracellular signaling pathways to exert 
their downstream affects.   
The important role of COX-generated mediators in the regulation of inflammation, fever and 
pain, is highlighted by the clinical efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), 
common analgesics that prevent COX enzymatic activity through competitive inhibition of active-site 
binding (193).  However, widespread use of these drugs can potentiate gastric maladies, further 
illustrating the significant role of prostanoids in tissue maintenance, as well.  These toxic side effects 
are attributed to a loss of gastroprotective COX-1 derived prostanoids and resulted in the 
development of COX-2 specific inhibitors, coxibs.  While utilization of these products reduces GI 
tract toxicities, coxib usage is linked to adverse cardiovascular events, emphasizing that both isoforms 
of the COX enzyme participate in maintaining homeostasis. (194)   
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Prostaglandin E2  
PGE2 is the most ubiquitously expressed prostanoid in the body.  Initially, the isomerization 
of this enzyme from PGH2 was attributed to three PGE2 specific synthases: microsomal PGE2 
synthases (mPGES) 1 and 2, as well as cytosolic PGE2 synthase (cPGES).  The first synthase to be 
described, mPGES1, was originally isolated from bovine and sheep vesicular glands and found to be 
dependent on glutathione as a cofactor (195, 196).  The human form of this synthase was later 
purified in1999 (197).  Expression of mPGES1 has been demonstrated at varying levels in many 
tissues and cell types (197).  Similar to COX-2, expression of mPGES1 increases dramatically in 
response to inflammatory stimuli including LPS and IL-1β, however coupling of mPGES1 with 
COX-1 in the production of PGE2 has also been observed (189, 198).  The in vivo contribution of this 
synthase was originally described by Trebino et al. who demonstrated that mice lacking mPGES1 
synthase have reduced arthritis related inflammation and have attenuated pain responses resulting 
from deficits in PGE2 production (199).  Mice deficient in mPGES1 also show reduced angiogenesis 
(200). 
A second proposed glutathione-dependent PGE2 synthase, cPGES, was purified from the rat 
brain in 2000 and is identical to p23, a chaperone that binds heat shock protein-90.  Initial in vitro 
analysis of this factor suggested that cPGES couples with COX-1 to produce PGE2.  In support of 
this, constitutive expression of cPGES was observed in multiple tissues although elevated expression 
was also measured in brain tissue following LPS exposure (198).  However, the generation of cPGES-
deficient mice does not support a role for this synthase in the in vivo production of PGE2 (201).  
While levels of this prostanoid are attenuated in null animals, COX levels and the levels of additional 
prostanoids are also reduced, suggesting a more pleiotropic function for this factor in the prostanoid 
pathway (201).  
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A third synthase, mPGES2, was isolated from bovine heart tissue and shown in vitro to 
convert PGH2 to PGE2 independently of glutathione (202).  Although the name of this synthase arose 
from its membrane location at discovery, further analysis identified that mPGES2 is golgi-associated 
at synthesis and the proteolytic removal of its N-terminal hydrophobic domain results in a mature 
cytosolic mPGES2 with expression in many organs (203).  In vitro, coupling of mPGES2 is observed 
with both COX-1 and COX-2, however mPGES2 demonstrates a preference for COX-2 (203).  In 
spite of this in vitro data, no phenotype or alterations in PGE2 production are observed in genetically-
engineered mPGES2- deficient animals, arguing that mPGES2 does not contribute to the in vivo 
production of this prostanoid (204). 
Following synthesis, PGE2 exerts pleiotropic autocrine and paracrine functions (205).  
Actions by this mediator occur through selective binding to four G-protein-coupled E prostanoid (EP) 
receptors: EP1-4.  Binding of the Gq coupled EP1 receptor results in an increase of intracellular Ca
2+
 
levels while actions by the Gs coupled EP2 and EP4 receptors occur through elevation of intracellular 
cyclic adenosine monophosphate (cAMP).  EP3 is unique in that alternative splicing allows this 
receptor to bind to multiple G-coupled receptors and subsequently activate distinct downstream 
pathways.  Depending on the variant, EP3 can couple with the Gi, Gs, and Gq-protein receptors to 
reduce or enhance cAMP levels or elevate intracellular calcium, respectively, although coupling with 
Gi appears to predominate (206).  PGE2 is de novo synthesized, rather than stored, and is rapidly 
metabolized within minutes of its synthesis by the actions of 15-hydroxyprostaglandin dehydrogenase 
(PGDH) (207).   
Owning to the fact that PGE2 synthesis can be initialized by 2 cyclooxygenase isoforms and 
can then bind with high affinity to four distinct receptors, each with unique expression patterns 
throughout the body, it is not surprising that this prostanoid is implicated in many, sometimes 
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seemingly opposing functions in the body.  While release of PGE2 is a critical step in the maintenance 
of many biological processes, it is also implicated in inflammation:  Indeed high levels of this 
prostanoid have been measured at sights of inflammation (208, 209) and injection of PGE2 is 
sufficient to cause many of the cardinal symptoms associated with an acute inflammatory response 
(210).  This mediator has been demonstrated to enhance vascular permeability and vasodilation, 
which give rise to the redness and swelling associated with inflammation.  In a model of ear edema, 
mice lacking the EP3 receptor have significantly reduced levels of edema and protein extravasation 
(211).  Production of this prostanoid also increases hyperalgesia; animals missing key components of 
the PGE2 pathway have attenuated pain responses (199, 212).  PGE2 is additionally implicated in the 
fever response (213). 
PGE2 plays a significant role in normal gastrointestinal processes where it is thought to 
promote a cytoprotective environment, emphasized by the fact that gastric toxicities associated with 
chronic NSAID usage are attributed to loss of mucosal surface integrity maintained by this mediator.  
Production of PGE2 can reduce gastric acid and pepsin secretions (214), stimulate mucus (215) and 
bicarbonate secretions (216), enhance mucosal blood flow, and promote renewal of mucosal 
progenitor cells (217-219).  Additionally this mediator aids motility by alternately stimulating 
contraction of longitudinal smooth muscle and relaxation of circular smooth muscle (220)  However 
production of PGE2 is also linked to several diseases in the gut including colorectal cancer (221, 222).  
Research indicates that PGE2 can enhance cellular proliferation, inhibit cell apoptosis, promote 
angiogenesis, and suppress tumor destruction mediated by the immune system (223).  
PGE2 production is also vital for blood flow, regulation of salt and water excretion, vascular 
resistance, and renin secretion in the kidney during periods of physiological stress (224).  In the 
reproductive organs, this prostanoid contributes to vasodilation and smooth muscle stimulation.  
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PGE2 promotes erection, ejaculation, and sperm transport in males while playing a role in embryo 
implantation and uterine contractions during the initiation of labor in females. (225, 226)  Further, 
PGE2 production has been implicated in both bone formation, as well as bone resorption, and research 
shows that this mediator can increase bone cancer growth (227, 228).   
Prostaglandin E2 and Leukocytes 
Beyond its ability to mediate inflammatory responses through the potent actions it exerts on 
structural cells, PGE2, has significant effects on the leukocytes that shape adaptive immune reactions, 
beginning with DCs and macrophages.  In addition to being a major source of PGE2 synthesis in the 
immune system, these APCs also show expression, to varying levels, of EP receptors in both humans 
and mice and can respond to PGE2 released by bronchial epithelial cells (229, 230).  While exceptions 
have been noted (231), most evidence indicates that early exposure of immature DCs to PGE2 
promotes cell maturation, and may be critical for the upregulation of certain costimulatory molecules 
present on these APCs (232, 233).  Additionally PGE2 has been shown to augment expression of 
chemokine receptors, such as CCR7, that promote migration of DCs to local lymph nodes (229, 234).  
This finding is supported by in vivo research showing that maturation and migration of Langerhans 
cells is impaired in mice deficient of the EP4 receptor (235).  PGE2 may also determine how antigen is 
presented to naïve T cells by DCs.  Data indicates that DCs cultured in vitro with exogenous PGE2 
have enhanced production of IL-10 and reduced production of IL-12p70 to favor either a TH2 or a Treg 
cell response, possibly depending on cofactors present in the milieu.  DCs matured in the presence of 
PGE2 can either promote or suppress T cell proliferation depending on additional factors present 
during maturation (229-231, 233, 236).  In macrophages, PGE2 can inhibit phagocytosis (237).  
Additionally, this prostanoid reduces production of TNF-α and IL-6 by these cells resulting in part 
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through upregulation of IL-10 (238, 239).  PGE2 also suppresses MHC expression on macrophages 
(240) 
Beyond shaping the reactions of T cells indirectly through its actions on DCs, PGE2 can act 
directly on CD4
+
 T cells to shape immune responses.  Early experiments conducted in vitro 
demonstrated that PGE2 downregulates T cell proliferation and TH1 cytokine production.  In these 
works, the addition of exogenous PGE2 to either committed or naïve CD4
+
 T cell populations resulted 
in inhibition of IL-2 and IFN-γ production.  TH2 cytokines, including IL-4 and IL-5, were unaffected 
or slightly elevated.  These affects are thought to be mediated by elevation of intracellular cAMP and 
subsequent activation of protein kinase A (PKA).  (241-245)  Indeed, suppression of responder cell 
proliferation by PGE2 is attenuated in the mixed lymphocyte response when cells are obtained from 
mice deficient of the EP2 or EP4 receptor (246).   
It is now clear that the actions of PGE2 on T cells are more complex.  While inhibition of TH1 
proliferation has largely been assigned to elevated cAMP levels, the downstream events were not well 
understood.  T cell activation is primarily influenced by T cell receptor (TCR) antigen stimulation and 
one downstream effect of this stimulation is activation of lymphocyte-specific protein tyrosine kinase 
(Lck).  Recent work demonstrates that elevation of cAMP and PKA mobilization by PGE2 signaling 
leads to the phosphorylation and activation of C-terminal Src kinase.  This factor in turn 
phosphorylates the C-terminal tyrosine of Lck and inactivates it.  Thus, PGE2 suppresses T cell 
proliferation by antagonizing activation of Lck (247).  Given this knowledge, Yao and colleagues 
have recently demonstrated that low concentrations of exogenous PGE2 enhance TH1 differentiation 
in the presence of strong TCR stimulation (248).  Similar to PGE2-mediated cell suppression, this 
stimulatory effect is dependent on EP2//EP4 signaling; however, instead of PKA activation, the 
phosphoinositide-3-kinase pathway is critical.    
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Accumulating evidence suggests that PGE2 can also mediate TH17 responses.  In vitro data 
generated in murine cells shows that addition of PGE2 suppresses TH17 differentiation from naïve T 
cells.  However, this prostanoid stimulates production of IL-23, a cytokine essential for TH17 cell 
expansion, from DCs in an EP4 and cAMP-dependent manner.  Further, although IL-23, on its own, is 
able to only modestly stimulate TH17 cell proliferation, PGE2 significantly enhances this expansion 
through EP2/EP4 and upregulation of cAMP and PKA (248).  In humans, IL-1β also enhances TH17 
expansion and work shows that PGE2 enhances this process (249, 250).  Using mice to model contact 
hypersensitivity and multiple sclerosis, diseases mediated by both TH1 and TH17 cells, Yao et al. 
show in vivo that loss a of PGE2 signaling through the EP4 receptor attenuates disease.  Further, ex 
vivo cells obtained from sensitized animals show reduced proliferation and produce attenuated levels 
of IFN-γ and IL-17 when cocultured with an EP4 antagonist (248). 
PGE2 additionally mediates activities of Treg cells.  In vitro data conducted with T cells from 
both mice and humans demonstrates that incubation with this prostanoid enhances the suppressive 
capacities of CD4
+
CD25
+
 T cells and confers regulatory T cell functions on CD4
+
CD25
-
 cells.  This is 
accomplished through upregulation of FOXP3 mediated by EP2/EP4 binding (251-253)  Further, 
adaptive Treg cells have been shown in vitro to produce PGE2, although this production is not 
observed by naturally occurring Treg cells (253).   
Other cell populations involved in atopic immune responses can also be influenced by PGE2.  
Actions of PGE2 on B cells are complex.  In vitro data generated using murine B cells suggests that 
while exogenous PGE2 enhances production of IgE from uncommitted B cells by promoting class 
switching to the ε transcript, it also suppresses maturation and proliferation of these cells.  These 
functions are mediated through binding of EP2/EP4 and upregulation of cAMP (254-256).  Other 
works have argued that PGE2 can suppress IgE formation (257).  Mast cells, which bind IgE, can also 
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be influenced by this prostanoid.  Both in vitro and in vivo data generated in mice supports a role for 
this prostanoid in mast cell recruitment and degranulation through an EP3 dependent mechanism 
which becomes more pronounced with age (258-260).  These findings have been corroborated using 
human mast cells (261).   
Prostacyclin 
 Prostacyclin (PGI2) is another prostanoid produced downstream of COX signaling.  
Discovery of this prostanoid occurred in 1976 when Vane et al. isolated an enzyme from the aortas of 
sheep and pigs that was found to inhibit platelet aggregation (262).  PGI synthase (PGIS) is 
responsible for the conversion of prostacyclin from the intermediate PGH2.  This synthase is a 
hemoprotein originally purified from bovine aorta in the early 1980’s and is a cytochrome p450 
(263).  PGIS colocalizes with both COX-1 and COX-2 in the nuclear envelope and endoplasmic 
reticulum (264).  Following its synthesis, PGI2 can be released into the extracellular milieu where it 
binds to the I-prostanoid (IP) receptor which, like the EP2 and EP4 receptors, preferentially couples 
with Gs and activates adenylyl cyclase to elevate intracellular cAMP levels.  Accumulating evidence 
suggests that endogenously produced PGI2 may also be capable of entering the nucleus and activating 
peroxisome proliferator activated receptors (265).  PGI2 is unstable under physiological conditions, 
giving it a very short half-life of less than 2 minutes in vivo before it is metabolized to its inactive 
form, 6-keto-PGF1α (266).   
PGI2 is known most notably for its profound effects on the cardiovascular system.  Indeed, 
prostacyclin is the most abundant prostanoid produced in vascular tissues with endothelial cells 
representing the most significant source of this mediator (267).  Synthesis of PGI2 is often coupled 
with COX-2 and it is believed that the cardiovascular risks associated with the use of coxibs results 
from inhibition of prostacyclin (268).  In the vasculature, PGI2 is a potent vasodilator and its release is 
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critical for preventing platelet aggregation, dispersing existing aggregates, relaxing and inhibiting 
proliferation of vascular smooth muscle cells, suppressing atherogenesis and controlling leukocyte 
adhesion (268-271).   
Similar to PGE2, the capacity of prostacyclin to relax smooth muscle cells and blood vessels 
is important in systems beyond the cardiovascular system.  PGI2 is produced at high levels by the 
kidneys and mice lacking PGIS develop kidney abnormalities (272).  In vivo work shows this 
prostanoid contributes to renal blood flow and renin production and secretion (273).  These attributes 
also contribute to inflammation.  Mice lacking the IP receptor have reduced edema and vascular 
permeability in models of inflammation (274, 275) and this prostanoid is also implicated in 
nociceptive pain (274).  Further, IP-deficient animals have attenuated arthritic scores compared to 
wildtype controls (276).   
Prostacyclin can also serve as a protective mediator.  An analog of this prostanoid, iloprost, is 
used in the treatment of pulmonary arterial hypertension where it has been shown to improve overall 
symptoms and confer a survival benefit (277).  Similarly, PGI2 appears to be beneficial in the 
prevention of idiopathic pulmonary fibrosis.  Animals lacking the IP receptor are more susceptible to 
bleomycin-induced pulmonary fibrosis and treatment with iloprost is protective against this form of 
pulmonary fibrosis when administered to wildtype mice (278, 279).     
Prostacyclin and Leukocytes 
Like PGE2, prostacyclin has profound effects on immune cells.  DCs express the IP receptor 
and are capable of producing at least modest quantities of PGI2 (280).  In vitro stimulation of bone 
marrow derived DCs with various prostacyclin analogs suppresses maturation and upregulation of 
costimulatory molecules including CD86, CD40, and MHC II (281, 282).  Additionally these analogs 
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inhibit the release of cytokines including IL-12, TNF-α, and IL-6 from DCs in a dose-dependent 
manner while enhancing the production of IL-10 (281), suggesting that PGI2 has an anti-
inflammatory effect on DC activity.  These actions are controlled, in part, by IP-dependent protein 
kinase A (PKA) activation, given that the effects of these analogs were not observed in IP -/- mice 
and were attenuated when stimulation occurred in the presence of a PKA inhibitor (282).  Further, 
analog stimulation suppresses the ability of DCs to promote T cell proliferation.  BALB/c-derived 
OVA-specific TCR (DO11.10) TH2 cells cocultured with analog-treated OVA-pulsed DCs produce 
attenuated TH2 cytokines IL-4, IL-5 and IL-13 and elevated quantities of IFN-γ and IL-10 (281, 282).   
Evidence suggests that naïve CD4
+
 cells are not a source of prostacyclin (280).  Further, 
while exceptions have been noted (280), expression of the IP receptor is not typically observed on 
these cells (283, 284), suggesting that PGI2 does not directly mediate differentiation into effector T 
cell populations.  Like naïve CD4
+
 cells, committed T cells do not produce PGI2 (283), however 
upregulation of the IP receptor is identified, to various degrees, by different TH cell types. While 
reports are in agreement that activated TH2 cells express high levels of this receptor (283, 284), there 
is disagreement in the field regarding IP expression on TH1 cells.  While some groups observe 
elevated levels of IP expression on this cellular population, others indicate that there is little to no 
expression of this receptor on TH1 cells (283-285). 
The impact of prostacyclin on TH1 cells is not clearly defined.  In one in vitro study, murine 
TH1 cells restimulated in the presence of PGI2 analog produced reduced levels of IFN-γ (285).  
However, when another group restimulated DO11.10 TH1 cells, IFN-γ levels were unaffected by the 
addition of prostacyclin (284) and a third study found that analog enhanced IFN-γ levels (280).  The 
responses of TH1 cells in the presence of PGI2 or its analogs may depend on the strength of 
costimulatory signals.  IFN-γ production was reduced when CD28 engagement was absent (285); 
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however, iloprost significantly enhances production of IFN-γ from TH1 cells in an anti-CD28 dose-
dependent manner, even when IL-12 is absent (280).  In vivo findings are equally ambiguous, and 
suggest that PGI2-mediated responses on TH1 cells may be organ-specific.  In a model of respiratory 
syncytial virus (RSV) mice overexpressing PGIS in the respiratory epithelium have significantly 
reduced disease and IFN-γ protein expression in the lung while IP -/- animals have augmented lung 
IFN-γ protein (286).  However, prostacyclin augments inflammation in a TH1-biased contact 
hypersensitivity model (280). 
The actions of prostacyclin on TH2 cells are equally controversial.  In one study, in vitro TH2 
cells cocultured with prostacyclin analog during restimulation produced attenuated levels of IL-4, IL-
10, and IL-13 (285).  However, a separate group has consistently observed that TH2 cells produce 
comparable levels of IL-4 and IL-5 regardless of the presence of PGI2 analog, instead measuring 
augmented IL-10 (284).  It has also been demonstrated that unlike TH1 cells, iloprost reduces the 
number of IL-4 producing cells regardless of the degree of CD28 engagement (280).   
Little is known regarding the effect of prostacyclin on TH17 and Treg cells; however, 
experimental evidence suggests that both TH17 cells and CD4
+
CD25
+
Foxp3
+
 express the IP-receptor, 
suggesting that this mediator can indeed influence these cell types (283, 287)  A recent report 
indicates that PGI2 augments TH17 responses in the lung.  Using an OVA/alum model, Li and 
colleagues demonstrate that inflamed COX-2 deficient mice have reduced levels of TH17 cells and 
TH17 cytokines in their lungs and airways.  TH17 levels and IL-17a cytokine quantities could be 
restored when CD4
+
 T cells were pretreated with a prostacyclin analog or when PGI2 was 
administered by osmotic pump (287).   
Recently, work was conducted to elucidate the actions of prostacyclin on AMs.  This study 
found that while AMs express the IP receptor, PGI2-mediated responses in these cells are weak 
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compared to the responses by peritoneal macrophages (PMs) to prostacyclin.  In vitro analysis reveals 
that while prostacyclin analog has potent inhibitory effects on phagocytosis, cytokine release, and 
bacterial killing in PMs while only weakly controlling these responses in AMs (288).   
Prostanoids in Lung Allergy 
The relevance of prostanoids to asthma and lung inflammation is highlighted by the existence 
of aspirin-exacerbated respiratory disease (AERD) first described in 1922 by Widal, representing a 
severe form of asthma in which use of aspirin or other NSAIDs initiates an allergic response in 
asthmatic individuals.  Symptoms of AERD include bronchospasms, profuse rhinorrhea, nasal 
congestion, sneezing, and itching.  In severe instances, episodes of AERD can result in life-
threatening anaphylactic reactions.  The exact prevalence of AERD is unclear, given that many 
asthmatics avoid the use of NSAIDs or may not correlate worsening symptoms with NSAID 
ingestion; however review of studies administering aspirin challenges placed the prevalence of AERD 
at 20% in asthmatics.  Patients with AERD tend to have elevated levels and activation of eosinophils 
and mast cells. (289) 
The expression of COX enzymes in the airways of asthmatics is controversial.  While some 
studies fail to see upregulation of either enzyme in these individuals, other reports have observed 
increased levels of one or both isoforms (290-292).  Studies using genetically-engineered animals 
lacking these enzymes and the use of pharmaceutical agents which alter the functions of COX 
isoforms have enhanced our knowledge regarding the contribution of prostanoids to allergy in the 
lung (Table 1.1).  When lung allergy is induced, mice lacking either COX-1 or COX-2 have an 
augmented allergic response compared to wildtype (WT) animals, with elevated eosinophilia, IgE, 
and mucus production (182) suggesting that the ultimate effect of COX-dependent prostanoid 
production is to limit allergic responses in the lung.  These finding are corroborated by studies 
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conducted using COX-inhibitors (293, 294).  The degree to which each isotype promotes this 
protection and the range of allergic responses effected, however, is controversial.  For instance, these 
works disagree on the ability of the individual COX isoforms to prevent AHR.  Some data suggests 
that inhibition of COX-1 is more detrimental in the lung than COX-2, while other works find an equal 
contribution from each isoform. (182, 293, 294) 
A loss of all prostanoid production by either COX enzyme may exacerbate allergy in the 
respiratory system; however, the contribution of individual prostanoids to this process is more 
complex.  Research demonstrates that production of some of these prostanoids exacerbate disease 
manifestations. This implies that in addition to preventing pulmonary allergy, prostanoid production 
can also contribute to disease.  PGD2 is released in abundance by activated mast cells and is believed 
to promote the pro-inflammatory responses generated by these cells following allergen challenge in 
the lung (295).  Results generated from overexpression of the PGD2 synthase in the mouse lung are 
consistent with this assumption.  These mice experience exacerbated allergy in response to antigen 
sensitization and challenge marked by elevated eosinophilia and TH2 cytokine levels (296).   
Actions of PGD2 occur through binding to the D prostanoid 1 (DP1) receptor and 
chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2, DP2).  Immunized 
mice lacking the DP1 receptor display attenuated inflammation and airway responses following 
allergen challenge (297).  CRTH2 is thought to be involved in leukocyte trafficking.  Consistent with 
this, agonists for this receptor initiate recruitment of eosinophils (298, 299); however the use of 
CRTH2-deficient animals to elucidate the role of endogenous signaling has proven controversial.  
Dependent on the genetic background of the animals used, CRTH2-deficient mice display no 
differences in disease parameters or enhancement of allergy (298, 300)   
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TXA2 binds to the T prostanoid (TP) receptor to exert its functions.  This prostanoid is known 
most notably for its role in platelet aggregation.  Data generated in our lab suggests that although loss 
of the TP -/- receptor does not alter pulmonary inflammation, a TP-agonist induces 
bronchoconstriction in naïve animals and AHR in the inflamed murine airway (301).  The functions 
of PGF2α are most well-studied in the female reproductive system where this prostanoid contributes to 
the birthing process (218).  Data regarding the function of this prostanoid in lung allergy is scare 
however studies suggest that this mediator promotes airway constriction and plasma exudation (302, 
303).  
Prostaglandin E2 and Lung Allergy 
Elevated levels of PGE2 are measured in the sputum and plasma of asthmatic individuals 
(304-306).  Further, PGE2 is produced by many cell types which contribute to disease in asthma 
including epithelial cells, ASM cells, AMs, and DCs, with an even broader range of cells expressing 
the receptors for this mediator (307-309).  Evidence supporting both pro- and anti-inflammatory 
functions in asthmatic responses has been described for this prostaglandin.   
PGE2 is generally considered a potent bronchodilator.  PGE2 administration can limit AHR in 
asthmatic individuals and rodents (302, 310-314) and can also inhibit airway constriction in exercise 
and aspirin-induced asthma (315, 316).  However, a subclass of individuals develop heightened 
bronchoconstriction in response to PGE2 (302, 317) and administration is often associated with a 
coughing reflex (318) , limiting its usefulness as a clinical prophylactic. The ability of PGE2 to serve 
as an airway relaxant has been assigned to selective EP2 receptor binding, while the adverse effects 
are likely due to activation of cholinergic neurons by alternate EP receptors (319).  
Animal models have also provided some evidence that PGE2 may contribute to aspects of 
airway disease, however the exact nature of this mediation is unclear. In a model of OVA-induced 
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lung allergy, mice lacking the EP3 receptor developed elevated eosinophilia and augmented TH2 
cytokine production, while OVA-specific IgE production was unaffected by signaling through this 
receptor (320).  However in a pulmonary allergy model using house dust mite antigen, animals 
lacking the mPGES1 synthase and wildtype animals had similar levels of IgE, BALF cell infiltrate 
and eosinophilia while showing augmented airway remodeling (321).  These results suggest that the 
effects of PGE2 in the airway are complex and may differ depending on the model being studied. 
Prostacyclin and Lung Allergy 
In the lung PGI2 is generally thought to be protective.  For example, PGI2 is thought to limit 
disease associated with respiratory syncytial virus (RSV).  In a murine model of this condition, 
animals overexpressing PGIS in the lung were protected compared to wildtype animals, while mice 
lacking the IP-receptor had augmented illness (286).  Further, this prostanoid appears to ameliorate 
bleomycin induced ideopathic pulmonary fibrosis.  Animals lacking the IP receptor have augmented 
disease while administration of iloprost is protective (278, 279).  Prostacyclin analogs are also used as 
an effective treatment for pulmonary arterial hypertension in humans (322). 
Studies analyzing the contribution of PGI2 to lung allergy suggest that this mediator 
attenuates all phases of disease.  When either acute or chronic allergy are induced following 
sensitization and challenge with OVA antigen, mice lacking the IP-receptor have elevated cellularity 
in their BALF, predominantly reflecting augmented eosinophilia.  Further, these receptor-deficient 
animals have enhanced IgE levels, elevated vascular permeability, and exacerbated TH2 cytokines 
(323, 324).  Additionally, when chronic lung allergy is induced, IP-deficient mice have significantly 
elevated TGF-β1 and hydroxyproline levels.  Histological analysis additionally reveals augmented 
goblet cell hyperplasia and collagen deposition in these mice (324).  Splenocytes from sensitized 
animals produced enhanced quantities of IL-4 and IFN-γ when restimulated with OVA (323).  
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Immunoglobulin levels in IP-deficient mice and their ex vivo splenocyte responses suggest 
that PGI signaling contributes to allergic sensitization.  Idzko et al. employed a model in which 
antigen sensitization can be tracked.  When tolerogenic pDCs are depleted from the lung, exposure of 
the airways to antigen causes sensitization and lung allergy following subsequent antigen challenge.  
This response relies on antigen presentation by mDCs (81).  Adoptive transfer of OVA-pulsed mDCs 
into the airways of naïve pDC-depleted mice results in eosinophilia, goblet cell hyperplasia, and 
elevated BALF TH2 cytokine levels.  In vitro treatment of OVA-pulsed mDCs with iloprost prior to 
adoptive transfer significantly abolishes disease parameters in recipients, supporting the idea that 
PGI2 mediates allergic sensitization in the airways.  In addition, lymph node cells obtained from 
animals receiving iloprost treated OVA-pulsed mDCs produced attenuated levels of TH2 cytokines 
when restimulated; however, IFN-γ and IL-10 cytokine levels were enhanced in these populations. 
(282) 
Conversely, data indicates that PGI2 can independently contribute to the effector phase of 
lung allergy.  Administering iloprost to sensitized animals prior to each antigen challenge 
significantly reduces eosinophilia, AHR, and goblet cell hyperplasia.  Further, restimulated lymph 
node cells from these animals produce attenuated TH2 cytokine quantities (282).   
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Figure 1.1 Differentiation of Naïve T Cells 
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Figure 1.1 Differentiation of Naïve T cells  The differentiation of naïve T cells into specific 
effector  T cell subsets is controlled by the cytokines present during stimulation with antigen.  TGF-β 
or IL-10 leads to the production of regulatory T (TReg) cells.  Differentiation into the helper classes 
TH1, TH2, or TH17 occurs in the presence of IL-12, IL-4, or TGF-β and IL-6 respectively.  IL-23 
stabilizes and expands the TH17 population.  These classes of T cells release unique cytokine profiles 
to exert their effects on immune responses.  
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Figure 1.2 Sensitization to Antigen 
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Figure 1.2 Sensitization to Antigen  Particles entering the airway lumen can be sampled by 
dendritic cells (DCs) forming tight junctions with the epithelium.  When an antigen is taken up, DCs 
undergo a maturation process and travel to local lymph nodes where they can present antigen to naïve 
T cells.  Activation occurs through interactions with the major histocompatibility complex (MHC) II, 
as well as other costimulatory receptors and, in the presence of IL-4, results in the acquisition of TH2 
characteristics.  These antigen-specific TH2 cells undergo expansion and produce large quantities of 
IL-4 and IL-13.  Interaction of these TH2 cells with costimulatory molecules on B cells initiates 
immunoglobulin class-switching resulting in the production of antigen-specific IgE antibody.  IgE 
diffuses out of the lymph nodes and binds to the high-affinity receptor for IgE (FcεRI) on mast cells 
and basophils, sensitizing them to respond upon subsequent exposure to antigen.  
     
  
 
40 
 
Figure 1.3 Acute Allergic Response in the Lung 
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Figure 1.3 Acute Allergic Response in the Lung  When an allergen gains entry to a previously 
sensitized host, it is taken up by DCs and presented to antigen-specific TH2 cells circulating the 
mucosal system.  Activated effector T cells release specific cytokines into the airways resulting in the 
symptoms associated with allergy in the lung including airway hyperresponsiveness (AHR), cell 
recruitment, vasodilation, elevated vascular permeability, and increased mucus.  Antigen can also 
bind and aggravate FcεRI/IgE complexes on mast cells resulting in degranulation and the release of 
preformed mediators as well as de novo synthesized factors, which exacerbates allergic responses in 
the airway.  
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Figure 1.4 Prostanoid Biosynthesis Pathway 
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Figure 1.4 Prostanoid Biosynthesis Pathway  Prostanoids are synthesized by the actions of 
cyclooxygenase (COX) enzymes on arachidonic acid (AA).  AA is released from the plasma 
membrane by phospholipases and converted into unstable intermediate products, prostaglandin G2 
(PGG2) and prostaglandin H2 (PGH2) by two isoforms of the COX enzyme, COX-1 and COX-2.  The 
intermediate PGH2 is converted to 5 bioactive prostanoids: thromboxane (TXA2), prostacyclin (PGI2), 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α) through synthesis 
by prostanoid-specific synthases.  Prostanoids exert their autocrine and paracrine effects through 
binding to specific G-coupled protein receptors.  Common analgesics, non-steroidal anti-
inflammatory drugs (NSAIDs), inhibit the actions of COX enzymes, thus preventing synthesis of 
prostanoids.
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Table 1.1 In Vivo Contributions of Prostanoids to Pulmonary Allergy 
Mouse  Treatment Model Eos  IgE Th2 cyto Mucus AHR Remod Reference 
COX-1 -/-    Acute OVA/alum  ↑ ↑ ↑ ↑ ↑   Gavett 1999 
COX-1 -/-    Acute OVA/alum  ↑ ≈ ↑   ≈   Church 2012 
COX-2 -/-    Acute OVA/alum  ↑ ↑ ≈ ↑ ≈   Gavett 1999  
COX-2 -/-    Acute OVA/alum  ↑ ≈ ↑   ≈   Church 2012 
WT non-specific COX inhibitor Acute OVA/alum   ≈ ↑ ≈ ↑   Peebles 2000 
WT COX-1 inhibitor Acute OVA/alum ≈   ↑ ≈ ↑   Peebles 2002 
WT coxib Acute OVA/alum ≈   ↑ ≈ ↑   Peebles 2002 
WT TH2  DO11.10 + coxib Adoptive Transfer ↑   ↑ ↑ ↑   Jaffar 2002 
DP -/-   Acute OVA ↓ ≈ ↓ ↓ ↓   Matsuoka 2000 
CRTH2 -/-    Acute OVA/alum ↑           Chevalier 2005 
CRTH2 -/-    Acute OVA/alum ≈           Shiriashi 2008 
PGDS tg 
+   Acute OVA/alum ↑ ≈ ↑       Fujitani 2002 
WT TXA2 Analog Acute OVA/alum         ↑   Allen 2006 
TP -/-   Acute OVA/alum ≈ ≈ ≈ ≈     Allen 2006 
WT  PGF2α Analog naïve          ↑   Arakawa 1993 
EP3 -/-   Acute OVA ↑ ↑ ↑       Kunikata 2003 
mPGES1 
-/-   Chronic der f ≈ ≈   ↑   ↑ Lundequist 2010 
mPGES1 
-/-   Acute OVA/alum ↓ ≈ ↓   ≈   Church 2012 
IP -/-   Acute OVA/alum ↑ ↑ ↑       Takahashi 2002 
IP -/-   Chronic OVA/alum ↑ ↑ ↑     ↑ Nagao 2003 
WT TH2  DO11.10 /coxib Adoptive Transfer ↑   ↑ ↑ ↑   Jaffar 2002 
WT TH2  DO11.10/PGI2 Analog Adoptive Transfer ↓   ↓   ↓   Jaffar 2007 
WT PGI2 Analog Acute OVA/alum ↓   ↓ ↓ ↓   Idzko 2007 
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Table 1.1 In Vivo Contributions of Prostanoids to Pulmonary Allergy  Animals are a useful tool for 
delineating the in vivo contributions of a specific factor in a desired system through the use of 
genetic-engineering and pharmacological reagents.  This table summarizes the major findings 
observed in the airways when aspects of the prostanoid pathway are manipulated. (Model identifies 
the manner in which an animal was sensitized.)  
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CHAPTER II 
PGE2 PRODUCED BY THE LUNG AUGMENTS THE EFFECTOR PHASE OF 
ALLERGIC INFLAMMATION
1 
 
 
Prostanoids are a family of bioactive lipid mediators produced in almost every cell type by 
the actions of prostaglandin-endoperoxide synthases (cyclooxygenase, COX) on arachidonic acid 
(AA).  Synthesis is initialized when phospholipase A2 releases AA from membrane phospholipids in 
response to a diverse range of stimuli.  The AA is then catalyzed to prostaglandin H2 (PGH2) by one 
of two isoforms of the COX enzyme, COX-1 or COX-2 (218, 325)  COX-1 is constitutively 
expressed by most cell types and is thought to be responsible for basal levels of prostanoid production 
while COX-2 expression is generally undetectable in most tissues under homeostatic conditions and is 
upregulated in response to inflammatory stimuli (218), although exceptions have been noted.  For 
example, COX-1 expression increases dramatically in the lactating mammary gland (189) and COX -
2 expression can easily be detected in the healthy lung of both mice and humans (186, 197).  PGH2 
generated by either COX -1 or COX -2 is subsequently converted into a family of related molecules: 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), prostacyclin (PGI2), 
and thromboxane A2 (TXA2) by pathway specific synthases. These lipids mediate their actions 
through the selective binding to G-coupled protein receptors, each with a unique but overlapping 
pattern of expression (218, 325).  PGE2 binds with a high affinity to four receptors, E prostanoid (EP) 
1-4, all of which are expressed in the lung (326, 327).   
1
 Church, R.J., L.A. Jania, and B.H. Koller. 2012. Prostaglandin E2 produced by the lung augments the 
effector phase of allergic inflammation. J Immunol 188(8):4093-102 
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PGE2 levels are elevated during most inflammatory responses; however, elevated synthesis of 
this lipid mediator may reflect an attempt by the organism to limit ongoing inflammation and protect 
the airways from collateral damage.  Certainly, PGE2 mediated pathways capable of limiting 
inflammation and restoring homeostasis in the lung have been identified.  PGE2 is a potent smooth 
muscle relaxant and through the EP2 receptor can limit constriction of the airways (319).  Indeed, 
administration of this mediator into the airways ameliorates airway hyperresponsiveness (AHR) 
caused by several bronchoconstrictive agents in humans and animals (302, 310-314) and attenuates 
aspirin-induced and exercise-induced bronchoconstriction (315, 316).  PGE2 can induce ion secretion 
and thus alter the composition of the airway surface liquid, facilitating mucociliary clearance (328).  
Furthermore, exogenous PGE2 can limit T cell proliferation and TH1 type cytokine release from LPS-
stimulated macrophages through stimulation of the EP2 and EP4 receptors, respectively (246).  In 
addition to its capacity to down-regulate pro-inflammatory cytokine release from immune cells, PGE2 
can also stimulate release of IL-10, a cytokine generally thought to be protective in the immune 
system (329).     
 Perhaps the strongest indication that PGE2 might function to limit allergic inflammation in 
the lung comes from animal studies conducted using pharmacological and genetic approaches to limit 
prostaglandin synthesis in a model of ovalbumin (OVA) induced lung allergy.  Mice of mixed genetic 
background and lacking either COX -1 or COX -2 were reported to develop far more severe disease 
than wildtype animals (182).  Consistent with this, treatment of mice with indomethacin, a non-
steroidal anti-inflammatory drug (NSAID) which suppresses the actions of both COX -1 and COX -2, 
or alternatively, with COX-specific NSAIDs induced elevated eosinophilia and IL-13 production in 
the lung (293, 294); although these approaches did not allow for the identification of the specific 
prostaglandin(s) responsible for limiting the allergic response.  Another study, however, reported 
increased allergic inflammation in mice lacking EP3 receptors (320), suggesting that loss of PGE2 is at 
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least partly responsible for heightened inflammation observed in COX-deficient and NSAID treated 
animals. 
PGE2 production occurs through the metabolism of PGH2 by the microsomal PGE2 synthase-
1 (mPGES1) (197).  While initially two additional enzymes, cytosolic PGE2 synthase (cPGES) and 
microsomal PGE2 synthase-2 (mPGES2) were thought to be capable of this enzymatic conversion, 
studies using mutant mouse lines carrying mutations in the genes for these synthases, mPges1, 
cPges/p23 or mPges2 respectively, have failed to support this in vivo function for any product other 
than mPGES1 (199, 201, 204).  mPGES1 is expressed in many tissues and cell types of both humans 
and animals, including in the lung and leukocytes (197, 330, 331).  Similar to COX-2, the expression 
of mPGES1 increases dramatically in response to inflammatory mediators suggesting coupling with 
this enzyme; however, evidence demonstrates that mPGES1 can couple with both COX-1 and COX-2 
to synthesize PGE2 (197-199, 330).  Furthermore, studies using mice lacking mPGES1 in models of 
pain nociception, rheumatoid arthritis, atherogenesis, and abdominal aortic aneurysm provide 
evidence that this synthase contributes to the pathogenesis of both acute and chronic inflammation 
(199, 200, 332, 333).  
Here we elucidate the contribution of mPGES1-derived PGE2 in the development of allergic 
lung disease, a mouse model of asthma.  First, using congenic mouse lines lacking either COX-1 or 
COX-2, we confirm the role of this pathway in our model.  We then evaluate the role of PGE2 
produced by mPGES1 expressed by resident airway cells and PGE2 released from recruited 
inflammatory cells in this allergic response.  
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Materials and Methods 
Experimental Animals 
All animal colonies were maintained according to standard guidelines as defined by the NIH Guide 
for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committee guidelines of the University of North Carolina at Chapel Hill. Experiments were 
carried out on age and sex matched mice between 8-12 weeks of age.  C57BL/6 (B6) (backcrossed  
>10 generations) COX-1 -/-, B6 x 129S6/SvEv (129) fililal generation (F)1 COX-2 -/-, and B6 
(backcrossed >10 generations) mPGES1 -/- (187, 199, 334).  B6 OVA-Specific TCR-Transgenic 
(OT-II) mice were purchased from The Jackson Laboratories (Bar Harbor, Ma).  OT-II mice were 
crossed to mPGES1 -/- mice to generate OT-II/mPGES1 -/- animals.  
OVA Sensitization and Challenge 
All mice were sensitized systemically on days 0 and 14 with an i.p injection of 40µg OVA (Sigma-
Aldrich) emulsified in aluminum hydroxide (alum) (Sigma-Aldrich).  One week following the second 
injection, experimental mice were challenged for 5 consecutive days (days 21-25) with an aerosol 
instillation of 1% OVA in 0.9% sodium chloride (NaCl) for 1 hour each day.  Control animals were 
challenged with 0.9% NaCl only.  24 hours after the final challenge, lung mechanics were measured 
and bronchoalveolar lavage fluid (BALF), serum, and whole lungs were collected for further analysis.  
For experiments examining allergic sensitization, animals were immunized as described and 
harvested on day 21. 
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Measurement of Cell Proliferation 
Splenocytes were prepared by mechanical dispersion of spleen over a 70 μm cell strainer (BD 
Falcon).  Red blood cells were lysed in lysis buffer (4.1g  NH2Cl, 0.5g KHCO3, 100 μl 0.5M EDTA 
dissolved in 500 ml dH20) and splenocytes were washed twice in PBS.  Cells were plated at a density 
of 2.5 X 10
6
 cells/ml in RPMI 1640 media enriched with 10% FBS, 100 units/ml penicillin, 100 
units/ml streptomycin, and .29 µg/ml L-glutamine.  OVA was added to splenocyte cultures at 
concentrations ranging from 0 µg /ml to 100 µg/ml.  After incubation for 72 hours at 37°C, cell 
proliferation was assessed using WST-1 reagent (Roche) according to the manufacturer’s instructions.  
Measurement of Airway Mechanics in Intubated Mice 
Mechanical ventilation and airway mechanic measurements were conducted as previously described 
(335).  Briefly, mice were anesthetized with 70-90 mg/kg pentabarbitol sodium (American 
Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated with a 
computer-controlled small-animal ventilator.  Once ventilated, mice were paralyzed with 0.8 mg/kg 
pancaronium bromide.  Forced Oscillatory Mechanics (FOM) was measured every 10 seconds for 3 
minutes.  These measurements allowed for the assessment of airway resistance in the central airways 
(Rn), as well as in tissue damping (G).  Increasing doses (between 0 and 50mg/ml) of methacholine 
chloride (Mch) were administered to animals through a nebulizer to measure airway 
hyperresponsiveness (AHR).  These data are presented as percent above baseline. 
BALF Collection and Cell Counts 
Following measurements of lung mechanics, mice were humanely euthanized.  Lungs were lavaged 
with five 1ml aliquots of HBSS (Gibco).  100µl of BALF was reserved for cell count analysis and 
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total cell counts were measured by hemacytometer.  Differential cell counts were collected using 
cytospin preparation stained with Hema 3 and/or Fast Green.  All remaining BALF was centrifuged to 
remove cells, and stored at -80° c for immunoassay. 
PGE2, IgE and Cytokine Production 
Levels of cytokines and PGE2 were determined by immunoassay in BALF, lung tissue homogenate, 
and/or tissue culture supernatant.  To determine cytokine production by stimulated splenocytes, cells 
were prepared as described above.  Cells were cultured at a density of 1 X 10
7
 cells/ml in the presence 
of 100 μg/ml OVA.  After 72 hours, supernatants were collected and stored at -80°C prior to 
evaluation by ELISA.  To determine lung cytokine levels, lungs were flash frozen in liquid nitrogen, 
weighed, and stored at -80°C. Lung tissue was pulverized and homogenized in buffer containing 150 
mM NaCl, 15 mM Tris-HCl, 1mM CaCl2, 1mM MgCl2 supplemented with protease inhibitor 
(Roche).  Values shown represent the total quantity of cytokine or mediator measured divided by 
tissue weight.  Cytokines were determined by ELISA following manufacturer’s protocols:  IL-13 
(R&D Systems), IFN-γ (R&D Systems), IL-4 (R&D) and IL-17a (eBiosciences). For quantification of 
PGE2, lung tissue was pulverized then homogenized in 1XPBS/1mM EDTA and 10 µM 
indomethacin.  Lipids were purified through octadecyl C18 mini columns (Amersham Biosciences for 
mPGES1; Alltech Associates for COX-1 and COX-2), and prostanoid content was determined using 
an enzyme immunoassay kit (Assay Designs) according to the manufacturer's instructions.  Blood 
was obtained by cardiac puncture, allowed to coagulate, and centrifuged to isolate serum.  IgE levels 
were determined by immunoassay using 96 well EIA/RIA plates (Costar).  Plates were coated with 
IgE capture antibody (Pharmingen; clone R35-72), blocked with 1% BSA/PBS and then incubated 
with IgE standard (Pharmingen) or serum followed by biotinylated rat anti-mouse IgE (Pharmingen; 
clone R35-118).  Detection was carried out using streptavidin-horseradish peroxidase (HRP) 
     
  
 
52 
 
(Pharmingen) and hydrogen peroxide /2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS).  Absorbance at 405nm was measured.   
Bone Marrow Chimera Generation 
Recipient mice were exposed to 5 grays irradiation from a Cesium g-irradiator at 0 and 3 hours.  
Femurs and tibias were collected from donor mice and flushed with cold PBS to isolate bone marrow.  
Bone marrow was introduced by tail vein injection into recipient mice immediately following the 
second round of radiation and after 8 weeks animals were sensitized and challenged with OVA.   
Statistical Analysis 
Statistical analysis was performed using Prism 4 (GraphPad Software).  Comparisons of the mean 
were made by F test, Student’s t-test or ANOVA followed by Tukey-Kramer’s HSD post hoc test as 
necessary.  Data are shown as mean ± SEM.  Differences with p<0.05 were considered statistically 
significant. 
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Results 
Allergic Asthma in the COX-1 and COX-2 deficient mice 
We first verified, using congenic mouse lines, the contribution of prostanoids to allergic lung 
disease induced by sensitization and challenge with OVA antigen.  COX-1 -/- B6 congenic mice were 
generated by >10 crosses between mice carrying a null allele at this locus and commercially 
purchased B6 mice.  COX-2 mice survive poorly on most inbred genetic backgrounds, in part due to a 
patent ductus arteriosus (190, 336), and thus most experiments assessing COX-2 function have 
utilized > F2 mice; mice expected to carry a random assortment of 129 and B6 derived alleles.  To 
circumvent this problem, we generated two lines of COX-2 mutant mice, the first line on the co-
isogenic 129 genetic background and the second congenic line on the B6 genetic background.  129 
COX-2 +/- females were intercrossed with B6 +/- males to generate congenic F1 progeny.  The COX-
2 -/- and COX-2 +/+ littermates were used in the experiments presented here.  Allergic airway disease 
was induced through sensitization by an i.p. injection of OVA emulsified in aluminum hydroxide and 
challenged with repeated aerosols of antigen.  Inflammation and airway mechanics were assessed 
twenty four hours after the final antigen challenge. 
As expected, our immunization protocol induced a robust cellular influx in B6 wildtype mice 
(COX-1 +/+), compared to saline treated animals (Fig 2.1A).  The F1 OVA-treated controls (COX-2 
+/+) displayed a similar pattern of increased cellularity.  Surprisingly, the loss of either COX-1 or 
COX-2 had comparable impacts on recruitment of cells into the airways: in each line, the total 
number of cells recovered by BALF was about twice that observed in the genetically matched 
controls.  The cellular infiltrate present in the airways following antigen challenge was marked by 
heightened levels of eosinophils, typical of TH2 type allergic responses (Fig 2.1B).  Characteristic of 
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this type of response, IL-13 levels were elevated in the BALF of wildtype mice with allergic lung 
disease compared to saline controls (Fig 2.1C).  Loss of either COX-1 or COX-2 led to increased 
levels of this cytokine in the airways. Again the magnitude of this increase, relative to the wildtype 
control, was surprisingly similar in the two lines.  Elevated IgE levels were observed in both B6 
COX-1 +/+ and B6/129 F1 COX-2 +/+ wildtype animals (Fig 2.1D).  However, unlike inflammatory 
disease in the lung, the loss of neither the COX-1 nor the COX-2 pathway significantly altered levels 
of this immunoglobulin isotype.  AHR following challenge with methacholine (Mch), a potent airway 
constrictor, was quantified in intubated animals using a computer-controlled small-animal ventilator.  
This method allows for measurement of resistance in the central airway (Rn) and tissue damping (G).  
As reported previously for the B6 strain (337-339), we failed to observe AHR in response to Mch in 
mice with allergic lung disease.  This was also true of the B6/129 F1 mice.  Even in the COX-1 and 
COX-2 mice, which showed elevated levels of inflammation, no difference was observed in the 
response to methacholine in either parameter (Fig 2.2). 
Contribution of mPGES1 to PGE2 production in the naïve and inflamed lung 
The ability to catalyze the conversion of PGH2 to PGE2 has been assigned to three distinct 
enzymes, mPGES1, mPGES2 and cPGES (197, 340, 341).  However, studies using mutant mouse 
lines have shown in vivo alteration of PGE2 levels only in the mPGES1 mice (199, 342). We therefore 
first determined whether PGE2 levels are elevated in this model of allergic lung disease and if so, 
whether this increase is dependent on the mPGES1 synthase.  Allergic lung disease was induced in 
congenic mPGES1 -/- mice and their B6 controls (mPGES1 +/+), as described above.  Lungs were 
harvested and the levels of PGE2 were determined by enzyme immunoassay (Fig 2.3).  PGE2 
production could be detected in the lungs of healthy mice exposed to saline.  This production was 
significantly reduced in the lungs obtained from mPGES1 -/- mice, indicating that mPGES1 is active 
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in the normal lung and contributes to the basal levels of PGE2 in this organ.  PGE2 levels were 
substantially potentiated in the lungs of wildtype mice with allergic lung disease.  This increase was 
entirely dependent on expression of the mPGES1 synthase, indicating that animals lacking this 
synthase provide an appropriate model for determining whether loss of this COX1/2 downstream 
pathway contributes to the increased disease observed in the COX-1 and the COX-2 deficient 
animals.  
Impact of PGE2 on allergic lung inflammation 
PGE2 levels in the lung increase dramatically after allergic lung disease and this increase is 
absent in both the COX-1 and the COX-2 deficient mice (Fig 2.4), supporting the hypothesis that loss 
of this prostanoid could contribute to the increased disease observed in both of these mouse lines.  To 
test this hypothesis, mice lacking mPGES1, and their congenic controls, were sensitized and 
challenged, as previously described.  Twenty four hours after the final challenge, the impact of 
mPGES1 synthase on inflammation of the airways, IgE production and airway mechanics was 
assessed.  Surprisingly, and contrary to our prediction based on analysis with the COX-1/COX-2 
deficient mice, mice lacking mPGES1 had significantly less cellular infiltrate and associated 
eosinophilia in comparison to OVA-challenged wildtype animals (Fig 2.5A,B).  A significant 
decrease in IL-13 production was observed in the BALF of the mPGES1 -/- mice compared to 
wildtype control animals (Fig 2.5C).  No difference in serum IgE levels was observed between 
mPGES1-/- mice and their genetic controls (Fig 2.5D).  IL-4 production is critical for IgE isotype 
switching (343), therefore we characterized IL-4 concentrations present in lung homogenate 
following induction of allergy in this model (Fig 2.5E).  No difference was observed in the 
production of this TH2 cytokine between the inflamed lungs of wildtype and mPGES1 -/- mice.  To 
study this further, an additional experiment was carried out to examine proliferation and cytokine 
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production by splenocytes from immunized and challenged mice (Fig 2.6).  The proliferative 
response of the mPGES1 -/- cells to antigen did not differ significantly from that of control cultures 
(Fig 2.6A), nor was a significant difference observed in the production of IFN-γ or IL-17a (Fig 
2.6C,D).  Similar to the BALF, a decrease in IL-13 levels was observed in these cultures (Fig 2.6B), 
although in this case the decreased production by mPGES1 -/- cells did not achieve statistical 
significance.  
Changes in airway mechanics were determined, as previously described.  As was the case for 
the COX-1 and COX-2 deficient cohorts, inflammation and allergic airway disease induced using this 
immunization protocol did not result in AHR in any parameter, either in the wildtype animals or in 
the mPGES1 -/- line (Fig 2.7).     
 Effect of PGE2 on lung inflammation in mice carrying a transgenic OVA- specific T cell receptor   
The observation that IL-4 and IgE concentrations were unaffected by endogenous levels of 
PGE2 suggests that pro-inflammatory actions mediated by this prostanoid occur subsequent to the 
sensitization phase of antigen.  To explore this, we examined the induction of IgE and the response of 
splenocytes to antigen in sensitized animals prior to challenge with aerosolized antigen (Fig 2.8).  No 
difference was observed in serum IgE between wildtype and mPGES1-deficient mice (Fig 2.8A).  
Splenocytes isolated from wildtype and mPGES1 -/-  animals a week after booster sensitization 
demonstrate similar proliferative responses (Fig 2.8B) and no difference was observed in the 
production of IL-13, IFN-γ, or IL-17a between groups (Fig 2.8C-E).  Collectively, these results 
indicate that the reduced inflammation observed in the mPGES1 -/- lungs is unlikely to reflect 
alterations in the sensitization of mice to antigen, but rather the response of exposure of the lungs in 
sensitized animals to antigen.   
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To explore this further, we determined whether loss of mPGES1 would alter the development 
of allergic lung disease in OT-II mice.  These mice carry a transgenic T cell receptor specific to 
ovalbumin (344) and thus, exposure of the airways to this antigen results in inflammation in non-
sensitized animals.  In this case, however, the prominent cell type in the BALF is the neutrophil and 
thus this response is thought to model non-atopic allergic lung disease (345).  Mice lacking mPGES1 
were crossed to congenic B6 mice carrying the OT-II transgene to characterize the in vivo 
contribution of mPGES1 to the effector phase of allergic disease.  As expected, mice lacking the 
transgene, OT-II (-), showed little inflammation in response to OVA challenge (Fig 2.9A).  In 
contrast, robust cell recruitment was observed in transgenic wildtype mice.  Transgenic mPGES1 -/- 
animals showed a significant attenuation in cell infiltration compared to wildtype controls.  This 
attenuation reflects significantly fewer granulocytes present in the BALF of the mPGES1-deficient 
animals (Fig 2.9B).  In addition, IL-13 levels were assessed.  The levels of this cytokine in the 
BALF of wildtype animals was low, compared to that measured in OVA/alum sensitized animals, in 
agreement with the neutrophil-dominated response observed in this model. These levels were further 
reduced in animals lacking mPGES1, consistent with overall reduced levels of inflammation in the 
lungs of these mice (Fig 2.9C).  
Individual contributions of lung and recruited inflammatory cells to PGE2 mediated allergic 
responses 
As shown above, mPGES1 contributes to the PGE2 present in the healthy lung.  To determine 
the relative contributions of mPGES1 produced by the lung and that produced by the recruited 
immune cells to this model of allergic lung disease, we studied the development of allergy in bone 
marrow chimeras.  We first established that the contribution of mPGES1 to the allergic response was 
not altered in animals undergoing this experimental procedure.  The difference in the OVA-induced 
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cellularity of the BALF between wildtype mice irradiated and reconstituted with wildtype marrow 
(WT→WT) compared to that observed in mPGES1 -/- animals irradiated and reconstituted with 
autologous marrow [knockout (KO→KO)] recapitulated the differences observed between these 
groups in previous experiments (Fig 2.10 compared to Fig 2.5A).       
We next asked whether PGE2 produced by the immune cells recruited to the lung during 
allergic inflammation contributes to allergic airway disease.  To address this, wildtype mice were 
irradiated and reconstituted with either wildtype (WT→WT) or mPGES1-/- (KO→WT) bone 
marrow.  Reconstitution of mice with mPGES1-deficient bone marrow had only a modest impact on 
the inflammatory response; however, no statistically significant changes were seen in total BALF 
cellularity, eosinophil numbers, IL-13 production or serum total IgE (Fig 2.11A-D).   
Since the PGE2 produced by recruited immune cells contributed little to the inflammation in 
the lung, we next addressed the possibility that the primary source of this pro-inflammatory PGE2 was 
from the lung itself.  We evaluated whether mPGES1 -/- animals reconstituted with wildtype bone 
marrow (WT→KO) would have attenuated allergy compared to animals in which all cells are capable 
of producing PGE2 (WT→WT).  Lung inflammation was attenuated in OVA sensitized and 
challenged WT→KO animals compared to animals in which both the lung and the bone marrow 
express mPGES1 (WT→WT).  A significant decrease in BALF cellularity was observed, again 
primarily reflecting reduced recruitment of eosinophils (Fig 2.12A, B).  IL-13 production was also 
reduced in this group (Fig 2.12C).  These observations suggest that mPGES1 produced by cells in the 
lung, not recruited leukocytes, contributed to the development of allergic disease in response to 
ovalbumin.  Consistent with the studies reported above, IgE levels were not significantly affected by 
loss of lung mPGES1 (Fig 2.12D).   
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Figure 2.1 Effect of OVA Sensitization and Challenge on Inflammation in Congenic COX-1 and 
COX-2 -/- Mice  
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Figure 2.1 Effect of OVA Sensitization and Challenge on Inflammation in Congenic COX-1 and 
COX-2 -/- Mice  Mice were sensitized i.p with OVA and alum and challenged with aerosolized 
antigen. Twenty-four hours after the final challenge serum IgE and lung inflammation were assessed.  
A.  OVA exposed animals display an increase in the number of cells present in the BALF.  Higher 
total cell counts are observed in the BALF collected from mice lacking either COX-1 or COX-2 
compared to genetically matched controls (*,+ p<0.001).  B. Cell differentials determined for the 
BALF showed that this increase is due primarily to an increase in the number of eosinophils.  A 
significant increase in eosinophil numbers is observed in the wildtype OVA treated animals and this 
is further augmented in the COX-1 -/- and COX-2 -/- animals relative to the OVA treated controls (* 
p<0.001, + p<0.05).  C. IL-13 levels in the BALF of the COX-1 -/- and COX-2 -/- mice are also 
significantly higher than levels measured in the OVA-treated wildtype controls (* p<0.01, + 
p<0.001).  D.  OVA sensitization and challenge leads to increased total serum IgE, however, IgE 
levels do not differ significantly between COX deficient and control animals. (For COX-1: +/+ saline 
n=5, -/- saline n=4, +/+ OVA n=8, -/- OVA n=9; for COX-2: +/+ saline n=5, -/- saline n=4, +/+ OVA 
n=11, -/- OVA n=12)  
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Figure 2.2 Measurements of Airway Mechanics in COX-1 -/- and COX-2 -/- Mice 
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Figure 2.2 Measurements of Airway Mechanics in COX-1 -/- and COX-2 -/- Mice Airway 
mechanics were assessed in COX-1 -/- mice and their congenic controls (A) and COX-2 -/- mice and 
their congenic controls (B).  Anesthetized and intubated mice, attached to a computer-controlled 
small-animal ventilator, were exposed to increasing concentrations of aerosolized Mch and central 
airway resistance (Rn) and tissue damping (G) were assessed.  No significant differences are observed 
between any groups at any concentration for either parameter. (COX-1 data representative of 2 
independent experiments: +/+ saline n=7, -/- saline n=8, +/+ OVA n=15, -/- OVA n=13; for COX-2: 
+/+ saline n=5, -/- saline n=4, +/+ OVA n=11, -/- OVA n=12) 
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Figure 2.3 PGE2 Production by the Naïve and Allergic mPGES1 -/- Lung   
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Figure 2.3 PGE2 Production by the Naïve and Allergic mPGES1 -/- Lung  PGE2 levels were 
measured in lung homogenate, prepared from naïve mice or after sensitization and challenge with 
OVA.  In the naïve lung, concentrations of PGE2 are significantly attenuated in mPGES1 -/- mice 
relative to wildtype mice (* p<0.02).  PGE2 levels increase significantly in lungs collected from mice 
sensitized and challenged with OVA (+ p<0.05). In contrast no significant increase in PGE2 is 
observed in mPGES1 -/- mice. (mPGES1:  +/+ saline n=5, -/- saline n=5, +/+ OVA n=7, -/- OVA 
n=11)  
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Figure 2.4 Production of PGE2 in the Lungs of COX-1 and COX-2 Deficient Animals  
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Figure 2.4 Production of PGE2 in the Lungs of COX-1 and COX-2 Deficient Animals  PGE2 levels 
were assessed in lung homogenate obtained from naïve or OVA sensitized and challenged COX-1 -/- 
(A) or COX-2 -/- (B) mice and their congenic controls.  A.  The level of PGE2 measured in the lungs 
of naive COX-1 -/- mice is reduced compared to congenic wildtype controls (*p<0.05).  Following 
challenge with antigen in sensitized animals, wildtype mice have substantially elevated 
concentrations of lung PGE2 (# p<0.01).  No PGE2 augmentation is observed in the COX-1 -/- 
inflamed lung.  B.  Naïve COX-2 -/- animals and their congenic controls have similar levels of PGE2 
measured in lung homogenate. Wildtype animals sensitized and challenged with OVA experience a 
significant enhancement of lung PGE2 compared to saline treated controls (+ p<0.05).  No elevation 
of PGE2 is measured in the homogenate of inflamed lungs obtained from COX-2 -/- mice.  (For COX-
1: +/+ saline n=3, -/- saline n=3, +/+ OVA n=5, -/- OVA n=6; For COX-2: +/+ saline n=3, -/- saline 
n=3, +/+ OVA n=4, -/- OVA n= 6).  
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Figure 2.5 Inflammatory Response in mPGES1 -/- Mice Sensitized and Challenged with OVA   
 
0
50
100
150
200
250
mPGES1 +/+
mPGES1 -/-
saline
*
OVA
*
T
o
ta
l 
C
e
ll
s
 (
1
0
4
)
Mac Eos Neu Lym
0
25
50
75
100
125
150
175
mPGES1  +/+ Saline
mPGES1 +/+ OVA
mPGES1 -/- OVA
mPGES1  -/- Saline
T
o
ta
l 
 C
e
ll
s
 (
1
0
4
)
0
10
20
30
mPGES1 +/+
mPGES1 -/-
saline OVA
*
*
IL
-1
3
 (
p
g
/m
l)
0
5
10
15
20
25
mPGES1 +/+
mPGES1 -/-
saline OVA
IL
-4
 (
n
g
/m
l 
lu
n
g
h
o
m
o
g
e
n
a
te
)
0
250
500
750
mPGES1 +/+
mPGES1 -/-
saline OVA
T
o
ta
l 
Ig
E
 (
n
g
/m
l)
A B
C D
E
     
  
 
68 
 
Figure 2.5 Inflammatory Response in mPGES1 -/- Mice Sensitized and Challenged with OVA  A. 
OVA sensitization and challenge leads to an increase in total cells present in the BALF of wildtype 
mice.  While increased numbers of cells are also observed in BALF collected from  mPGES1 -/- 
animals, the total cell count is significantly reduced compared to similarly treated wildtype control 
animals (* p<0.001). B. The decrease in the cellularity of the BALF of the mPGES1 -/- mice 
correlates with a significant decrease in the number of eosinophils in the BALF of these animals 
compared to the numbers present in the BALF from the control animals (* p<0.001).  C. IL-13 levels 
in the BALF collected from OVA sensitized and challenged animals are significantly higher than 
those measured in saline treated cohorts, both wildtype and mPGES1 -/- animals, however, higher 
levels are observed in the samples collected from OVA treated wild type animals relative to levels in 
BALF from  mPGES1 -/- animals (*p<0.05). D. OVA sensitization and challenge results in an 
increase in total serum IgE of a similar magnitude in wildtype and mPGES1 -/- animals. E. IL-4 
levels in whole lung homogenates do not differ significantly between samples prepared from 
mPGES1-/- mice and controls.  As expected both groups showed levels elevated in comparison to 
samples prepared from saline treated cohorts.  (For A-D: mPGES1 +/+ saline n=4, -/- saline n=3, +/+ 
OVA n=10, -/- OVA n=11; For E: mPGES1 +/+ saline n=2, -/- saline n=3, +/+ OVA n=5, -/- OVA 
n=5) 
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Figure 2.6:  Ex Vivo mPGES1 Splenocyte Responses in Antigen Challenged Mice   
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Figure 2.6:  Ex Vivo mPGES1 Splenocyte Responses in Antigen Challenged Mice  Wildtype and 
mPGES1 -/- animals were sensitized and challenged with OVA antigen as described.  24 hours after 
the final challenge, mice were euthanized and spleens were collected.  A. Splenocytes were plated in 
the presence of increasing concentrations of OVA.  Proliferation was assessed using WST-1 reagent 
after 72 hours.  No significant difference in proliferation is observed between mPGES1-deficient 
animals and wildtype controls.  B-D Splenocytes were plated in media containing 100 μg/ml OVA.  
Following a 72 hour incubation period, cell supernatants were collected and IL-13 (B), IFN-γ (C), 
and IL-17a (D) cytokine levels were measured.  OVA restimulation results in elevated cytokine levels 
from the splenocytes of challenged animals.  While a trend towards attenuation is observed in IL-13 
levels measured from mPGES1 -/- mice, supernatant levels do not differ significantly between 
challenged groups for any cytokine.  (For A: mPGES1 +/+ n=4, mPGES1 -/- n=4; For B-D mPGES1: 
+/+ saline n=4, -/- saline n=4, +/+ OVA n=9, -/- OVA n=7)  
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Figure 2.7 Evaluation of Airway Hyperresponsiveness in mPGES1 -/- Mice  
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Figure 2.7 Evaluation of Airway Hyperresponsiveness in mPGES1 -/- Mice  Increasing doses of 
aerosolized methacholine were administered to anesthetized and intubated mice attached to a 
computer-controlled small-animal ventilator to assess AHR in mPGES1 -/- mice.  No significant 
differences are observed between any groups, at any concentration, for Rn or G ( mPGES1: +/+ saline 
n=4, mPGES1 -/- saline n=4, mPGES1 +/+ OVA n=9, mPGES1 -/- OVA n=11) 
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Figure 2.8 Contribution of PGE2 to Proliferation of Sensitized Splenocytes  
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Figure 2.8 Contribution of PGE2 to Proliferation of Sensitized Splenocytes  Mice were sensitized on 
days 0 and 14 with OVA and one week later serum and splenocytes were collected. A. Sensitization 
with antigen results in elevated serum IgE in wildtype and mPGES1 -/- animals.  This augmentation 
does not differ significantly between groups.  B.   Splenocytes were plated in media supplemented 
with increasing concentrations of OVA.  Following 72 hours, cell proliferation was assessed by WST-
1 reagent.  Proliferation of splenocytes from mPGES1 -/- populations is significantly reduced at the 1 
μg/ml OVA dose measured by t test analysis (*p<0.05); however F test analysis reveals no overall 
differences in the proliferative response.  C-E. Splenocytes from OVA and saline sensitized animals 
were plated with 100 μg/ml OVA.  Following culture for 72 hours, cell supernatants were collected 
and IL-13 (C), IFN-γ (D), and IL-17a (E) levels were assessed.   Cytokine levels are elevated in both 
mPGES1 +/+ and mPGES1 -/- supernatants and these levels of augmentation do not differ 
significantly. (For A: mPGES1: +/+ saline n=4, -/- saline n=4, +/+ OVA n=6, -/- OVA n=7; For B 
mPGES1: +/+ OVA n=5, mPGES1 -/- n=7; For C and E mPGES1: +/+ saline n=6, -/- saline n=6, +/+ 
OVA n=5, -/- OVA n=7; For D  mPGES1: +/+ saline n=4, -/- saline n=4, +/+ OVA n=4, -/- OVA 
n=4) 
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Figure 2.9 OVA-induced Allergic Inflammation in mPGES1-/- Mice Carrying an OVA-specific 
Transgene  
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Figure 2.9 OVA-induced Allergic Inflammation in mPGES1-/- Mice Carrying an OVA-specific 
Transgene  OT-II mice, mPGES1-/- mice, OT-II/mPGES1-/- mice and wild type animals were 
challenged with aerosolized OVA and the development of lung inflammation was assessed.  A.  
BALF was collected 24 hours after the final challenge. Antigen challenge results in an increase in the 
number of cells in the BALF of both OT-II expressing cohorts, however, the total number of cells is 
significantly lower in the BALF from the OT-II/ mPGES1 -/- animals compared to OT-II/mPGES1 
+/+ mice. (* p< 0.001) B. Differential cell analysis demonstrates that transgenic animals have 
elevated granulocyte numbers measured in their BALF.  Mice lacking mPGES1 had significantly 
fewer granulocytes, compared to wildtype transgenic animals. (* p<0.05) C. BALF IL-13 levels are 
also significantly lower in samples collected from OT-II/mPGES1 -/- animals compared to OT-
II/mPGES1 +/+ animals expressing mPGES1 (p< 0.02). (For A: mPGES1 +/+ n=3, mPGES1 -/- n=4, 
OT-II/ mPGES1 +/+ n=12, OT-II/mPGES1 -/- n=12; For B: mPGES1 +/+ n= 4, mPGES1 -/- n=5, 
OT-II/mPGES1 +/+ n=6, OT-II/mPGES1 -/- n=9;  For C, OT-II/ mPGES1 +/+ n=7, OT-II/mPGES1 -
/- n=7) 
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Figure 2.10 Development of Allergic Inflammation in mPGES1 Bone Marrow Chimeras   
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Figure 2.10 Development of Allergic Inflammation in mPGES1 Bone Marrow Chimeras  Wildtype 
and mPGES1 -/- mice exposed to lethal doses of radiation, were reconstituted with bone marrow from 
autologous donors.  Eight weeks after reconstitution, mice were sensitized and challenged with OVA.  
Wildtype mice reconstituted with wildtype bone marrow (WT→WT) have significantly elevated cell 
counts relative to mPGES1 -/- mice reconstituted with mPGES1 -/- bone marrow (KO→KO) 
(p=0.05). (For WT→WT n= 6; For KO→KO n=8) 
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Figure 2.11 Contribution of PGE2 from Bone Marrow Derived Cell Populations to OVA-
induced Lung Inflammation   
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Figure 2.11 Contribution of PGE2 from Bone Marrow Derived Cell Populations to OVA-induced 
Lung Inflammation  Lethally irradiated wildtype mice were reconstituted with either wildtype bone 
marrow (WT→WT) or mPGES1 -/- bone marrow (KO→WT).  A.  As expected, an increase in the 
cellularity of the BALF is observed in samples collected from the animals sensitized and challenged 
with ovalbumin.  No significant difference is measured in the total number of cells present in the 
BALF of the two groups (WT→WT versus KO→WT). B. Morphological analysis of cell types 
present in BALF revealed elevated levels of eosinophils in both OVA-treated groups and again the 
numbers of these cells did not differ significantly between the animals that had received the wild type 
versus the mPGES1 -/- marrow. C.  No difference is observed in the level of IL-13 in the BALF of 
the two OVA-treated groups. D. Total serum IgE concentrations are elevated to a similar degree in 
groups sensitized and challenged with OVA. (For WT→WT: saline n=3, OVA n=8; KO→WT: saline 
n=2, OVA n=8) 
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Figure 2.12 Contribution of PGE2 Produced by Radiation Resistant Lung Populations to 
Allergic Inflammation   
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Figure 2.12 Contribution of PGE2 Produced by Radiation Resistant Lung Populations to Allergic 
Inflammation  Wildtype mice or mPGES1 -/- mice exposed to lethal doses of radiation were 
reconstituted with wildtype bone marrow, (WT→WT) and (WT→KO) respectively.  BALF was 
collected from OVA sensitized and challenged animals and total cell numbers (A) and cell 
differentials (B) were determined.  A decrease in both the total cell count and the number of 
eosinophils in the BALF is observed in samples from mPGES1 -/- mice reconstituted with wildtype 
marrow, compared to samples from similarly reconstituted and treated wildtype animals (WT→WT) 
(* p<0.01).  C.  IL-13 levels are significantly higher in the BALF from OVA-sensitized and 
challenged WT→WT mice compared to levels in BALF from similarly treated mPGES1-/- animals 
that received wildtype bone marrow ( WT→KO) (*p<0.05).  D. Total serum IgE concentrations are 
elevated to similar levels following OVA sensitization and challenge in both WT→WT and WT→KO 
animals. (For WT→WT: saline n=4, OVA n=8; WT→KO: saline n=4, OVA n=7) 
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Discussion 
Previous studies have shown that in the absence of COX-1 or COX-2, antigen exposure 
results in more severe allergic lung disease (182).  Using mice lacking mPGES1 synthase, we show 
that attenuation of PGE2 synthesis in the COX-1 and the COX-2 deficient mice does not account for 
the increase in disease observed in these mouse lines.  In fact, in this model mPGES1 deficient mice 
showed reduced airway inflammation, indicating that PGE2 enhances this aspect of allergic disease. 
The impact of the genetic composition of mouse lines on the development of various aspects 
of allergic lung disease has been well established (346-349).  The majority of the early studies 
assigning roles for COX-1 and COX-2 metabolites in inflammatory responses were carried out using 
mice of mixed genetic background, thus the representation of B6 and 129 genes in the COX deficient 
and control animals can be very different.  We therefore first verified that the protection that COX-1 
and COX-2 provided in this response could be observed when congenic animals were studied. 
Consistent with previous work, we report that both COX-1 and COX-2 dependent prostaglandins 
limit allergic inflammation in the lung. However, we show that both enzymes provided the mice with 
a similar level of protection.  This differs from previous studies in which loss of COX-1 was reported 
to have a greater role than COX-2 both in production of PGE2 in the naïve and inflamed lung as well 
as in limiting allergic inflammation (182).  Since COX-1 and COX-2 have unique but overlapping 
patterns of expression and, depending on the cell type, can lead to the preferential production of a 
particular eicosanoid, this observation suggests that multiple prostaglandins or prostaglandins made 
by different cells types limit inflammation in this model.  
  We saw no development of AHR in either the COX-1 or the COX-2 deficient animals.  This 
is not surprising given the genetic background of the mice.  AHR is often absent in B6 mice (346, 
347, 349).  In previous studies, inflammation associated with loss of COX-1 but not COX-2 was 
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reported to result in increased sensitivity to methacholine (182).  It is possible that this difference 
reflected differences in the segregation of 129 and B6 alleles in the two populations.  This would be 
expected, as the closure of the ductus arteriosus in mice lacking EP4 or COX-2 depends on the 
inheritance of a particular compliment of 129 and B6 alleles (190, 350). In contrast, no such selective 
pressure would skew inheritance of alleles in the COX-1 population.   
Early work suggested that PGE2 could play an important role in regulating the differentiation 
of mouse B lymphocytes to IgE secreting cells (351).  However, this role was not supported by the 
report that IgE levels were actually higher in the COX-1 and COX-2 antigen treated animals (182).  
Our study did not observe this increase in the COX-1 and COX-2 deficient animals compared to their 
genetically matched controls and therefore does not support a role for PGE2 in switching B cells to 
IgE production.  No difference was noted in serum IgE levels between COX-1 -/-, COX-2 -/- or 
mPGES1 -/- and their control animals after induction of a TH2 response. However, direct comparison 
of the IgE response of COX deficient animals reported here and those reported previously is difficult 
for a number of reasons.  Not only do our studies utilize congenic mice, the cohort examined here 
were between 8 to 12 weeks of age while previous studies examined mice that ranged in age from 5 
and 9 months.  In addition, these studies evaluated IgE levels in the BALF, while we examined serum 
IgE.       
In patients with allergic asthma, inhaled PGE2 is reported to attenuate both the early and late 
phase response after exposure to antigen (302, 310-312). PGE2 has also been shown to limit 
inflammation in animal models of asthma (313, 314, 352).  Given this, it seemed likely that the 
heightened inflammation observed in the COX deficient mice reflected a loss of this protective 
prostanoid.  Indeed, induction of allergic disease with ovalbumin dramatically increased PGE2 levels 
in the lung and this augmentation was not observed when COX-1, COX-2, or mPGES1 was absent, 
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suggesting that both enzymes are capable of coupling with mPGES1 to promote prostanoid 
production during lung inflammation.  However, unlike a genetic loss of COX enzymatic activity, a 
loss of mPGES1 did not result in heightened disease, in fact, quite the opposite; loss of this pathway 
attenuated the inflammatory response.  Instead, our results are consistent with a model in which the 
primary protective COX dependent eicosanoid is prostacyclin, not PGE2.  Mice lacking the I-
prostanoid (IP) receptor, specific for prostacyclin, were reported to have more severe allergic 
inflammation in the lung (323).  Prostacyclin, but not PGE2 was also shown to protect against the 
development of fibrosis in the bleomycin model of idiopathic pulmonary fibrosis (278), suggesting 
that, at least in the rodent lung, this might be the most important anti-inflammatory prostanoid.   
We cannot rule out the possibility that the lack of a protective role for PGE2 in this study is 
specific to this particular model and immunization protocol.  A recent study examining the function 
of mPGES1 in a house dust mite antigen (Der f)-induced allergic model reported that PGE2 limited 
vascular changes associated with chronic exposure to antigen while decreased PGE2 had no 
significant impact on total recruitment of inflammatory cells to the lungs after Der f challenge (321).  
However, the vascular remodeling which this study showed was enhanced in the mPGES1 -/- mice is 
associated with chronic models of asthma and is not apparent in the acute model used in our study, 
preventing extension of this finding to this model of allergic lung disease.  In contrast to our findings, 
decreased PGE2 had no significant impact on recruitment of inflammatory cells to the lungs after Der 
f challenge. Again this difference might reflect different roles for PGE2 in an acute allergic response, 
such as that induced by ovalbumin and adjuvant, versus a chronic model established by inhalation of 
a complex antigen with intrinsic ability to activate the innate immune response. Alternatively, it could 
reflect the fact that the mPGES1 -/- animals were compared to purchased wildtype B6 mice, whereas 
both the mPGES1 -/- and wildtype mice used in our studies were bred in the same facility, as studies 
have highlighted the importance of environmental factors, including the microbiome, in molding the 
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immune response (353-356) and it is possible that some phenotypes reflect such differences in 
addition to the genetic lesion under study.   
Both our findings and the phenotype of mPGES1 -/- animals in the Der f allergic model do 
not support early reports of heightened inflammation in EP3 -/- mice sensitized and challenged with 
ovalbumin (320).  The reason for this discrepancy is not apparent, however, we have been unable to 
reproduce this finding using B6 congenic EP3 -/- mice (unpublished data).  Furthermore, previous 
work in our lab has indicated that PGE2, through the EP3 receptor, can promote inflammation by 
augmenting IgE mediated mast cell degranulation and in some circumstances PGE2 alone is sufficient 
to mediate this response in rodents (258, 259).   
Much of the support for the hypothesis that PGE2 plays a protective role in the lung, limiting 
inflammation, comes from studies in which exposure of mice to antigen is accompanied by inhalation 
of PGE2, its stable analog, or a PGE2 receptor preferring antagonist and agonist (314, 352, 357).  In 
vitro studies have reinforced this hypothesis, with studies such as those which have shown PGE2 to be 
effective in limiting migration of eosinophils and increasing production of IL-10 by dendritic cells 
and naïve T cells (329, 357, 358).  However, extrapolating findings from either or both of these types 
of studies to develop models which predict the contribution of PGE2 to inflammatory responses in 
vivo has proven difficult.  Some of this difficulty is related to the fact that very few of the pathways 
attributed to PGE2 through pharmacological studies with inhaled PGE2 or PGE2 receptor preferring 
agonists/antagonists are supported by evaluation of mice lacking specific PGE2 receptors or 
combination of receptors.  In some cases, the discrepancies may reflect the effective dose and 
specificity of the reagents used.  For example, early studies assigning anti-coagulatory properties to 
PGE2 were later shown to reflect the ability of PGE2 at concentrations used in these studies to activate 
the prostacyclin receptor (359).  Thus it is possible that some of the protective actions of inhaled 
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PGE2 and EP receptor agonist are incorrectly assigned to the PGE2 pathway.  Carrying out these 
experiments in mice lacking the IP receptor and or EP receptors should resolve many of these issues.  
In some cases, inconsistency between results obtained using the various approaches might simply 
reflect the fact that loss of a PGE2 receptor may have far less consequence for the organism than 
stimulation of the same pathway, due to compensatory pathways active in vivo.  For example, 
stimulation of naïve T cells with PGE2 in vitro can inhibit production of a pro-inflammatory 
cytokines, such as IFN-λ (358), but in vivo, the absence of PGE2 does not necessarily lead to altered 
expression of this cytokine following stimulation (321), emphasizing the point that many other 
inflammatory mediators, distinct from PGE2, can activate the same downstream pathways to 
upregulate responses.  Inhaled PGE2 through the EP2 receptor limits airway constriction to 
methacholine (319).  However, in mice with inflamed airways, the dose response curve is not shifted 
to the left in mice lacking EP2 (unpublished data), suggesting that in the inflamed airway other 
pathways available are capable of regulating airway tone.   
Not only were we unable to assign a protective role to PGE2, our studies indicate a novel role 
for PGE2: in some allergic responses PGE2 acts as a pro-inflammatory mediator, enhancing 
inflammation in the lung.  To further define this pro-inflammatory action of PGE2, we generated bone 
marrow chimeras, animals in which either the lung or the recruited immune cells were deficient in the 
enzyme.  The results from studies with these animals indicated that PGE2 produced by the lung, rather 
than from the recruited immune cells, contributed to the inflammatory response.  Furthermore, PGE2 
does not alter the development of antigen specific T and B cell populations, but rather plays a role 
either in the expansion of these populations after challenge or in the recruitment of the cells to the 
lung.  This interpretation was supported by study of mPGES1 deficient animals carrying an 
ovalbumin specific transgene.  Loss of PGE2 synthesis limited the development of inflammation 
when these animals were challenged with antigen, implicating PGE2 in the effector phase of this 
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response in the lung.  The lack of a role for PGE2 in the sensitizing phase of the allergic response 
correlates well with the studies of these mice in the Der f allergic model (321).  No difference was 
observed in the repertoire of T cells elicited by this antigen.   
We cannot yet identify precise mechanisms by which PGE2 contributes to the inflammatory 
response in the lung.  As discussed above, PGE2 can augment mast cell degranulation in vitro and in 
vivo and this action is mediated through the EP3 receptor (258, 259), suggesting that perhaps PGE2 
augments inflammation by increasing the release of mediators from these cells.  However, the 
immunization protocol used here is not mast cell dependent (158), making it unlikely that this effector 
cell contributes substantially to the inflammatory response. PGE2 can also increase vascular 
permeability and thus increase vascular leakage and formation of inflammatory exudates (211). For 
example, instillation of PGE2 was reported to increase migration of neutrophils into airways in 
response to complement exposure (360).  This response was attributed to vascular changes as it was 
attenuated by treatment with a vasoconstrictor.  PGE2 has been reported to influence many aspects of 
epithelial cell physiology, including chemokine and cytokine profiles, release of mucins, ion transport 
and ciliary beat (361-365).  For instance, PGE2 can stimulate the release of IL-6 from many cell types 
(259, 361, 366, 367) and IL-6 can contribute to inflammation in some allergic models (367, 368). 
Additional experiments will be required to define precisely the circumstances and the mechanism by 
which inhibition of PGE2 limits disease in this allergic lung.  
In summary, our studies show that loss of mPGES1, the primary enzyme required for 
production of PGE2 from COX-1 and COX-2 metabolites, is not required for TH2 polarization 
following sensitization of mice to OVA.  However, while PGE2 has largely been considered 
protective, playing a role in limiting the inflammatory response during the effector phase to inhaled 
allergens, we show that under some circumstances, this is not the case.  Acute inflammation in 
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response to ovalbumin is attenuated in mice with decreased levels of PGE2, both in mice carrying an 
OVA specific transgene and in mice sensitized by exposure to antigen in the presence of adjuvant.  
These findings emphasize the complexity of the role for this prostanoid in immune responses and 
underscore the challenges of targeting PGE2 and its receptors in the treatment of lung diseases.    
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CHAPTER III 
PROSTACYCLIN ALTERS THE FUNCTIONS OF LEUKOCYTES TO 
ATTENUATE ALLERGIC LUNG INFLAMMATION 
 
 Prostacyclin (PGI2) is one of 5 bioactive prostanoids produced from the enzymatic 
conversion of C20-unsaturated fatty acid.  Synthesis is initiated by the actions of prostaglandin-
endoperoxide synthases (cyclooxygenase, COX) on free arachidonic acid (AA) released from 
phospholipids by phospholipase A2 (PLA2) (325).  COX-1 is responsible for the majority of basal 
level prostanoid production.  Constitutive expression of this isoform is present in most cell types; 
however COX-1 expression can be upregulated and can contribute to inflammatory processes.  In 
mice, COX-1 is the important isoform for mediating ear edema following treatment with AA (334).  
Conversely, expression of COX-2 is undetectable in most cells during homeostasis and is instead 
induced in response to a diverse range of stimuli including growth factors, LPS, and IL-1.  
Constitutive expression of COX-2 is detected, however, in multiple tissues of human and mice 
including the lung, brain, and testes (369).  Both COX enzymes function by converting AA into the 
unstable intermediate products prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2).  Pathway 
specific synthases complete the conversion of prostanoids from these intermediates and prostaglandin 
I synthase (PGIS) is responsible for the final step in PGI2 production (370).  The autocrine and 
paracrine functions of PGI2 are mediated through specific binding to the Gs-coupled IP receptor and 
upregulation of cAMP before this prostanoid is rapidly metabolized to its inactive byproduct 6-keto-
PGF1α  (327). 
 91 
 
9
1
 
 
PGI2 is detected at high levels in the lung and production of this prostanoid is assigned to 
multiple cell types, most notably to endothelial cells (371).  Consistent with this observation, PGI2 
contributes significantly to vasodilation and prevention of thrombosis (372).  While PGI2 synthesis 
promotes inflammation in some tissues (274, 276, 280), multiple lines of evidence suggest that this 
prostanoid is protective in the pulmonary system.  Aerosolized iloprost, a PGI2 analog, is a well-
accepted form of therapy for the treatment of pulmonary arterial hypertension (322) and both 
pharmacological and genetic-based animal studies indicate that this prostanoid is protective in models 
of bleomycin-induced pulmonary fibrosis (278, 279).  Further, prostacyclin attenuates disease 
parameters secondary to respiratory syncytial virus in mice (286)  
Animal studies utilizing mice lacking either the COX-1 or COX-2 enzyme provide evidence 
that overall, prostanoid production in the respiratory system limits multiple disease parameters 
observed during allergic responses in the lung.  Following sensitization and challenge with ovalbumin 
(OVA) antigen, both COX-deficient mutants have elevated eosinophilia and TH2 cytokine levels in 
their airways (182) and these findings are corroborated by studies utilizing NSAIDs to 
pharmacologically inhibit prostanoid production (293, 294).  Initially these prophylactic properties 
were ascribed to synthesis of PGE2 by COX enzymes, given that this prostanoid is upregulated in the 
sputum of asthmatics (304-306) and its administration attenuates airway hyperresponsiveness (AHR) 
(302, 311).  However, we have recently shown that loss of mPGES1 ameliorates OVA-induced lung 
inflammation (373), demonstrating that production of PGE2 cannot account for the protection 
afforded by COX-dependent prostanoid synthesis during pulmonary allergy.   
PGI2 levels are elevated following allergic episodes in the lungs of both humans and animals 
and administration of this mediator inhibits bronchoconstriction (323, 374-378).  Further, in vitro 
experiments suggest that PGI2 analogs can alter the responses of both dendritic cells (DCs) and T cell 
populations (281, 282, 285).  The most compelling evidence that PGI2 limits allergic inflammation in 
the lung, however, comes from in vivo studies assessing the consequences of an IP deficiency in this 
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system.  Mice lacking the IP receptor (IP -/-) experience both exacerbated lung inflammation (323) 
and enhanced airway remodeling (324) following sensitization and challenge with antigen.  
Conversely, treatment with PGI2 or its analogs is effective in attenuating pulmonary inflammation 
when administered either before antigen sensitization or before each antigen challenge (282, 283).  
Collectively these data imply that prostacyclin limits disease during both acute and chronic lung 
allergy and may potentiate COX-dependent protection in this system.  However, to date, no study has 
been conducted which directly compares the development of pulmonary inflammation in IP -/- and 
COX-deficient cohorts.  
Herein, we demonstrate that following sensitization and challenge with OVA, IP -/- mice 
have similar levels of pulmonary inflammation compared to COX-1-/- animals, although important 
exceptions are observed.  We find that PGI2 limits allergy during both the sensitization and effector 
phases, although its contribution appears to be more prolific following antigen challenge, which may 
reflect tissue specificity.  Additionally, we present preliminary data that suggests administration of the 
prostacyclin analog, iloprost, may limit pulmonary inflammation in COX-1 -/- animals by 
suppressing inflammatory cytokine levels, although administration of analog was unable to 
significantly prevent augmented cellularity in the airways.  This effect may extend beyond atopic 
allergy to other models of inflammation in the lung, including allergy induced in OT-II animals.  
Finally, we identify bone-marrow derived leukocytes as a significant target for PGI2 mediation in this 
system.  . 
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Materials and Methods 
Experimental Animals 
All animal colonies were maintained according to standard guidelines as defined by the NIH Guide 
for the Care and Use of Laboratory Animals were approved by the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill.  Experiments were carried 
out on age and sex matched mice.  C57BL/6 (B6) (backcrossed  >10 generations) COX-1 -/- and B6 
(backcrossed  >10 generations)  IP -/- mice were generated as previously describe (268, 334) 
Wildtype (WT) B6 mice (backcrossed  >10 generations) were used as controls.  B6 OVA-Specific 
TCR-Transgenic (OT-II) mice were purchased from The Jackson Laboratories (Bar Harbor, Ma). 
OVA Sensitization and Challenge  
Mice were sensitized systemically with an i.p injection of 20µg OVA (Sigma-Aldrich) emulsified in 
aluminum hydroxide (alum) (Sigma-Aldrich) or saline on day 0.  Two weeks later, animals were 
challenged for one hour with 1% aerosolized OVA on three consecutive days.  In some experiments, 
animals received 0.2 μg iloprost (Cayman Chemicals) 30 minutes prior to antigen challenge by 
intratracheal (i.t.) instillation.  24 hours after the final antigen exposure, mice were euthanized and 
blood and BALF were collected for further analysis.  For ex vivo experiments examining responses in 
sensitized animals, mice received an i.p. injection of 50 µg OVA emulsified in alum.  Twelve days 
later, animals were euthanized and spleens and serum were collected for further analysis. 
Measurement of Cell Proliferation 
Splenocytes were prepared by mechanical dispersion of spleen over a 70 μm cell strainer (BD 
Falcon).  Red blood cells were lysed in lysis buffer (4.1g NH2Cl, 0.5g KHCO3, 100 μl 0.5M EDTA 
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dissolved in 500 ml dH20) and splenocytes were washed twice in PBS.  Cells were plated at a density 
of 2.5 X 10
6
 cells/ml in RPMI 1640 media enriched with 10% FBS, 100 units/ml penicillin, 100 
units/ml streptomycin, and .29 µg/ml L-glutamine.  OVA was added to splenocyte cultures at 
concentrations ranging from 0 µg /ml to 100 µg/ml.  After incubation for 72 hours at 37°C, cell 
proliferation was assessed using WST-1 reagent (Roche) according to the manufacturer’s instructions.  
BALF Collection and Cell Counts 
Following euthanasia, lungs were lavaged with five 1ml aliquots of HBSS (Gibco) and total cell 
counts were determined by hemacytometer.  Cellular composition was evaluated morphologically 
using cytospin preparation stained with Hema 3 or Fast Green.  All remaining BALF was centrifuged 
to remove cells and stored at -80° c for immunoassay. 
6-keto-PGF1α, Cytokine, and Immunoglobulin Production 
Levels of 6-keto-PGF1α and cytokines present in BALF, lung homogenate and/or tissue culture 
supernatant were determined by immunoassay.  To determine cytokine production by stimulated 
splenocytes, cells were prepared as described above.  Cells were cultured at a density of 1 X 10
7
 
cells/ml in the presence of 100 μg/ml OVA.  After 72 hours, supernatants were collected and stored at 
-80°C prior to evaluation by ELISA.  Cytokines were determined by ELISA following manufacturer’s 
protocols:  IL-13 (R&D Systems), IFN-γ (R&D Systems) and IL-17a (eBiosciences).  For 
quantification of 6-keto-PGF1α, lungs were flash frozen in liquid nitrogen, weighed, and stored at -
80°C.   The left lobe was pulverized then homogenized in 1XPBS/1mM EDTA and 10 µM 
indomethacin.  Lipids were separated from tissue supernatant using octadecyl C18 mini columns 
(Alltech Associates), and prostanoid levels were determined using an enzyme immunoassay kit 
(Assay Designs) according to the manufacturer's instructions.  Values shown represent the total 
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quantity of mediator measured divided by tissue weight.  Blood was obtained by cardiac puncture, 
allowed to coagulate, and centrifuged to isolate serum.  IgE levels were determined by immunoassay 
using 96 well EIA/RIA plates (Costar).  Plates were coated with IgE capture antibody (Pharmingen; 
clone R35-72), blocked with 1% BSA/PBS and then incubated with IgE standard (Pharmingen) or 
serum followed by biotinylated rat anti-mouse IgE (Pharmingen; clone R35-118).  Detection was 
carried out using streptavidin-horseradish peroxidase (HRP) (Pharmingen) and hydrogen peroxide 
/2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS).  Absorbance at 405nm was 
measured.   
Bone Marrow Chimera Generation 
Recipient mice were exposed to 5 grays irradiation from a Cesium g-irradiator at 0 and 3 hours.  
Femurs and tibias were collected from donor mice and flushed with cold PBS to isolate bone marrow.  
Bone marrow was introduced by tail vein injection into recipient mice immediately following the 
second round of radiation and after 4.5 weeks animals were sensitized and challenged with OVA as 
described.   
Statistical Analysis 
Statistical analysis was performed using Prism 4 (GraphPad Software).  Comparisons of the mean 
were made by F test, Student’s t-test or ANOVA followed by Tukey-Kramer’s HSD post hoc test as 
necessary.  Data are shown as mean ± SEM.  Differences with p<0.05 were considered statistically 
significant. 
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Results 
Allergic lung inflammation in IP -/- and COX-1 -/- animals 
We have shown that sensitized congenic COX-deficient animals have heightened airway 
inflammation following challenge with OVA and that a loss of PGE2 synthesis in this system cannot 
account for this augmented disease (373).  Instead, a role for PGI2 and its IP receptor in this process is 
supported by experimental evidence (323); however no reports exist that directly compare respiratory 
disease parameters arising in IP -/- and COX-deficient animals.  To this end, we utilized our 
established allergy protocol to examine the development of lung inflammation in IP -/- and COX-1 -/- 
cohorts and their congenic wildtype (WT) controls in parallel.  This COX isoform was selected for 
study because the knockouts (KOs) for both COX-1 and the IP-receptor are maintained on a B6 
background.  COX-2 -/- animals survive poorly on most inbred strains, due to a patent ductus 
arteriosus (190), and therefore experimental F1 progeny produced from intercrossing 129S6/SvEv 
and B6 heterozygotes are utilized.  The genetic background of the COX-2 -/- animals makes direct 
comparisons to IP -/- animals challenging.   
Animals were sensitized systemically to antigen by an i.p. injection of 20 μg OVA emulsified 
in alum.  Two weeks later, animals were challenged with saline or 1% aerosolized OVA for one hour 
on 3 consecutive days.  Inflammation was assessed in these animals 24 hours after the final antigen 
challenge.  As anticipated, sensitization and challenge with OVA induced a robust cellular infiltration 
in the airways of all animals, both WT controls and genetic KOs, compared to saline treated animals 
(Fig 3.1A,B).  Cellularity was elevated approximately two-fold in the IP -/- animals, compared to IP 
+/+ controls (Fig 3.1A).  While COX-1 -/- animals also experienced an enhanced cellular influx, 
compared to their WT controls (Fig 3.1B), the magnitude was not as substantial as that observed in IP 
-/- animals.  IL-13 measurements, used as a marker for TH2 cell cytokine release, were quantified in 
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the BALF (Fig 3.1C,D).  Levels of this cytokine were enhanced in the airways of all mice exposed to 
antigen.  Loss of the IP-receptor (Fig 3.1C) or COX-1 (Fig 3.1D) induced similar increases in the 
levels of IL-13 measured above their respective WT controls.  Finally, total IgE was quantified in 
these cohorts.  Typical of atopic allergy, IgE was elevated in the serum of all rodents sensitized and 
challenged with OVA (Fig 3.1 E,F).  However, while IP -/- had IgE levels markedly higher than IP 
+/+ controls (Fig 3.1E), COX-1 -/- mice had IgE levels similar to WT mice (Fig 3.1F).   
Contribution of COX-1 to PGI2 production in the inflamed lung 
 Our observations suggest that lost production of PGI2 may account for the augmented lung 
inflammation observed in COX-1 -/- mice.  Therefore, we next examined whether PGI2 levels are 
altered in the inflamed COX-1 -/- murine lung.  Prostacyclin is extremely labile at physiological pH 
and is rapidly metabolized to its inactive byproduct 6-keto-PGF1α. (327).  We assessed concentrations 
of this metabolite, as a marker for PGI2 production, present in the lung homogenate of naïve and 
allergic COX-1 -/- animals and their congenic controls (Fig 3.2).  6-keto-PGF1α is observed in the 
naïve lung of WT animals.  Concentrations of this metabolite are reduced in lung tissue of naive 
COX-1 -/- animals, consistent with the idea that this isomer contributes to production of PGI2 in the 
lung during homeostasis.  Following challenge with antigen in sensitized animals, significantly more 
6-keto-PGF1α is measured in the lung homogenate of WT animals.  In contrast, no increase in this 
metabolite is observed in the inflamed COX-1 -/- lung.  This data confirms that production of PGI2 is 
inhibited in the lungs of COX-1 deficient animals during atopic allergy, supporting the hypothesis 
that a loss of this prostanoid may account for the exacerbated lung inflammation observed in COX-1 -
/- rodents.    
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Contribution of PGI2 to ex vivo immune responses 
Although the pulmonary inflammation observed in IP -/- mice is similar to the inflammation 
observed in COX-1 -/- animals, the phenotypes are not identical.  We therefore sought to determine 
whether the heightened inflammation observed in the airways of COX-1 -/- mice can be reduced upon 
exogenous administration of the PGI2 analog iloprost, used clinically in the treatment of pulmonary 
arterial hypertension (277).  Experimental evidence suggests that local application of iloprost to the 
airways of immunized mice prior to each antigen challenge is sufficient to attenuate pulmonary 
inflammation in these animals (282).  However, the elevated level of IgE measured in our IP -/- mice 
suggests that PGI2 synthesis during allergic sensitization may be influential in its ability to limit 
inflammation in the lung.   
To delineate the contribution of PGI2 signaling to allergic sensitization, WT and IP -/-animals 
were sensitized i.p. with OVA/alum.  IgE levels and ex vivo splenocyte responses were assessed 12 
days later, prior to antigen challenge.  We observed that antigen sensitization, alone, was sufficient to 
measure significant, albeit modest, elevations in the IgE levels of IP -/- mice compared to immunized 
WT controls (Fig 3.3A).  PGI2 might limit antigen sensitization by suppressing the expansion of 
immune cells.  To evaluate this possibility, splenocytes from immunized WT and IP -/- mice were 
isolated and incubated with increasing concentrations of OVA antigen.  Proliferative responses were 
subsequently assessed using WST-1 reagent (Fig 3.3B).  No difference was observed in the 
proliferative curves generated by cells isolated from WT and IP -/- animals.  We next tested whether 
PGI2 limits atopic allergic sensitization by altering T cell polarization.  To do so, we measured IL-13 
(Fig 3.3C), IFN-γ (Fig 3.3D), and IL-17a (Fig 3.3E) levels present in splenocyte supernatants as 
markers for typical TH2, TH1, and TH17 cytokine profiles, respectively.  There were no significant 
differences observed in any of these cytokine levels between IP+/+ and IP -/- cell supernatants. 
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The effects of iloprost on lung inflammation in COX-1 -/- and IP -/- mice 
While a modest elevation is observed in the IgE levels of IP -/- animals following antigen 
sensitization, our data suggests that the majority of protection afforded by this lipid mediator occurs 
during allergy elicitation in the lung.  To this end, we examined the consequence of iloprost 
administration to pulmonary inflammation in the COX-1 -/- animals during the effector phase of 
allergy.  COX-1 -/- mice and their WT controls were sensitized and challenged with antigen, as 
previously described.  A subset of these COX-1 -/- animals received 0.2μg iloprost (Ilo) by i.t. 
administration 30 minutes prior to each antigen challenge (Ilo/COX-1 -/-) while all other animals 
were exposed to vehicle (Veh).  As anticipated, BALF cellularity was enhanced in COX-1 -/- mice 
pretreated with vehicle (Veh/COX-1 -/-), compared to WT controls (Fig 3.4A).  This cellular 
infiltration, while modestly reduced, was not significantly attenuated in Ilo/COX-1 -/- mice.  IL-13 
levels were next assessed in the BALF.  Veh/COX-1 -/- mice had significantly elevated cytokine 
levels, compared to WT animals; however, no significant elevation was observed in Ilo/COX-1 -/- 
mice (Fig 3.4B).  As a final test, IgE was measured in the serum of experimental animals (Fig 3.4C).  
Consistent with our previous observations, no significant difference was observed between WT and 
Veh/COX-1 -/- mice.  Treatment with iloprost had no significant impact on the concentration of this 
immunoglobulin.   
 To confirm the involvement of the IP-receptor in our above generated data, an identical round 
of experiments was conducted utilizing IP -/- mice.  Immunized animals were challenged following 
pretreatment with Veh (WT and Veh/IP -/-) or iloprost (Ilo/IP -/-) as previously described.  The 
cellularity measured in the BALF of Veh/IP -/- animals was elevated compared to WT animals (Fig 
3.5A).  Cellular levels quantified in Ilo/IP -/- mice did not significantly differ from Veh/IP -/- 
     
  
 
100 
 
controls.  Additionally, BALF IL-13 levels and serum IgE were similarly augmented in Veh/IP-/-  and 
Ilo/IP -/- mice when compared to WT mice (Fig 3.5B,C).   
The effects of iloprost on OT-II mice 
 Our evidence suggests that iloprost significantly ameliorates aspects of lung inflammation 
which develop during atopic allergic responses, demonstrated by reduced levels of TH2-specific 
cytokine IL-13.  We examined whether this protection by iloprost could be extended to non-atopic 
models of lung inflammation, as well, utilizing OVA TCR-specific (OT-II) mice.  These mice harbor 
a transgenic TCR specific for OVA-antigen and exposure of their airways to OVA induces lung 
inflammation without a prior necessity for antigen sensitization.  The pattern of disease these animals 
develop is characterized by elevated neutrophilia and may reflect a TH17-driven response (345).  We 
challenged the airways of OT-II transgenic (OT-II tg +) mice and their WT (OT-II tg -) controls for 5 
consecutive days with 1% OVA.  Airway inflammation in these animals was assessed 24 hours later.  
A subset of these animals received 0.2μg i.t. iloprost 30 minutes prior to each challenge.   
A robust cellular infiltration was observed in the airways of OT-II tg+ mice, compared to OT-
II tg- animals.  Administration of iloprost did not significantly alter the cellularity observed in OT-II 
tg+ mice (Fig 3.6A).  As an additional test, IL-17a levels were quantified in the BALF of OT-II tg+ 
animals (Fig 3.6B).  A modest reduction in the level of this cytokine was observed in iloprost treated 
animals; however this value failed to reach statistical significance (p=0.06). 
Contribution of leukocytes to lung inflammation in IP -/- animals 
Experimental evidence indicates that, in the inflamed lung, stromal cells are the predominant 
source of PGI2; however, both leukocytes and structural cells express high levels of the IP receptor 
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(283).  We therefore sought to determine which cell type is being altered by production of PGI2 
during allergy in the lung.  To elucidate whether IP-signaling on leukocytes is responsible for the 
exacerbated pulmonary inflammation observed in IP -/- mice, we studied the development of allergy 
in bone marrow chimeras.  Bone marrow, harvested from WT or IP -/- animals was transplanted into 
irradiated WT animals to generate mice with normal IP expression on structural cells of the lung 
while possessing either WT (WT→WT) or IP-deficient (knockout [KO]→WT) immune cells.  
Following reconstitution, these animals were sensitized and challenged as previously described.   
While elevated cell infiltration was confirmed in the airways of both WT→WT and 
KO→WT animals immunized and challenged with OVA, this cellularity was significantly augmented 
in KO→WT mice (Fig 3.7A), reflecting a significantly enhanced eosinophil population (Fig 3.7B).  
Consistent with IP -/- mice, IL-13 cytokine levels were significantly increased in the BALF of OVA-
treated KO→WT animals compared to OVA-treated WT→WT mice (Fig 3.7C).  Additionally, 
KO→WT mice receiving antigen had substantially greater concentrations of serum IgE, compared to 
WT→WT controls (Fig 3.7D).   
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Figure 3.1 Allergic Lung Inflammation in IP -/- and COX-1 -/- Mice   
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Figure 3.1 Allergic Lung Inflammation in IP -/- and COX-1 -/-mice  IP -/- mice, COX-1 -/- mice 
and their WT controls were sensitized i.p. with saline or 20 μg OVA emulsified in alum.  Two weeks 
following sensitization, animals were challenged for three consecutive days with saline or 1% 
aerosolized OVA.  Twenty four hours after the final exposure, airway inflammation was assessed.  
A,B. Sensitization and challenge with antigen resulted in elevated cellularity in the BALF of IP -/- 
mice, COX-1 -/- mice, and their WT controls.  This elevation is significantly augmented in both IP -/- 
mice compared to their inflamed WT controls (A) (*p<0.01) and COX-1 -/- animals compared to 
their OVA-treated WT controls (B) (*p<0.05).  C,D. Induction of allergy augmented BALF IL-13 
levels in all mice, compared to saline controls.  IP -/- animals (C) and COX-1 -/- animals (D) both 
have cytokine measurements significantly higher than their WT controls (**p<0.001).  E,F. Total 
serum IgE is elevated following allergy induction in all mice.  IP -/- mice have increased IgE 
compared to WT controls (E) (***p<0.0001).  In contrast, COX-1 -/- mice have IgE levels similar to 
their WT controls (F). (For IP saline: IP +/+ n=3, IP -/- n=3; For IP OVA: IP +/+ n=7, IP -/- n=8; For 
COX-1 saline: COX-1 +/+ n=5, COX-1 -/- n=4; For COX-1 OVA: COX-1 +/+ n=7, COX-1 -/- n=8)  
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Figure 3.2 The Contribution of COX-1 to PGI2 Production in the Inflamed Lung 
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Figure 3.2 Contribution of COX-1 to PGI2 Synthesis in the Inflamed Lung  Levels of the PGI2 
metabolite, 6-keto-PGF1α, were assessed in the lung homogenate of naïve and inflamed COX-1 -/- 
animals and their WT controls.  In the naïve lung, concentrations of 6-keto-PGF1α are significantly 
attenuated in COX-1 -/- animals, compared to WT controls (*p<0.05).  6-keto-PGF1α levels increase 
significantly in lungs collected from WT mice sensitized and challenged with OVA (*p<0.05).  In 
contrast, no enhanced production of 6-keto-PGF1α  occurs in the inflamed COX-1 -/- lung. (For 
Saline: COX-1 +/+ n=5, COX-1 -/- n=4; For OVA COX-1 +/+ n=5; COX-1 -/- n=6) 
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Figure 3.3  Immune Responses in IP -/- Animals Following Antigen Sensitization   
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Figure 3.3  Immune Responses in IP -/- Animals Following Antigen Sensitization  WT and IP -/- 
mice were sensitized with 50 μg OVA in alum and 12 days later, mice were euthanized and blood and 
spleens were collected for analysis.  A. Total IgE levels were measured in the serum of antigen 
sensitized animals.  IP -/- mice have significantly higher serum IgE compared to WT controls (* 
p<0.05).  B.  Splenocytes isolated from WT and IP -/- sensitized animals with increasing 
concentrations of OVA.  Following a 72 hour incubation period, cell proliferation was assessed using 
WST-1 reagent.  No significant difference in splenocyte proliferation is observed between wildtype 
and IP -/- cells.  C-E. Splenocytes from naïve and OVA-sensitized animals were cultured with 100 
μg/ml OVA for 72 hours.  IL-13 (C), IFN-γ (D), and IL-17a (E) cytokine levels were quantified in 
cell supernatant.  No significant differences are observed in cytokine production between IP +/+ and 
IP -/- cells. (For saline: IP +/+ n=4, IP -/- n=4; For OVA: IP +/+ n=5, IP -/- n=4)  
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Figure 3.4 The Effect of Iloprost on Lung Inflammation in COX-1 -/- Mice 
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Figure 3.4 The Effect of Iloprost on Lung Inflammation in COX-1 -/- Mice  COX-1 -/- animals and 
their wildtype congenic controls were sensitized and challenged with OVA antigen as previously 
described.  30 minutes prior to each challenge, mice received i.t. administration of 0.2μg iloprost 
(Ilo/COX-1 -/-) or vehicle (WT and Veh/COX-1-/-).  24 hours after the final challenge, animals were 
euthanized and BALF, serum, and lungs were collected.  A. Veh/COX-1 -/- animals have elevated 
levels of cellularity in their BALF, compared to WT mice.  Ilo/COX-1 -/- animals do not have 
significantly altered cellularity, compared to Veh/COX-1 -/- controls.  B. IL-13 levels are 
significantly augmented in the BALF of allergic Veh/COX-1 -/- animals, compared to WT mice 
(*p<0.05).  In contrast, Ilo/COX-1 -/- mice do not develop enhanced IL-13 levels, compared to WT 
controls  C. WT and Veh/COX-1 -/- mice have comparable levels of total serum IgE.  Ilo/COX-1-/- 
mice do not have a significant effect on IgE concentrations. (COX-1 +/+ n=8, Veh/COX-1 -/- n=4, 
Ilo/COX-1 -/- n=4) 
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Figure 3.5 The Effect of Iloprost on IP -/- Mice 
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Figure 3.5 The Effect of Iloprost on IP -/- Mice  Animals were sensitized and challenged with OVA 
antigen, as previously described.  Prior to each antigen challenge, mice received an i.t. delivered dose 
of 0.2μg iloprost or vehicle (Ilo/IP -/- compared to WT and Veh/IP -/-).  24 hours after the final 
challenge, BALF, serum and lungs were collected from all animals.  A. Cellularity in the BALF of 
Veh/IP-/- mice is augmented compared to WT animals.  Ilo/IP -/- have no significant difference in the 
cell levels measured, compared to Veh/IP -/- controls.  B. Il-13 cytokine levels measured in Veh/IP -/- 
mice are dramatically elevated, compared to WT controls.  This augmentation is not affected in 
Ilo/IP-/- mice.  C. Total serum IgE levels are enhanced in IP -/- mice compared to WT controls.  No 
significant difference is observed between Veh/IP-/- mice and Ilo/IP -/- groups. (WT  n=4, IP -/-/Veh 
n=5, IP -/-/Ilo n=5) 
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Figure 3.6 The Effect of Iloprost on OT-II Mice 
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Figure 3.6 The Effect of Iloprost on OT-II Mice  Mice harboring a transgene specific for the OVA 
TCR (OT-II tg +) and their WT controls (OT-II tg -) were challenged for 5 consecutive days with 1% 
aerosolized OVA to induce inflammation.  Half of these mice received 0.2μg i.t. iloprost 30 minutes 
prior to each challenge.  24 hours after the final challenge, BALF was collected for analysis.  A. 
BALF cellularity is increased following OVA challenge in all OT-II tg + animals, compared to OT-II 
tg- controls.  Administration of iloprost prior to challenge had no significant effect on BALF cell 
levels.  B IL-17a cytokine levels were assessed in the BALF of OT-II tg + animals.  Pretreatment with 
iloprost resulted in a modest, insignificant, reduction in IL-17a (p=0.06) (For OT-II tg-: Veh/WT n=3, 
Ilo/WT n=2, Veh/OT-II n=5, Ilo/OT-II n=5) 
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Figure 3.7 IP-signaling on Leukocytes  
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Figure 3.7 IP-signaling on Leukocytes  Lethally irradiated WT mice were reconstituted with either 
WT (WT→WT) or IP-deficient (KO→WT) bone marrow.  4 ½ weeks following reconstitution, 
animals were sensitized and challenged with saline or OVA as described.  A. All animals receiving 
OVA have elevated BALF cellularity; however cell levels are significantly augmented in KO→WT 
mice compared to allergic WT→WT controls (*p<0.05).  B. The increased cellularity observed in the 
BALF of allergic KO→WT mice compared to WT→WT controls results from significantly enhanced 
eosinophilia (*p<0.02).  C. IL-13 cytokine levels measured in the BALF following sensitization and 
challenge with OVA are significantly augmented in KO→WT mice compared to WT→WT mice 
(*p=0.05).  D. Allergy-induction with OVA antigen results in significantly elevated concentrations of 
total serum IgE in KO→WT animals compared to WT→WT controls.  (For saline: WT→WT n=3, 
KO→WT n=3; For OVA: WT→WT n=7, KO→WT n=9) 
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Discussion 
 Our previous work has demonstrated that COX-1 enzymatic activity limits the inflammation 
associated with atopic lung allergy; a loss of this isoform augments disease in mice, compared to 
congenic controls (373).  This is consistent with data generated using animals of a mixed genetic 
background (182).  While this phenomenon was initially thought to reflect a specific loss of PGE2 
synthesis in these animals, we have recently shown that PGE2 enhances disease parameters in this 
model (373).  Instead, utilizing IP -/- and COX-1 -/- cohorts, we have examined the contribution of 
PGI2 to the heightened disease in COX-1 -/- animals.  We observed that allergic IP -/- and COX-1 -/- 
cohorts develop similar levels of inflammation in the lung, although important differences between 
the two groups are observed.  Further, we have demonstrated that although PGI2 limits atopic disease 
during both the sensitization and effector phases, the contribution of this mediator is more prolific 
during allergy elicitation.  We have additionally presented preliminary evidence suggesting that 
iloprost can attenuate effector phase atopic allergy in the airways of COX-1 -/- mice by suppressing 
IL-13 cytokine levels.  Finally, we show that PGI2 targets IP receptors on leukocytes to mediate its 
effects in the lung. 
 Using an identical protocol, we observed that a genetic loss of either COX-1 or IP increases 
parameters of lung inflammation following sensitization and challenge with OVA antigen.  In this 
model, both COX-1 -/- and IP -/- animals have significantly elevated cellularity in their airways; 
however, the magnitude of this influx is more substantial in IP -/- animals, compared to COX-1 -/- 
mice.  Two explanations might account for this difference.  This observation most likely arises from 
the fact that, unlike IP -/- animals, COX-1 -/- mice lose the ability to produce all downstream 
prostanoids whose synthesis are dependent on this isoform, representing both pro- and anti-
inflammatory mediators.  IP -/- animals, however, lose PGI2-signaling only.  These animals retain the 
ability to produce and respond to alternate prostanoids.  We have demonstrated that PGE2 promotes 
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inflammation in this system and therefore may be the source of the enhanced cellularity in IP -/- 
animals.  Alternatively, although we show that production of the stable PGI2 metabolite, 6-keto-
PGF1α, is drastically inhibited in the inflamed COX-1 -/- lung, we cannot rule out the possibility that 
low levels of this prostanoid are being produced by COX-2 in this system.  This query can be 
addressed by examining the levels of 6-keto-PGF1α in the inflamed lungs of COX-1 -/- animals 
pretreated with indomethacin.  Unlike cellular infiltrate measurements, IL-13 cytokine levels in the 
airways of COX-1 -/- and IP -/- mice are comparable.  This finding suggests that the attenuated IL-13 
cytokine levels observed in COX-1 -/- may result specifically from aberrant PGI2 synthesis. 
Consistent with our previous findings, a loss of COX-1 enzymatic activity does not augment 
concentrations of serum IgE in response to OVA, compared to WT controls.  In contrast, a specific 
loss of prostacyclin signaling significantly increases observed IgE levels.  This is in agreement with 
other reports examining the actions of PGI2 in the lung (323) and demonstrates that prostanoid 
production does in fact contribute to IgE concentrations.  The lack of a measurable phenotype in the 
COX-1-/- animals suggests that a careful balance exists between prostanoids in this process and that 
the actions of pro- and anti-inflammatory prostanoids contribute equally to levels of IgE.  Although 
no significant difference was measured in IgE levels resulting from a loss of mPGES1 (373), we have 
often observed a reduced trend in concentrations of this immunoglobulin in mPGES1 -/- mice 
following sensitization (data not shown).  PGD2, acting through the DP1 receptor, is also described to 
enhance OVA-induced lung inflammation (297).  Like mPGES1 -/- animals, DP1-deficient mice have 
only modestly reduced levels of IgE that fail to reach statistical significance (297).  Collectively this 
data suggests that although pro-inflammatory cytokines, including PGE2 and PGD2, independently 
contribute only minimally to IgE synthesis in the lung, synergy between these prostanoids can 
effectively antagonize the suppression PGI2 exerts on IgE levels.   
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To more precisely delineate the mechanism underlying IP-dependent suppression of antigen 
sensitization, we conducted ex vivo experiments measuring the responses of splenocytes in the 
absence of IP signaling.  Total splenocyte numbers quantified after mechanical dispersion and red 
blood cell lysis were comparable (data not shown), suggesting that endogenous PGI2 does not prevent 
immune cell trafficking into this organ.  During atopic antigen sensitization, antigen presentation 
results in antigen-specific TH2 differentiation and proliferation of immune cells populations.  No 
differences were observed in the proliferative curves or cytokine levels generated by IP +/+ and IP -/- 
splenocytes.  These results imply that PGI2 does not limit IgE in this model by suppressing cellular 
expansion or altering polarization.  
Given that PGI2 does not appear to abrogate T cell responses following antigen presentation, 
it is possible that IgE levels are altered in this model as a result of impaired immunoglobulin 
production by B cells.  While IP is present on effector TH2 cells, expression of this receptor is not 
observed on activated B cells (283), suggesting that PGI2 acts indirectly on these cells to inhibit IgE 
synthesis.  B cells require signals from activated TH2 cells to induce immunoglobulin class switching 
to IgE.  Among these, TH2 cells physically interact with B cells through CD40L/CD40 and 
CD23/CD21 ligand-binding (379).  Prostacyclin may potentially alter IgE levels by blunting 
expression of CD40L or CD23 on TH2 cells, thus reducing their ability to stimulate activation of B 
cells.  To our knowledge, expression of these ligands on TH2 cells in response to PGI2 has not been 
explored.  Elucidating the levels of alternative immunoglobulins present in IP -/- animals subsequent 
to antigen sensitization may clarify this issue. 
Additionally, release of IL-4 induces germline ε transcript expression and the presence of this 
cytokine is essential for isotype switching to occur (380).  In agreement with our findings, Jaffar and 
colleagues observed in their studies that PGI2 does not suppress TH2 cytokine levels or cellular 
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proliferation following in vitro restimulation of OVA-specific DO11.10 (DO11.10) cells (283).  
Instead, this prostanoid augments the IL-10 levels measured (284).  While levels of IL-10 cytokine 
were not assessed in our work, it stands to reason that a loss of this anti-inflammatory cytokine may 
indirectly enhance IgE levels by altering the IL-10/IL-4 balance and promoting ε transcript 
expression.  Although we measured IL-4 concentrations in our supernatants, values in all splenocyte 
cultures were below the level of detection (data not shown).  Finally, CD4
+
CD25
+ 
Treg cells produce 
IL-10 and have been shown to express IP receptors (283).  A loss of IP-signaling may impede the 
suppressive capabilities of Treg cells.  Further work is necessary to elucidate which mechanism PGI2 
utilizes to inhibit IgE levels following antigen sensitization. 
It is currently unclear why other groups have observed in vitro deviations in cellular 
proliferation and cytokine levels resulting from PGI2 signaling; however variations in culturing 
protocols make direct comparisons challenging (281, 285, 323).  For example, maturation of naïve 
cells in vitro may not accurately reflect the endogenous factors present during the in vivo stimulation 
of our splenocytes.  Further, multiple studies measured cellular responses following addition of PGI2 
analog rather than examining the contribution of endogenous prostacyclin signaling through the IP 
receptor (281, 285).  Indeed, one group reported that suppression of T cell responses by analogs was 
only partially inhibited in IP -/- cells, suggesting that addition of exogenous analog can stimulate 
multiple pathways (285).  Differences in T cell responses may also reflect variations in costimulatory 
conditions.  While PGI2 inhibits TH1 cytokine release when CD28 stimulation is absent; data shows 
that this prostanoid promotes TH1 responses in a CD28 dose-dependent manner (280).  In another 
report, the actions of IP-signaling on effector T cell cytokine release varied depending on whether 
cells were stimulated with antigen or anti-CD3 antibody (323). 
     
  
 
120 
 
While a significant difference in IgE is measured in immunized IP -/- animals, this difference 
fails to achieve the magnitude of change observed following allergen challenge.  This may suggest 
that the overwhelming contribution of PGI2 in limiting IgE levels is specific to the respiratory tract.  
In support of this theory, additional groups administering antigen systemically have failed to observe 
a significant difference in IgE values until after challenge of the airways occurred (323, 324).  
Further, fewer DO11.10 cells were measured in the lungs of recipient rodents following adoptive 
transfer and subsequent antigen challenge, when cells were stimulated in vitro with PGI2.  In contrast, 
PGI2- and Veh-treated DO11.10 cells were observed at similar levels in lymph nodes and in the 
spleen (283).  Finally, recent work by Idzko and colleagues, employing a model in which tolerogenic 
plasmacytoid DCs are depleted from the airways, reports that the administration of iloprost during 
local sensitization to the airways is sufficient to inhibit the pulmonary inflammation arising in Veh-
treated animals following antigen challenge (282).   
To further delineate the contribution of aberrant PGI2 production to the effector phase of lung 
inflammation in COX-1 -/- mice, we administered local doses of iloprost to COX-1 -/- animals prior 
to antigen challenge.  While cellularity in the BALF of Ilo/COX-1 -/- mice was modestly reduced 
compared to Veh/COX-1 -/- controls, no statistically significant differences in airway cellularity and 
serum IgE levels were observed as a result of iloprost treatment.  IL-13 concentrations were 
significantly augmented in the BALF of Veh/COX-1 -/- animals, compared to WT mice; however, no 
augmentation occurred in Ilo/COX-1 -/- mice.  This result supports our observation in IP -/- and 
COX-1 -/- mice that elevated IL-13 levels result from a loss of PGI2 synthesis.  This effect was 
specifically occurring through the IP receptor; iloprost treatment had no consequence on IL-13 levels 
in IP -/- mice. Collectively, these results suggest that production of prostacyclin by COX enzymes 
suppresses cell recruitment, to a degree, but exerts most of its effects by suppressing cytokine release 
from immune cells.  Research indicates that following antigen challenge, T cells are recruited to the 
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lung but require restimulation by DCs present in the lung for inflammation to occur (381)  PGI2 has 
been shown to suppress maturation of DCs, preventing their abilities to present antigen to T cells 
(281, 282).  This could explain why cell levels are only modestly reduced, yet cytokine production is 
suppressed.   
Although iloprost appears to suppress cytokine release in the lung following antigen 
challenge in a model of atopic allergy, we explored whether this effect could be extended to non-
atopic models of lung inflammation.  To this end, OT-II transgenic mice were administered iloprost 
prior to challenge with OVA.  In agreement with our observations in COX-1 -/- mice, treatment with 
this analog did not significantly prevent the recruitment of cells to the airway, nor did it significantly 
suppress IL-17a levels.  While a modest reduction was observed in measurements of this cytokine 
following iloprost treatment, these observations seem to suggest that the actions of PGI2, in the 
airway, act predominantly on TH2-driven responses. 
While resident cells of the lung appear to be the predominant source of PGI2 synthesis in the 
inflamed lung, both structural cells and leukocytes express elevated levels of the IP receptor (283).  
Given that prostanoids can act in both an autocrine and paracrine manner, it was of interest to 
elucidate which cell type PGI2 manipulates to exert its inhibitory functions.  To this end, we 
generated bone marrow chimeras with normal IP-signaling in the lung but lacking IP expression on 
leukocytes.  Following induction of allergy, chimeras had significantly enhanced airway eosinophilia 
and IL-13 levels, as well as augmented IgE, compared to animals reconstituted with WT bone 
marrow.  This data demonstrates that IP-signaling through recruited immune cells is important for the 
protection afforded by PGI2 in the lung.   
While further work is needed to clarify which class of leukocyte PGI2 exerts its effects on, 
evidence supports a model in which multiple cell types can be controlled by this prostanoid.  A recent 
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study reported that administrating iloprost prior to antigen challenge ameliorates lung inflammation 
and AHR, resulting from inhibition of DC maturation and migration (282).  However, a separate 
group made the observation that EPO levels in the airways of naive IP +/+ and IP -/- animals 
transferred with WT OT-II TH2 cells were similar following challenge.  Additionally, naive mice 
transferred with PGI2-treated DO11.10 TH2 cells had reduced EPO levels compared to animals 
receiving Veh-treated cells (283), suggesting that PGI2 acts on TH2 cells during pulmonary 
inflammation.  Collectively, these observations imply that the actions exerted by PGI2 produced by 
stromal cells during atopic lung allergy are not limited to one cell type.   
In conclusion, we have shown that PGI2 production inhibits atopic inflammation in the 
murine lung following challenge in immunized recipients.  While mediation by this prostanoid is 
active in both the sensitization and effector phases, in this model prostacyclin seems to play a more 
critical role following antigen challenge; possibly suggesting that protection from inflammation by 
this mediator is specific to the lung.  We have also presented preliminary data suggesting that PGI2 
exerts its effects not by preventing recruitment to the lung, but by suppressing cytokine levels.  Taken 
together, we propose a model in which COX-1 generation of PGI2 in the lung limits inflammation by 
downregulating expression of costimulatory signals on leukocytes.  Following local exposure to 
antigen, PGI2 may suppress DC maturation thus reducing the ability of these APCs to migrate to local 
lymph nodes and activate naïve T cells.  Suppression of DC maturation also prevents restimulation of 
effector T cells recruited to the airways and may additionally reduce costimulatory molecules on TH2, 
attenuating their ability to release cytokines and stimulate B cells.  
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CHAPTER IV 
AIRWAY IMMUNE TOLERANCE IN THE ABSENCE OF PGE2 SIGNALING 
 
Normal respiration exposes the mucosal surface of the airway to a continuous array of both 
pathogenic and innocuous antigens ubiquitous in the external environment.  The ability to efficiently 
recognize and combat harmful material while avoiding unnecessary responses to non-pathogenic 
allergens, which would lead to chronic inflammation and barrier damage, is a central challenge the 
immune system faces at mucosal surfaces.  Experimental evidence suggests that a tight regulation 
exists to promote immune tolerance to harmless environmental particles and this is controlled, in part, 
by the ability of epithelial cells to release mediators into the milieu, creating a protective 
microenvironment at the time of antigen exposure (68).  A breakdown of this system precipitates 
chronic allergy, inflammation, and asthma (65).   
Prostaglandin E2 (PGE2) is an important bioactive lipid mediator with pleiotropic functions, 
produced by most cells.  The synthesis of this prostanoid is initialized when arachidonic acid (AA) is 
released from membrane phospholipids by phospholipase A2.  AA is converted into the intermediate 
products, prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) by cyclooxygenase (COX) enzymes 
existing in two isoforms encoded by unique genes, COX-1 and COX-2.  Following conversion to 
PGH2, production of PGE2 is completed by a prostanoid specific synthase.  Three distinct synthases 
have been described for synthesis of this mediator: microsomal PGE synthases (mPGES) -1 and -2, 
and cytosolic PGE synthase (cPGES) (197, 340, 341); however study of these synthases in vivo, using 
gene-specific knock out technology, only supports a role for mPGES-1 in mediating this conversion 
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(199, 201, 204).  Following its synthesis and transport from the cell, the autocrine and paracrine 
actions of PGE2 are initiated by ligand-binding to four distinct G-coupled E prostanoid (EP) 
receptors, EP1-4, with overlapping functions.  Ligand-binding to EP1, a Gq-coupled receptor, results in 
elevation of intracellular calcium levels.  Downstream actions following binding of EP2 or EP4, Gs-
coupled receptors, occur through augmentation of cyclic AMP (cAMP). The EP3 receptor is unique in 
that it exists in multiple isoforms which can couple with distinct G-protein receptors.  Depending on 
the variant, EP3 can couple with the Gi, Gs, and Gq-protein receptors to attenuate or increase cAMP 
levels or elevate intracellular calcium levels, respectively (382).  Varying levels of expression have 
been observed in the murine lung for of all four EP receptors (327, 383). 
The concept that prostanoids, including PGE2, can influence the microenvironment at 
mucosal surfaces and promote antigen tolerance is supported by data generated in the gastrointestinal 
(GI) tract which, much like the airways, is a mucosal system with continuous exposure to innocuous 
particles in the form of food antigens and commensal bacteria.  Chronic use of non-steroidal anti-
inflammatory drugs (NSAIDs), analgesics that suppress COX-dependent synthesis of prostanoids, can 
augment disease in patients with inflammatory bowel syndrome (IBS) (384, 385).  In fact, using a 
murine model in which all T cells recognize a single defined antigen, Newberry et al. demonstrated 
that prostanoid production by COX-2, constitutively expressed by the lamina propria, is crucial for 
induction of GI immune tolerance and this was attributed to production of PGE2 by this enzyme (185, 
386).   
While evidence supports a role for PGE2 in immune tolerance generated at the mucosal 
surface of the GI tract, little is known regarding its contribution to the establishment of antigen 
tolerance in the airways.  However, similar to the gut mucosa, experimental evidence suggests that 
both COX isoforms are present during homeostasis in epithelial cells of the airway and constitutive 
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production of PGE2 by these cells is noted in both humans and mice (329, 387).  Further, constitutive 
expression of COX-2 and PGE2 is reported in lung cancers where they are thought to prevent tumor 
destruction by promoting a microenvironment permissive for tumor development, in part by 
decreasing responses from host effector cells (388).  In an in vivo model of murine lung cancer, 
neutralization of PGE2 significantly reduced the presence of Treg cells (252). 
In vitro studies examining the actions of PGE2 suggest several mechanisms this prostanoid 
might utilize to promote airway tolerance.  Culture with this mediator is demonstrated to 
downregulate expression of MHC II (240, 389), reduce T and B cell proliferation (246, 390), and 
suppress the release of inflammatory cytokines such as IFN-γ and TNF-α while promoting the release 
of suppressive cytokines, such as IL-10 and TGF-β, from T cells, DCs, and macrophages (238, 241, 
242, 246, 358, 391).  Additionally, evidence suggests that PGE2 can promote the differentiation and 
inhibitory functions of both naturally occurring and adaptive T regulatory (Treg) cells (251, 253, 392).   
In this chapter, we utilize mice deficient in key components of the PGE2 pathway to evaluate 
the contribution of this prostanoid to immune tolerance in the airways in response to an innocuous 
antigen. We show that a loss of EP2, EP3, EP4, or additionally a complete loss of PGE2 does not 
prevent pulmonary immunosuppression to antigen in this model.  Instead, we provide evidence that 
signaling through the prostacyclin-specific IP receptor may contribute to antigen tolerance in the 
lung.    
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Materials and Methods 
Experimental Animals 
All animal colonies were maintained according to standard guidelines as defined by the NIH Guide 
for the Care and Use of Laboratory Animals and the Institutional Animal Care and Use Committee. 
Experiments were carried out on age and sex matched mice between 8-12 weeks of age.  Mice 
lacking the EP2, EP3, EP4, and IP receptors or mPGES1 were generated as previously described (268, 
334, 350, 393, 394).  EP2, EP3, and IP mice were backcrossed >10 generations onto the C57BL/6 (B6) 
background.  mPGES1 mice were backcrossed >10 generation onto the BALB/c background.  EP4 -/- 
animals and their controls are maintained on a recombinant inbred strain consisting of B6, DBA/2, 
and 129/Ola.  
 OVA Tolerance, Sensitization and Challenge 
To induce airway tolerance, a subset of experimental mice (OVA/OVA) were exposed to aerosolized 
1% OVA (Sigma-Aldrich) for 10 minutes on 3 consecutive days.  All other mice were exposed to 
aerosolized saline.  One week later, OVA/OVA animals and inflamed controls (Sal/OVA) were 
sensitized with an i.p injection of 20µg OVA emulsified in aluminum hydroxide (alum) (Sigma-
Aldrich).  Two weeks following antigen sensitization, OVA/OVA and Sal/OVA mice were 
challenged for one hour on 3 consecutive days with 1% aerosolized OVA. Naïve controls (Sal/Sal) 
were challenged with saline.  Airway inflammation was assessed 24 hours after the final challenge. 
BALF Collection and Cell Counts 
Following euthanasia, lungs were lavaged with five 1ml aliquots of HBSS (Gibco) and total cell 
counts were determined by hemacytometer.  Cellular composition was evaluated morphologically 
     
  
 
127 
 
using cytospin preparation stained with Hema 3 or Fast Green.  All remaining BALF was centrifuged 
to remove cells and stored at -80° c for immunoassay. 
IgE Analysis 
Blood was obtained by cardiac puncture, allowed to coagulate, and centrifuged to isolate serum.  IgE 
levels were determined by immunoassay using 96 well EIA/RIA plates (Costar).  Plates were coated 
with IgE capture antibody (Pharmingen; clone R35-72), blocked with 1% BSA/PBS and then 
incubated with IgE standard (Pharmingen) or serum followed by biotinylated rat anti-mouse IgE 
(Pharmingen; clone R35-118).  Detection was carried out using streptavidin-horseradish peroxidase 
(HRP) (Pharmingen) and hydrogen peroxide /2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS).  Absorbance at 405nm was measured.   
Statistical Analysis 
Statistical analysis was performed using Prism 4 (GraphPad Software).  Comparisons of the mean 
were made by Student’s t-test or ANOVA followed by Tukey-Kramer’s HSD post hoc test as 
necessary.  Data are shown as mean ± SEM.  Differences with p<0.05 were considered statistically 
significant. 
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Results 
Inhalation Induced Airway Tolerance 
 Evidence suggests that exposure to antigen via the airway mucosa prior to systemic 
sensitization suppresses subsequent production of IgE, typical of atopic allergic reactions (60).  
However, to our knowledge no study has been conducted to assess the contribution of the PGE2 
pathway to tolerance in the airways.  We first developed a method to effectively induce 
immunosuppression in response to our established protocol of sensitization and challenge with 
innocuous antigen.  Antigen tolerant mice (OVA/OVA) received 1% aerosolized OVA exposure for 
10 minutes daily on 3 consecutive days.  One week later OVA/OVA animals and allergic controls 
(Sal/OVA) were i.p. immunized with 20μg OVA emulsified in adjuvant.  Two weeks after systemic 
antigen sensitization, mice were exposed to 1% aerosolized OVA for 1 hour daily on 3 consecutive 
days.  Naïve mice (Sal/Sal) received saline exposure.  24 hours after the final aerosol challenge, 
animals were euthanized and airway inflammation was assessed.  As expected, Sal/OVA mice 
developed a robust cellular infiltration in their airways (Fig 4.1A) compared to Sal/Sal controls.  In 
contrast, OVA/OVA animals had cellular levels comparable to naïve controls.  Differential cell 
counts were established by histological analysis of cytospin preparation and granulocyte numbers 
were recorded.  The elevated cell infiltrate observed in the airways of Sal/OVA mice reflected 
significantly increased granulocyte numbers (Fig 4.1B) compared to Sal/Sal and OVA/OVA animals.  
Finally, IgE levels, elevated in atopic allergic responses, were measured in the serum.  Allergy 
induction increased IgE in Sal/OVA mice, compared to Sal/Sal controls (Fig 4.1C).  In contrast, 
OVA/OVA animals have no augmented production of IgE.  These observations demonstrate that our 
protocol is appropriate for studying the contribution of the PGE2 pathway to airway tolerance in mice.  
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Airway tolerance in EP-receptor deficient animals 
The immunosuppressive effects of PGE2 are overwhelmingly attributed to actions occurring 
through EP2/EP4 binding and elevation of intracellular cAMP.  PGE2 binding of these receptors is 
demonstrated to enhance IL-10 release and from DCs (230), reduce T cell proliferation (246, 247), 
and suppress cytokine release from macrophages (246).  Further, EP2 and EP4 agonists upregulate 
expression of Foxp3 and PGE2-mediated Foxp3 expression is attenuated in cells obtained from EP2 -/- 
or EP4 -/- mice (252).  Therefore, we focused our work on receptors capable of altering cAMP levels.  
We first examined airway tolerance in mice lacking the EP2 receptor (EP2 -/-) and their 
congenic controls (EP2 +/+).  Tolerance or sensitivity to OVA antigen was induced as described 
earlier.  As expected, a robust cellular recruitment into the airways occurred in both EP2 +/+ Sal/OVA 
and Sal/OVA EP2 -/- controls (Fig 4.2A).  Pre-exposure to aerosolized antigen attenuated cellular 
reductions to comparable levels in both EP2 +/+ and EP2 -/- OVA/OVA mice.  Elevated cell counts in 
Sal/OVA animals correspond to increased granulocyte numbers (Fig 4.2B); however, this 
enhancement is not observed in either EP2 +/+ or EP2 -/- OVA/OVA cohorts.  Serum IgE is similarly 
elevated in all Sal/OVA mice (Fig 4.2C).  In contrast, OVA/OVA animals do not have augmented 
IgE levels, regardless of genotype.   
We next analyzed lung inflammation in Sal/Sal, Sal/OVA, and OVA/OVA EP4 -/- mice and 
their congenic controls.  Our results following this round of experiments were similar to those 
observed in EP2 animals.  Sal/OVA EP4 -/- mice experience similar levels of airway cellularity 
compared to EP4 +/+ controls (Fig 4.3A).  All OVA/OVA mice have comparable cellular reductions.  
Differential cell analysis reveals elevated numbers of granulocytes in the BALF of both Sal/OVA 
groups, regardless of EP4 expression (Fig 4.3B).  OVA/OVA animals have attenuated granulocyte 
content, compared to Sal/OVA mice, in both cohorts.  This reduction does not vary significantly 
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between EP4 +/+ and EP4 -/- animals.  Sensitization and challenge with OVA results in augmented 
concentrations of serum IgE in both EP4 +/+ and EP4 -/- Sal/OVA mice (Fig 4.3C).  OVA/OVA 
animals have significantly less IgE.  This reduction is comparable between EP4 +/+ and EP4 -/- mice. 
Although our data generated with EP2 and EP4 receptor deficient mice suggests that PGE2 
elevation of intracellular cAMP does not contribute significantly to airway tolerance, alternative 
splicing of EP3 allows this receptor to couple with the Gi and Gs proteins to reduce or elevate cAMP 
levels, respectively (206).  Therefore, utilizing EP3 -/- animals and their congenic controls, we 
evaluated whether a loss of this receptor would alter airway tolerance.  Elevated cellularity is 
observed in the airways of all Sal/OVA mice following allergic sensitization and challenge (Fig 
4.4A).  The reduced cell numbers measured in OVA/OVA animals does not differ significantly 
between EP3 -/- mice and their EP3 +/+ controls.  Both EP3 +/+ and EP3 -/- Sal/OVA animals have 
augmented granulocyte numbers in their BALF (Fig 4.4B).  Similar reductions occur in all 
OVA/OVA mice.  Measurements taken from the serum of wildtype Sal/OVA animals reveal elevated 
IgE levels (Fig 4.4C).  Surprisingly, levels of this immunoglobulin in EP3 -/- mice are significantly 
diminished.  Both OVA/OVA cohorts have reduced levels of IgE compared to their respective 
Sal/OVA controls.  The percentage of IgE measured in wildtype OVA/OVA mice, compared to their 
Sal/OVA controls, is similar in degree to the percentage measured in OVA/OVA EP3 -/-, compared to 
their Sal/OVA EP3 -/- controls.   
Airway tolerance in mPGES1-deficient mice 
 While an individual loss of the EP2, EP3, or EP4 caused no apparent deviations on airway 
immune tolerance, this data could not rule out a role for the EP1 receptor or multiple receptors with 
overlapping functions in this system.  Therefore we next evaluated whether a complete loss of PGE2 
expression would alter immune tolerance to OVA antigen in the airways.  While research has 
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suggested the existence of three PGE2 synthases, in vivo data only supports a role for mPGES1 in this 
process (199, 228).  Therefore, we utilized mPGES1 -/- mice and their congenic controls to study the 
overall contribution of endogenous PGE2 to our model of airway immune tolerance.   
 Following harvest, OVA/OVA mice have reduced cellular levels in their BALF, compared to 
Sal/OVA controls (Fig 4.5A).  A similar trend is observed in mPGES1 -/- mice; however, this 
reduction fails to reach statistical significance.  Differential cell analysis reveals lower granulocyte 
numbers in OVA/OVA mice (Fig 4.5B).  These reductions are similar in both mPGES1 +/+ and 
mPGES1 -/- OVA/OVA groups, compared to Sal/OVA controls.  As expected, Sal/OVA mice have 
elevated levels of serum IgE (Fig 4.5C).  Loss of mPGES1 does not prevent or alter this 
enhancement.  All OVA/OVA mice showed similar reductions in IgE concentrations, regardless of 
mPGES1 production. 
OVA tolerance in IP receptor deficient mice 
 Prostacyclin, another prostanoid produced downstream of COX enzymatic activity on AA, 
exerts its effects through selective binding to the I prostanoid (IP) receptor and subsequent elevation 
of intracellular cAMP levels (327).  Our research, presented earlier in this dissertation, supports a role 
for PGI2 in attenuating atopic lung inflammation.  Therefore, utilizing animals lacking the IP receptor 
(IP -/-) and their congenic controls, we evaluated whether this prostanoid contributes to airway 
immune tolerance.  As we have previously shown, loss of the IP receptor leads to substantially 
elevated cellular recruitment in Sal/OVA mice, compared to wildtype controls (Fig 4.6A).  Both IP 
+/+ and IP -/- OVA/OVA mice have reduced airway cellularity, compared to their respective 
Sal/OVA controls.  However, a comparison of the percentage of cells in OVA/OVA mice, in respect 
to their Sal/OVA controls, reveals that the attenuation observed in IP -/- mice is significantly less than 
in IP +/+ animals.  Increased granulocyte numbers are observed in both groups of Sal/OVA animals, 
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compared to Sal/Sal controls, however the magnitude was much greater in IP -/- mice.  In both 
OVA/OVA groups, significantly fewer granulocytes are counted; however when the percent is 
analyzed in terms of respective Sal/OVA controls, the decrease in granulocyte number is significantly 
less in IP -/- mice (Fig 4.6B).  Sensitization and challenge with OVA results in elevated serum IgE 
which is increased in IP -/- mice (Fig 4.6C).  OVA/OVA treatment significantly ameliorates IgE 
concentrations in both IP +/+ and IP -/- groups.  Analysis of the percentage of IgE in these animals 
compared to their respective Sal/OVA controls reveals that the reduction occurs to a similar 
magnitude in both IP +/+ and IP -/- animals.  
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Figure 4.1 Airway Tolerance Induction in Wildtype Mice    
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Figure 5.1 Airway Tolerance Induction in Mice  Animals were exposed to 1% aerosolized OVA or 
saline for 10 minutes on days -9 through-7.  On day 0, experimental mice were sensitized to antigen 
via an i.p. injection of 20ug OVA emulsified in alum.  Mice were challenged two weeks later on 3 
consecutive days with 1% OVA for an hour each day.  24 hours after the final challenge, mice were 
euthanized and inflammation was assessed.  A.  Increased cellular infiltrate is observed in the BALF 
of Sal/OVA animals, compared to Sal/Sal controls.  The cellularity measured in OVA/OVA mice is 
significantly reduced compared to Sal/OVA mice (*p<0.001).  B. Differential cell analysis reveals 
that cell recruitment in Sal/OVA mice results from elevation of granulocytes.  OVA/OVA mice have 
significantly fewer granulocytes, compared to Sal/OVA mice (*p<0.001).  C. Sal/OVA mice have 
heightened concentrations of IgE, compared to Sal/Sal controls.  Total IgE levels are significantly less 
in OVA/OVA mice, compared to their allergic counterparts (*p<0.001). (Sal/Sal mice n=5; Sal/OVA 
n=10; OVA/OVA n=10)   
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Figure 4.2 Airway Tolerance in EP2 -/- Mice 
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Figure 4.2 Airway Tolerance in EP2 -/- Mice  EP2 -/- mice and their congenic controls were either 
tolerized (OVA/OVA) or sensitized (Sal/OVA) to OVA antigen as previously described and 
inflammation was subsequently assessed.  A. Sensitization/challenge with antigen results in 
comparable increases in cellularity in both Sal/OVA groups compared to saline controls.  Similar 
degrees of attenuation in cellularity are observed in EP2 +/+ and EP2 -/- OVA/OVA cohorts (*,# 
p<0.05).  B. All Sal/OVA animals have elevated BALF granulocyte numbers, independent of EP2 
receptor expression.  Reduced granulocyte counts measured in OVA/OVA animals are unaffected by 
the presence of absence of EP2 (* p<0.05, # p<0.01).  C. Total serum IgE concentrations were 
assessed.  Alterations in IgE measurements do not differ significantly as a result of EP2 receptor 
expression in either Sal/OVA or OVA/OVA groups (* p<0.05, # p<0.001).  (For EP2 +/+ mice: 
Sal/Sal n=3, Sal/OVA n=7, OVA/OVA n=7; For EP2 -/- mice: Sal/Sal n=2, Sal/OVA n=7, 
OVA/OVA n=7) 
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Figure 4.3 Airway Tolerance in EP4 -/- Mice  
 
  
0
50
100
150
200
250
300
350
EP4 +/+
EP4 -/-
Sal/Sal Sal/OVA OVA/OVA
*
*
#
#
T
o
ta
l 
 C
e
ll
s
 (
1
0
4
)
0
100
200
300
EP4 +/+
EP4 -/-
Sal/Sal Sal/OVA OVA/OVA
*
*
#
#
T
o
ta
l 
G
ra
n
u
lo
c
y
te
s
(1
0
4
)
0
500
1000
1500
2000
2500
3000
3500
4000
4500
EP4 +/+
EP4 -/-
Sal/Sal Sal/OVA OVA/OVA
*
*
#
#
T
o
ta
l 
 S
e
ru
m
  
Ig
E
(n
g
/m
l)
A. B.
C.
     
  
 
138 
 
Figure 4.3 Airway Tolerance in EP4 -/- Mice  Lung inflammation was assessed in EP4 +/+ and EP4 -
/- mice either tolerant (OVA/OVA) or sensitive (Sal/OVA) to antigen.  A. All Sal/OVA mice, 
regardless of EP4 expression, have significantly enhanced BALF cellularity compared to Sal/Sal 
controls.  This cellularity is reduced to a similar degree in both OVA/OVA groups (* p<0.001, # 
p<0.01).  B. Granulocyte levels are augmented in both Sal/OVA groups.  OVA/OVA animals have 
reduced granulocytes in their airways.  This reduction does not vary significantly between EP4 +/+ 
and EP4 -/- animals (* p<0.001, # p<0.01).  C. Serum IgE is enhanced in both EP4 +/+ and EP4 -/- 
Sal/OVA groups.  IgE levels are reduced to a similar degree in all OVA/OVA animals (* p<0.001, # 
p<0.01).  (For EP4 +/+ mice: Sal/Sal n=4, Sal/OVA n=10, OVA/OVA n=10; EP4 -/- mice: Sal/Sal 
n=2, Sal/OVA n=9, OVA/OVA n=7) 
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Figure 4.4 Airway Tolerance in EP3 -/- Mice   
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Figure 4.4 Airway Tolerance in EP3 -/- Mice  Tolerance or allergy were induced in the airways of 
EP3-/- mice and their congenic controls, as previously described.  A. All Sal/OVA animals, regardless 
of EP3 expression, have similar elevations in BALF cellularity compared to Sal/Sal controls.  Cellular 
reductions observed in OVA/OVA mice are unaffected by a loss of the EP3 receptor (* p<0.001, # 
p<0.01).  B. Sal/OVA animals have enhanced granulocyte numbers and these levels are significantly 
attenuated in OVA/OVA mice.  The observed reduction is similar in EP3 +/+ and EP3 -/- cohorts (* 
p<0.001, # p<0.01).  C. Total serum IgE is increased in Sal/OVA animals, however this increase is 
significantly less in EP3 -/- animals (δ p<0.05).  Both OVA/OVA groups have significantly attenuated 
IgE levels compared to their Sal/OVA controls (*,# p<0.05).  The percent of IgE measured in 
OVA/OVA groups, compared to respective Sal/OVA controls, does not differ significantly between 
EP3 +/+ and EP3 -/- animals.  (For EP3 +/+ mice: Sal/Sal n=4, Sal/OVA n=10, OVA/OVA n=10; EP3 
-/- mice: Sal/Sal n=5, Sal/Ova n=10, OVA/OVA n=10) 
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Figure 4.5 Airway Tolerance in mPGES1 -/- Mice  
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Figure 4.5 Airway Tolerance in mPGES1 -/- Mice  Following treatment with aerosolized OVA or 
saline, mPGES1 -/- mice and their congenic controls were sensitized and challenged with OVA.  
Airway inflammation was assessed following challenge.  A. Both mPGES1 +/+ and mPGES1 -/- 
Sal/OVA animals have similar increases in BALF cellularity.  Reduced cellularity is observed in 
OVA/OVA mice, compared to Sal/OVA controls, however this difference only reaches statistical 
significance in mPGES1 +/+ animals (* p< 0.01).  B. Granulocyte numbers are enhanced to a similar 
degree in all Sal/OVA animals.  Comparable reductions of granulocyte numbers occur in both 
mPGES1 +/+ and mPGES1 -/- mice, although these reductions do not reach statistical significance.  
C. All Sal/OVA animals have elevated serum IgE.  OVA/OVA animals have similar reductions in 
IgE, regardless of mPGES1 production (*,# p<0.01).  (For mPGES1 +/+ mice: Sal/Sal n=3, Sal/OVA 
n=6, OVA/OVA n=7; mPGES1 -/- mice: Sal/Sal n=5, Sal/OVA n=6, OVA/OVA n=8)   
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Figure 4.6 Airway Tolerance in IP -/- Mice  
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Figure 4.6 OVA Tolerance in IP -/- Mice  Lung inflammation in Sal/Sal, Sal/OVA, and OVA/OVA 
animals was studied using IP -/- mice and their congenic controls.  A. Increased cellularity is 
observed in the BALF of all Sal/OVA animals compared to Sal/Sal controls.  This enhancement is 
dramatically greater in IP -/- mice.  OVA/OVA animals have significantly attenuated cell counts in 
both IP +/+ and IP -/- OVA/OVA groups (*,# p<0.001).  The percent of cells in OVA/OVA mice, 
compared to respective Sal/OVA controls, is significantly greater in IP -/- mice (* p<0.02).  B. 
Increased cellularity following OVA treatment corresponds to elevated granulocyte numbers in both 
IP +/+ and IP -/- animals, however the increase is substantially higher in IP -/- mice.  Inducing 
tolerance results in decreased granulocyte numbers in both OVA/OVA groups, compared to their 
Sal/OVA controls (*,# p<0.001).  The percent of granulocytes counted in OVA/OVA animals, 
compared to respective Sal/OVA controls, is greater in IP -/- animals (* p<0.0001).  C. While more 
substantial in IP -/- mice, all Sal/OVA mice have augmented IgE compared to Sal/Sal controls.  
Significantly reduced IgE concentrations are measured in all OVA/OVA mice (*,# p<0.001).  The 
percent of IgE measured in OVA/OVA groups, compared to respective Sal/OVA controls, is not 
significantly different between IP +/+ and IP -/- cohorts. (For IP +/+ mice: Sal/Sal n=5, Sal/OVA 
n=11, OVA/OVA n=9; IP -/- mice: Sal/Sal n=5, Sal/OVA n=11, OVA/OVA n=9) 
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Discussion 
 While both COX-2 and PGE2 have been implicated in mucosal immune tolerance established 
in the GI tract in response to innocuous antigens (386), the contribution of the PGE2 pathway to this 
process in the airways has not been elucidated.  To evaluate the role of PGE2 in this system, we 
utilized a protocol in which exposure to antigen via the airways prior to sensitization and challenge 
attenuates subsequent allergic lung inflammation.  In agreement with previous data (60), we observed 
that when a novel antigen is encountered by the airway mucosa prior to systemic sensitization, 
secondary challenge results in a dramatic attenuation of total serum IgE and BALF granulocyte 
cellularity.   
We subjected mice deficient in individual EP receptors to our model of airway tolerance in 
order to characterize the in vivo contribution of PGE2 signaling to our model of mucosal 
immunosuppression in the respiratory tract.  We found that a genetic loss of the EP2, EP3, or EP4 
receptor was insufficient to alter the suppressed inflammation observed when wildtype animals are 
pre-exposed to antigen.  An inability to signal through these receptors did not prevent reduction in 
serum IgE levels or BALF granulocyte counts.   
Surprisingly, we found that a loss of the EP3 receptor results in significantly reduced IgE 
levels in Sal/OVA animals, compared to EP3 +/+ controls, suggesting that a pathway downstream of 
EP3-signaling enhances IgE during allergy in the lung.  In Chapter 3, we demonstrated that a loss of 
the IP receptor significantly augments IgE levels in the serum of animals sensitized and challenged 
with antigen.  However, no alterations in this immunoglobulin are observed in the inflamed airways 
of mice lacking either isoform of the COX enzyme (373).  Collectively, this suggests that actions of 
one or more pro-inflammatory prostanoid can effectively balance the PGI2-mediated suppression of 
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IgE during lung allergy.  Our data supports a role for PGE2-dependent activation of EP3 in enhancing 
IgE levels.   
Alternative splicing produces distinct EP3 isoforms that can activate unique downstream 
pathways.  In a model of cutaneous edema, activation of the EP3 receptor, and upregulation of 
intracellular calcium, promotes mast cell degranulation, indirectly enhancing inflammation (211, 258, 
259).  EP3 signaling may elevate IgE levels in our system by enhancing the release of factors such as 
chymase, from mast cells, which have been shown to increase IgE production (395).  EP3 coupling 
with Gs or Gi proteins can elevate or reduce intracellular cAMP levels, respectively.  Increased levels 
of this second messenger have been shown to promote IgE isotype switching while suppressing 
proliferation of B cells (396).  Therefore it is conceivable that elevated levels of this immunoglobulin 
may result from EP3 coupling with Gs protein to enhance IgE isotype switching or alternatively, EP3 
coupling with Gi to reduce cAMP and promote proliferation of B cells.  Additionally, recent evidence 
by Singh and colleagues suggests that EP3-dependent signaling promotes the development of DCs 
both in vitro and in vivo and animals lacking this receptor have reduced DC numbers in their bone 
marrow and spleen (397).  It is possible that our animals lacking EP3 have fewer APCs available to 
activate the adaptive immune system in response to antigen, indirectly resulting in lower quantities of 
IgE.  Unlike EP3 -/- mice, IgE levels measured in mPGES1 -/- animals do not differ significantly from 
wildtype controls.  However we do tend to see a slight attenuation in levels of this immunoglobulin in 
mPGES1 -/- animals (data not shown).  This suggests that one or more of the alternative EP receptors 
antagonizes EP3 in its capacity to stimulate IgE. 
Our observation that EP3-signaling promotes IgE production is in contrast to work by 
Kunikata et al. who observed that animals lacking this receptor have elevated inflammation following 
sensitization and challenge with OVA and no apparent difference in IgE levels (320).  It is unclear 
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why the results of Kunikata and colleagues differ from our own; however we have been unable to 
repeat the findings of this group using our own congenic EP3 -/- animals (unpublished observations).  
Additionally, we cannot rule out the possibility that differences in protocol account for these 
discrepancies, given that the method of allergy induction employed by Kunikata and colleagues 
utilizes a mechanism distinct from our own (158). 
All three of the receptors studied in this work are capable of coupling with Gs protein to 
elevate levels of cAMP.  It is therefore conceivable that the contribution of these receptors to airway 
immune tolerance is redundant and that multiple receptors can perform an identical task.  In this 
scenario, a genetic loss of a single receptor may not be sufficient to observe an altered phenotype.  
Additionally, an elevation of intracellular calcium, following activation of an EP1-dependent 
pathway, could potentially prevent TH2 lung inflammation in this model of airway immune tolerance.  
In a model of contact hypersensitivity, a TH1 cell-type response, animals lacking the EP1 receptor had 
attenuated inflammation.  In this study, cells isolated from the lymph nodes of EP1 -/- mice produced 
significantly fewer TH1 cells when stimulated with antigen (398).  Therefore, activation of an EP1-
dependent pathway could potentially promote mucosal tolerance in the respiratory tract by 
suppressing TH2 cell differentiation in favor of TH1 cell polarization.   
To determine whether the lack of phenotype in our mice was due to pathway redundancy or a 
dependency on EP1 signaling, we evaluated airway tolerance in mice deficient of the mPGES1 
synthase, the only synthase with a documented contribution to PGE2 synthesis in vivo (199).  We 
observed that mPGES1 -/- animals exposed to aerosolized antigen prior to immunization experienced 
immunoglobulin and granulocyte levels that were comparable to their wildtype counterparts 
following allergen challenge.  While the attenuation in cellularity failed to reach statistical 
significance in mPGES1 -/- animals, the magnitude of change was similar to that observed in 
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wildtype controls, suggesting that tolerance was unaffected in these animals.  However, mice on this 
genetic background, BALB/c, often have poor granulocyte recruitment into the BALF (399).  We 
cannot rule out the possibility that a significant difference may have been observed in the BALF of 
mPGES1 -/- mice on a more permissible genetic background.  This can be clarified by studying the 
establishment of tolerance in C57BL/6 mice lacking mPGES1. 
 We and others have demonstrated that prostacyclin-mediated signaling suppresses 
inflammatory responses in models of lung allergy (278, 284, 323), therefore we evaluated the role of 
this prostanoid in airway tolerance.  In agreement with our previous data, we found that aspects of 
immunosuppression in our model were altered in mice lacking the IP receptor.  Specifically, IP -/- 
OVA/OVA mice did not experience the same magnitude of granulocyte cell attenuation observed in 
wildtype OVA/OVA animals. Surprisingly, we found that suppression of IgE occurred independently 
of prostacyclin signaling, implying that prostacyclin contributes to airway tolerance subsequent to 
initial antigen presentation or alternatively, that antigen sensitization must occur locally, in agreement 
with our previous data.   
Our findings support a model in which PGI2 released from stromal cells of the lung 
suppresses the actions of leukocytes including DCs and T cells.  This mediator may promote airway 
immune tolerance by inhibiting chemokine receptors on DCs that allow them to home to lymph 
nodes.  In support of this theory, Idzko et al. demonstrate that administration of iloprost, a stable 
prostacyclin analog, to mice not only inhibits the maturation of lung DC’s but also prevents the 
migration of these APC’s to local lymph nodes (282).  While our data fails to show a role for 
prostacyclin in the suppression of initial APC functions in this model, primed T cells require 
restimulation by antigen-loaded DCs to initiate secondary allergic responses (381).  Secondary 
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immune responses are effectively suppressed when iloprost is given to immunized mice prior to 
challenge resulting from suppressed maturation of DCs (282).  
Expression of prostacyclin may also suppress T cells recruited to the lung which escaped 
earlier tolerance mechanisms.  Our previous findings suggest that iloprost can attenuate IL-13 levels 
in the BALF.  Conversely, IP expression is upregulated on Foxp3
+
 Tregs (283) and treatment with 
prostacyclin enhances IL-10 levels released from CD4
+
 cells.  Elevated prostacyclin expression may 
therefore attract Tregs to the lung and enhance the release of anti-inflammatory cytokines that prevent 
the initiation of inflammatory responses mounted against innocuous antigens. 
In summary, our work provides evidence that the PGE2 pathway does not contribute to 
immune tolerance of innocuous antigens in the airway.  Instead, prostacyclin may promote immune 
suppression to innocuous antigens by selectively recruiting regulatory T cells to the mucosa while 
preventing the activation of effector T cells that would enhance deleterious immune responses.
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CHAPTER V 
CONCLUDING REMARKS 
Atopic allergy is a major risk factor for asthma: a chronic disease of the respiratory tract 
characterized by episodes of reversible airway obstruction and airway hyperresponsiveness.  
Worldwide, 300 million individuals are thought to suffer from asthma, making this affliction a major 
public health concern.  The etiology of asthma is complex; both environmental and genetic factors 
contribute to this disease emphasizing the necessity for research delineating underlying mechanisms. 
Atopic asthma develops when the immune system mistakenly interprets inhaled innocuous 
environmental antigens as harmful and mounts TH2-driven responses against them.  The severity of 
an attack is controlled, in part, by the cytokines and mediators released in the airways in response to 
that antigen.    
Prostanoids are lipid mediators produced by almost all cell types of the body.  These 
mediators are not stored but instead are de novo synthesized from arachidonic acid (AA) in response 
to a variety of stimuli.  Free AA, liberated from the phospholipid membrane by the actions of 
phospholipases is presented to cyclooxygenase (COX) enzymes which convert it into unstable 
intermediate products.  Synthesis into the five bioactive prostanoids is completed by prostanoid 
specific synthases.  These mediators exert their autocrine and paracrine functions through binding of 
specific G-coupled receptors that activate a diverse array of downstream pathways.  Prostanoids are 
implicated in a broad range of processes from tissue regulation to inflammation and tumorogenesis. 
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(400)  In this dissertation, we explored the overall contribution of prostanoids, and the specific 
contributions of PGE2 and PGI2, to allergy and mucosal tolerance in the lung.  
Our work in Chapter 2 demonstrates that while overall, COX-dependent prostanoid 
production limits allergic airway inflammation in the lung, a specific loss of PGE2 attenuates disease 
parameters in mice, suggesting that this prostanoid promotes inflammation in this system.  We 
provide evidence that structural cells of the lung, likely epithelial cells or airway smooth muscle cells, 
are responsible for the synthesis of this pro-inflammatory prostanoid.  However, more work is 
necessary to elucidate which cell type, specifically, is the source of this PGE2.  The use of conditional 
knockout animals may help to clarify this issue.  Mice homozygous for a loxP-flanked mPges1 gene 
can be crossed to animals expressing cre recombinase under promoters specific for smooth muscle 
cells or epithelial cells.  Tgln cre mice are used to study the loss of PGE2 production by smooth 
muscle cells while mice expressing cre under the human SP-C promoter are widely used to study 
pulmonary epithelial cells (401, 402). 
 The work conducted in Chapter 2 also does not identify which PGE2 receptor is being 
activated during allergy in the pulmonary system to promote inflammation.  However, allergy was 
induced in animals lacking receptors EP2, EP3, or EP4 in Chapter 4 of this dissertation, to establish 
controls for studying airway tolerance.  No differences in total cellularity or granulocyte numbers 
were observed in any of these knockout animals, compared to their WT controls, suggesting that an 
individual loss of these receptors cannot account for the phenotype we observed in mPGES1 -/- mice 
in Chapter 2.  Several possibilities exist that may explain this finding.  Chapter 4 did not study allergy 
in animals lacking the EP1 receptor so it is possible that a loss of this receptor may account for the 
attenuated inflammation observed when PGE2 production is absent.  Along with EP3, recent evidence 
suggests that EP1-signaling can promote the development of DCs both in vitro  and in vivo.  Indeed, 
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animals lacking this receptor have reduced levels of this APC in their bone marrow and spleen (397).  
It is therefore conceivable that signaling through the EP1 receptor promotes lung inflammation by 
potentiating the development of DCs and enhancing the presentation of antigen to the adaptive 
immune system.  However, given that PGE2 appears to exert its pro-inflammatory actions mainly 
during the effector phase of allergy in the airways, subsequent to antigen presentation, this possibility 
seems unlikely.  The contribution of EP1 to this process can be addressed by analyzing OVA-induced 
lung inflammation in mice lacking this receptor. 
More likely, our data may imply that the ability of PGE2 to enhance inflammation during 
allergy in the respiratory tract is controlled, redundantly, by multiple receptors and therefore a loss of 
only one receptor is not sufficient to reproduce the attenuated inflammation observed in mPGES1 -/- 
animals.  In Chapter 2, we hypothesize that PGE2 promotes inflammation by increasing vasodilation 
and vasculature permeability.  At least some research indicates that these functions can be controlled 
dually by the EP2 and the EP4 receptors and elevation of intracellular cAMP (403).  These receptors 
may work in concert to promote inflammation in our model of lung inflammation.  This idea is 
substantiated by data generated in a model of arthritis, showing that arthritic scores in mice are only 
attenuated when both the EP2 and the EP4 signaling pathways are inhibited (276).  Given that EP4 
mice do not survey on most common inbred backgrounds, this possibility may be addressed by 
treating EP2 -/- animals with an EP4 antagonist during antigen challenge.  Additionally, we observed 
in Chapter 4 that EP3 -/- animals have reduced IgE levels, compared to wildtype controls, suggesting 
that this receptor may also contribute to the pro-inflammatory actions of PGE2 in the lung.  Like, EP2 
and EP4, EP3 can alter intracellular cAMP levels, suggesting that all three of these receptors may act 
redundantly.  To identify whether EP2, EP3, and EP4 all contribute to allergic lung inflammation, EP2 
and EP4 antagonists can be given to EP3 animals.    
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Unlike PGE2, we show in Chapter 3 that PGI2 signaling through the IP receptor limits allergic 
inflammation in the lung during both the sensitization and effector phase.  Following sensitization 
with antigen, IP -/- mice have significantly elevated serum IgE levels.  Our ex vivo experiments with 
splenocytes provide evidence that PGI2 does not suppress IgE by altering immune cell proliferation or 
polarization; however, given that DCs represent only a small fraction of the cells present in 
splenocyte populations (397), this system may not accurately model antigen presentation and 
subsequent sensitization.  Analysis of cellular responses by cells obtained from draining lymph nodes 
or alternatively, coculture of isolated DC and naïve T cell populations may be more informative.  
Indeed, evidence in rats suggests that, following stimulation with antigen, IgE-producing plasma cells 
are concentrated at the highest levels in local draining lymph nodes (404).  Additionally, PGI2 may 
act downstream of TH2 cell differentiation and expansion.  This prostanoid may limit interactions 
between TH2 cells and B cells or alternatively, skew immunoglobulin production.  To test for these 
possibilities, costimulatory molecules on these immune cells which influence activation of plasma 
cells, such as CD23 or CD40 can be measured.  Finally, analysis of alternate immunoglobulin levels 
present in the serum of sensitized IP -/- mice may help determine how IgE levels are being limited by 
PGI2. 
While IP -/- animals have significantly increased levels of serum IgE following sensitization, 
compared to WT controls, the magnitude of this elevation is less than that observed following antigen 
challenge.  Given that our model relies on systemic sensitization, this finding may imply that the anti-
inflammatory actions of PGI2, in this system, are specific to the lung.  In support of this hypothesis, 
Idzko and colleagues have demonstrated that pulmonary inflammation can be suppressed when 
sensitization occurs in the airways using mDCs treated with iloprost (282).  Further work is needed to 
explore this possibility.  Data by Eisenbarth et al. has shown that inhaled OVA can induce atopic 
antigen sensitization when combined with low levels of LPS (74).  Utilizing this model to study 
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pulmonary allergy in IP-/- animals may provide information on tissue-specificity for PGI2-mediated 
airway protection.  Additionally, PGI2 may contribute mainly to the effector phase of an allergic 
response in the lung.  This can be examined by generating OT-II mice lacking the IP receptor.  While 
aerosolizing OVA to these animals does not provoke an atopic response, naïve T cells can be isolated 
from these animals and cultured to favor TH2 cell polarization.  These cells can be transferred into 
naïve IP -/- animals, allowing us to specifically study the contribution of IP-signaling to the effector 
phase of atopic allergy.  
Utilizing bone marrow chimeras, we demonstrate in Chapter 2 that PGI2 binds to receptors on 
leukocytes to limit inflammation during pulmonary allergy.  Several classes of immune cells 
upregulate IP expression in response to airway antigen challenge, including DCs and TH2 cells (103).  
Our work is unable to define which class of immune cell is being altered by IP-signaling in this 
system.  Employing the cre/lox system will again allow us to more precisely define the contributions 
of specific immune cell populations to PGI2-mediated protection in the lung.  Mating animals 
homozygous for a loxP-flanked Ptgir gene to mice expressing cre recombinase downstream of the 
Cd11c promoter (405) or alternatively the Cd4 promoter will delineate the importance of IP-signaling 
on DCs and T cells respectively.  IP -/- animals have augmented airway remodeling in a chronic 
allergy model (324).  Given that IP is upregulated on fibroblasts (103), it may be interesting to 
determine if IP-signaling on structural cells becomes important in limiting disease during chronic 
allergy.  Subjecting bone marrow chimeras expressing IP only on radioresistant cells to a chronic 
allergy protocol may provide more information on this question. 
We have provided preliminary evidence that while iloprost treatment causes only a slight 
reduction in BALF cellularity in COX-1 -/- animals, this drug has a more profound ability to limit IL-
13 levels in these mice.  Repeating these experiments with a larger cohort may give a more precise 
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understanding of the effect this PGI2 analog has on lung inflammation in these animals.  Given that 
IP-signaling on leukocytes appears to be important for the protection afforded by PGI2 in the airways, 
we propose that this prostanoid prevents the reactivation of memory T cells recruited to the lung 
following antigen challenge.  This may be explored further by isolating DCs from the inflamed lung 
and measuring their maturation state in terms of cell surface receptor levels along with their ability to 
stimulate T cells.  Additionally, crossing the leukocyte cell-specific cre recombinase animals outlined 
earlier to COX-1 -/- animals with a homozygous loxP-flanked Ptgir may further define the 
contribution of DC’s and T helper cells to the reductions in IL-13 levels measured following iloprost 
treatment.    
A novel cell type which produces high levels of IL-13 has recently been described by several 
groups (406-409).  These are non T/non B cells which respond to IL-25 and IL-33, both of which are 
thought to contribute to allergic responses in the lung following OVA sensitization and challenge 
(410, 411).  It stands to reason that this novel cell type is recruited to the airways during episodes of 
pulmonary allergy, although research has not yet confirmed this.  Given that treatment with iloprost 
reduces the levels of IL-13 measured in COX-1 -/- animals, it is possible that PGI2 alters the 
recruitment or function of these newly characterized cells.  Further work is needed to explore this 
possibility.  These cells lack conventional lineage markers but express c-Kit, as well as the receptors 
for IL-25 and IL-33 (406).  Analysis of cells with this spectrum of surface markers in iloprost-treated 
COX-1 -/- animals, and their vehicle treated controls, may provide further information on the effects 
of PGI2 on this class of cells.  
Given that iloprost treatment appears to attenuate certain parameters of inflammation in 
COX-1 -/- animals, it will be interesting to repeat these experiments in animals lacking COX-2 to 
elucidate whether iloprost can suppress the pulmonary allergy that develops in these mice and if so, if 
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the effects of this PGI2 analog are identical to those observed in COX-1 -/- animals.  Additionally, it 
will be important to identify whether iloprost can ameliorate allergy induced in the lungs of WT 
animals or if this drug is only capable of limiting disease in animals lacking COX production. 
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